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ABSTRACT OF THE DISSERTATION 
 
Comparative Studies of TSLP and IL-7 in Normal Early Human Neonatal and Adult 
 B Cell Development 
by 
Terry-Ann Milford 
Doctor of Philosophy, Graduate Program in Microbiology and Molecular Genetics 
Loma Linda University, June 2016 
Dr. Kimberly J. Payne, Chairperson 
 
Defining the role of cytokines in promoting human B cell development is 
important for understanding B cell leukemia and for developing strategies to restore B 
cell production that is lost during some therapies. The purpose of this study was to 
investigate the roles of the IL-7R ligands, thymic stromal lymphopoietin (TSLP) and IL-
7, in the early stages of normal postnatal and adult human B cell development. Using 
novel in vitro and in vivo model systems, we show that TSLP and IL-7 are able to expand 
B cell precursors individually and in combination from CB hematopoietic stem cells. In 
this model TSLP increases were seen in the CD34+ pro-B subset and maintained through 
subsequent stages of development. Adult B lymphopoiesis unlike CB B lymphopoiesis is 
IL-7– but may not be TSLP–dependent. We also used the expression of IL-7R, to 
identify a lymphoid progenitor that lacks myeloid potential. This information will be 
important in developing strategies for restoring B cell development after therapy and 
supports our ongoing leukemia studies by providing a rationale for targeting the TSLP 
signaling pathway in developing therapies for high-risk B cell acute lymphoblastic 
leukemia. 
 1 
CHAPTER ONE 
INTRODUCTION 
Sites of B Lymphopoiesis  
The sites of B lymphopoiesis change during ontogeny. During early to mid-
gestation, B cells can be found in the yolk sac, placenta, fetal liver and bone marrow of 
the fetus. From mid-gestation onward, the bone marrow becomes the primary organ for 
early B cell development (Magnon & Frenette, 2008). In the BM, hematopoietic stem 
cells (HSC) interact with stromal cells in specialized microenvironments described as 
niches (Tokoyoda, Egawa, Sugiyama, Choi, & Nagasawa, 2004). Here, the stromal cells 
secrete growth factors that direct lineage restriction of developing blood cells. They also 
express adhesion molecules that maintain cellular contact between the developing cells 
and the cytokine-secreting stromal cells (Ryan, Nuccie, Abboud, & Winslow, 1991; 
Tokoyoda et al., 2004). Some of the cytokines that regulate the nascent steps in early B 
cell differentiation include, Flt-3 ligand, IL-7 and TSLP. 
 
Stages of B Lymphopoiesis  
 To produce competent, non-self reacting, antibody-producing B cells, HSCs 
undergo multiple stages of specification, commitment and differentiation, beginning in 
the bone marrow. Mouse models of B cell development have been essential in 
understanding the complex network of cytokine-receptor signaling-transcription factor 
interactions that direct these processes early on. Flow cytometry and PCR are some of the 
techniques used to characterize the discreet stages of B lymphopoiesis – including pro-B, 
pre-B, immature B and mature B cells– by the expression of surface antigens and 
receptors as shown in Figure 1 (Parrish et al., 2009; Pribyl & LeBien, 1996; Rawlings, 
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Quan, Kato, & Witte, 1995; Scheeren et al., 2010). In mice, surface antigens including 
B220, AA4.1, CD43, CD19, CD24, Flt3, IL-7R and IgM are used to identify six stages 
(Hardy’s Fractions A-F) of developing B cells (Hardy, Carmack, Shinton, Kemp, & 
Hayakawa, 1991; Hardy & Hayakawa, 2001). Analogous populations are present in 
humans but some of the surface antigens used to identify them differ (Ichii, Oritani, & 
Kanakura, 2014). This review will focus primarily on the surface markers used to identify 
these subsets in human B cell development. 
 
 
 
 
 
Figure 1. A model of human B cell development based on the mouse.  For simplicity, B 
cell differentiation is viewed as a linear process.  As cells differentiate down the B lineage, 
they express combinations of surface markers and intracellular proteins that aid their 
identification. A summary of selected antigens and enzymes expressed at different stages 
of human B lymphopoiesis is shown above. Horizontal triangles indicate decreasing 
expression of the antigen and lines indicate sustained expression of the antigen. 
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Mouse HSCs are enriched in the Kit+Lin–Sca-1+ (KLS) fraction of the BM and 
account for 0.01% – 0.05% of total nucleated cells found there (Challen, Boles, Lin, & 
Goodell, 2009; Okada et al., 1992; Spangrude, Heimfeld, & Weissman, 1988). They 
undergo several rounds of restriction to generate progenitors from which erythroid and 
myeloid populations differentiate, and a common lymphoid progenitor (CLP), from 
which B, T and natural killer (NK) cells arise (Kondo, Weissman, & Akashi, 1997). The 
mouse CLP was initially identified as Lin−IL-7R+Thy-1.1− Sca-1loc-Kitlo (Kondo, 
Weissman, et al., 1997). This phenotype was later refined to include Flk2+ (Karsunky, 
Inlay, Serwold, Bhattacharya, & Weissman, 2008). Unlike the mouse, the human HSC 
was identified in the fetal bone marrow by the expression of a single marker, CD34, and 
absence of other lineage markers (Baum, Weissman, Tsukamoto, Buckle, & Peault, 
1992). While there is some consensus in the field about the phenotype of the mouse CLP, 
the phenotype of the human counterpart remains debatable.  
The combinations of markers used to identify these lymphoid-restricted 
progenitors in humans, vary according to the tissue being evaluated. In fetal and adult 
BM, Galy et al. used the phenotype CD34+Lin–CD38+CD10+ to identify lymphoid-
primed cells (Galy, Travis, Cen, & Chen, 1995).  Other groups identified these cells by 
IL-7Rα (Ryan et al., 1997), CXCR4 and TdT expression together with CD34 (Ishii et al., 
1999). Like adult BM, CB cultures of CD34+CD10–CD19–IL-7Rα+ cells generated 
lymphoid cells– NK, B and T cells– in addition to macrophages, suggesting that these 
cells are permissive depending on the cytokines supplementing the cultures (Reynaud, 
Lefort, Manie, Coulombel, & Levy, 2003).  An alternative phenotype, CD34+CD38–
CD7+ also describes a putative CLP in CB cultures (Hao et al., 2001). These lymphoid-
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restricted cells also express PU.1 and EBF, transcription factors that direct lymphocyte 
development along with TdT and RAG-1, -2, proteins that regulate immunoglobulin 
heavy chain rearrangement (Hystad et al., 2007; Reynaud et al., 2003; Rossi et al., 2003).  
In Chapter 6, we demonstrate that expression of IL-7R can be used to identify 
progenitors from CB that are biased toward lymphoid lineages. 
Between the CLP and committed progenitor B cell stages, a few B cell 
intermediates have been proposed based on expression of surface markers and B cell 
specific intracellular proteins. Hystad et al. defined the phenotype of the earliest B cell 
intermediate as CD34+CD38+CD10+CD19– (Hystad et al., 2007). These intermediates 
share the surface phenotype of the CLP thus making the two populations 
indistinguishable only by surface marker expression (Galy et al., 1995; LeBien, 2000).  
Whether these two populations are the same or different at the genetic level remains to be 
determined. The development of the immunoglobulin heavy chain begins in the early B 
cell with rearrangement of the D-to-J segments (Davi et al., 1997) and expression of 
associated genes and proteins including RAG-1,-2, TdT, and the pre-BCR components 
CD79a (also known as mb-1) and CD179a (also known as VpreB) (Dworzak, Fritsch, 
Froschl, Printz, & Gadner, 1998; Hystad et al., 2007; LeBien, 2000). The early B cell 
intermediate also expresses myeloid, T cell and NK cell associated genes (Hystad et al., 
2007). Another intermediate, the pre/pro-B cell with the phenotype, CD34+CD10–CD19+, 
is found in the fetal liver, fetal bone marrow and CB (Sanz, Alvarez-Mon, Martinez, & de 
la Hera, 2003; Sanz et al., 2010). Sanz et al. showed that the pre/pro-B cell is an alternate 
pathway to generate pro-B cells from CB HSCs (Sanz et al., 2010). Whether this alternate 
pathway for generating pro-B is active in adult BM remains undetermined. 
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The next stage of B cell development is the pro-B cell, conventionally described 
as CD19+CD34+CD10+ cells (Loken, Shah, Dattilio, & Civin, 1987; Rossi et al., 2003). 
TdT, RAG-1, and RAG-2 are expressed as V-to-DJ heavy chain rearrangement is 
completed (Ghia et al., 1996). Nonproductive VDJ rearrangement in the pro-B cell, 
results in death by apoptosis (LeBien, 2000).  The pro-B to pre-B cell transition is 
marked by cytoplasmic IgM (μHC) expression, cell surface expression of the pre-BCR 
and loss of CD34 and TdT (Ghia et al., 1996; LeBien, 2000). The pre-BCR complex is 
composed of μHC, CD179a, CD179b (surrogate light chains), and CD79a, CD79b (signal 
transduction heterodimers) (LeBien, 2000). Pre-BCR expression is a critical checkpoint 
in B cell development. It involves inhibition of further heavy chain rearrangement by 
suppressing RAG-1, and RAG-2; initiation of light chain rearrangement with re-
expression RAG-1, RAG-2 and increased proliferation of pre-BCR expressing cells 
(LeBien, 2000). The pre-B cell progresses to the immature B cell stage after successful 
light chain rearrangement, producing IgM on the B cell surface. At this stage, immature 
B cells migrate from the bone marrow into the periphery where they undergo further 
maturation. 
 
Transcription Factors Involved in Early B Cell Commitment 
 To successfully generate B cells, transcription factors act in an inter-dependent 
regulatory framework to, suppress non-B lineage genes, increase expression of cytokine 
receptors and surface markers and regulate immunoglobulin gene rearrangement. Based 
on mouse studies, Ikaros, PU.1, E2A, EBF and PAX-5 are major transcription factors 
involved in the differentiation of B cells from HSCs (Figure 2).  The roles of these 
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transcription factors in murine B cell differentiation are largely extrapolated to human. A 
proposed interplay between the transcription factors is illustrated in Figure 2. 
 
Ikaros and PU.1 
Ikaros and PU.1 are expressed in HSCs and multipotent progenitors (MPP) 
(Akashi, Traver, Miyamoto, & Weissman, 2000; Klug et al., 1998). Together, they 
repress non-B lineage fate and facilitate expression of lymphocyte-associated genes. 
Ikaros is required for the expression of the transcription factors E2A, EBF and PAX5, 
necessary for B cell specification and commitment (Bain et al., 1994; Kee & Murre, 
1998; Lin & Grosschedl, 1995; Nutt, Urbanek, Rolink, & Busslinger, 1997). In 
hematopoietic progenitors including the CLP, Ikaros and PU.1 activate lymphoid specific 
genes (Fuxa & Skok, 2007; Hagman & Lukin, 2006) including Flt-3 (Carotta et al., 2010) 
and IL-7Rα (DeKoter, Lee, & Singh, 2002).  In the absence of Ikaros or PU.1, 
hematopoietic progenitors show reduced expression of Flt3 (Nichogiannopoulou, 
Trevisan, Neben, Friedrich, & Georgopoulos, 1999) and IL-7R (DeKoter et al., 2002). B 
cells are also absent in the fetal liver and bone marrows of these mice (Wang et al., 
1996), possibly due to failure to increase expression of these receptors. 
 
E2A and EBF 
The E2A gene produces two spliced variants, E12 and E47. Together they 
regulate the expression of IL-7Rα, RAG-1/-2, EBF and pre-BCR components, CD79a, 
CD79b, CD179a and CD179b (Beck, Peak, Ota, Nemazee, & Murre, 2009; Kee & Murre, 
1998; Ye & Graf, 2007). B cell development is perturbed at the pro-B stage in the 
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absence of either E12 or E47 (Bain et al., 1994; Bain et al., 1997). EBF is required for B 
cell specification and is regulated by E2A (Smith, Gisler, & Sigvardsson, 2002), PU.1 
and IL-7R (Medina et al., 2004). EBF directly activates PAX-5 (O'Riordan & 
Grosschedl, 1999); regulates RAG-1 and RAG-2 (Lin & Grosschedl, 1995), the pre-BCR 
components CD79a (Sigvardsson et al., 2002), CD79b (B29) (Akerblad, Rosberg, 
Leanderson, & Sigvardsson, 1999), CD179a (Sigvardsson, O'Riordan, & Grosschedl, 
1997) and CD179b (Gisler & Sigvardsson, 2002). B cell generation is blocked at an early 
stage, in the absence of EBF, similar to the E2A absence (Lin & Grosschedl, 1995).  Loss 
of both EBF and E2A produce a more severe deficiency in B cell development than loss 
of the individual transcription factors (O'Riordan & Grosschedl, 1999). 
 
PAX-5 
PAX-5 induction is the first step in B cell commitment (Busslinger, 2004) as it 
induces the expression B cell specific genes CD19, increases CD79a, CD179a and 
CD179b (Ichii et al., 2014; Nutt, Heavey, Rolink, & Busslinger, 1999) and blocks the 
expression of the T cell gene, Notch1 (Monroe & Dorshkind, 2007; Souabni, Cobaleda, 
Schebesta, & Busslinger, 2002). B cells maintain PAX-5 expression until the mature B 
cell stage (Adams et al., 1992). In pro-B cells, inactivation of PAX-5 allows macrophage 
and T cell differentiation in vitro and in vivo, respectively (Mikkola, Heavey, Horcher, & 
Busslinger, 2002).  
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Cytokines in Early B Cell Development 
Flt-3 ligand (FL) 
Mouse and human FL are cross-reactive, sharing 72% amino acid identity (Lyman 
& Jacobsen, 1998). Several isoforms of FL exist. Humans express biologically active FL 
as both transmembrane and soluble forms (Lyman & Jacobsen, 1998; Lyman et al., 
1995). Using Northern blot, Lyman et al. found that FL expression was ubiquitous as it 
was detected in a variety of cells and tissues including PB leukocytes, spleen, thymus, 
liver, heart and skeletal muscle (Lyman et al., 1994). On the other hand, Flt-3 was 
primarily detected on hematopoietic stem and progenitor cells (Lyman & Jacobsen, 1998; 
Zeigler et al., 1994), thus constraining the activities of its ligand. The roles of FL–Flt-3 
signaling in B cell development include upregulation of the IL-7R (Borge, Adolfsson, 
Martensson, Martensson, & Jacobsen, 1999), and synergizing with IL-7 to expand and 
increase proliferation of primitive hematopoietic progenitors and pro-B cells (Ahsberg et 
al., 2010; Namikawa, Muench, & Roncarolo, 1996). In accordance with these functions, 
Flt-3 mutant mice exhibited reduced numbers of progenitors (Mackarehtschian et al., 
1995).  
 
Interleukin-7 (IL-7)  
IL-7, a 25 kDa protein, originally isolated from the supernatant of the IxN/A6 
murine bone marrow stromal cell line was able to stimulate proliferation and on its own 
support maintenance of B lymphoid progenitors in vitro (Namen, Lupton, et al., 1988; 
Namen, Schmierer, et al., 1988). Human IL-7 was cloned shortly afterward and it 
stimulated proliferation of both mouse and human B lineage progenitors (Goodwin et al., 
1989). Mouse IL-7 and human IL-7 share 81% homology in the coding region of the 
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nucleotide (Goodwin et al., 1989; Lupton et al., 1990) and 60% at the protein level 
(Goodwin et al., 1989). Stromal cells of the bone marrow and thymus are the primary 
producers of IL-7 (Hara et al., 2012).  Other cells that produce IL-7 include keratinocytes, 
intestinal epithelial cells, fetal and follicular DCs (Fry & Mackall, 2002). On the cells’ 
surface, IL-7 binds to a heterodimeric receptor complex of IL-7Ralso called CD127) 
and IL-2RG chains  (also known as common gamma chain, C, CD132) (Noguchi et al., 
1993). The IL-7R chain is shared only by one other cytokine receptor – discussed in the 
following section–unlike IL-2RG that is shared by other cytokine receptors, including IL-
2, IL-4, IL-9 and IL-15. Alternative splicing of the human IL-7R gene, produces a 
secreted form that binds IL-7 (Goodwin et al., 1990) but not TSLP (Lundstrom et al., 
2013). In vitro, soluble IL-7R  (sIL-7R) inhibited the effects of IL-7 (Crawley, 
Faucher, & Angel, 2010), while in vivo, sIL-7R enhanced IL-7’s activity (Lundstrom et 
al., 2013). Increased soluble IL-7R concentrations have been associated autoimmune 
conditions such as multiple sclerosis (MS) (Gregory et al., 2007; Lundstrom et al., 2013) 
and systemic lupus erythematosous (SLE) (Badot et al., 2013).  
While mouse and human IL-7 are homologous, their biological functions related 
to B cells are thought to differ. IL-7 stimulation increased the growth and proliferation of 
murine pro-B and pre-B cells but not mature B cells in vitro (G. Lee, Namen, Gillis, 
Ellingsworth, & Kincade, 1989; Namen, Lupton, et al., 1988). These in vitro findings, 
correlated with the phenotype of adult IL-7–/– mice that exhibited a block at the pro-B to 
pre-B cell progression and resulted in reduced numbers of mature B cells in the periphery 
and spleen (von Freeden-Jeffry et al., 1995). Carvalho et al., later showed that in the 
absence of IL-7, fetal and perinatal B lymphopoiesis were normal while adult B 
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lymphopoiesis was perturbed (Carvalho, Mota-Santos, Cumano, Demengeot, & Vieira, 
2001), thus demonstrating that IL-7 independent B cell development occurs in the early 
stages of life (Carvalho et al., 2001). }. Like IL-7–/– mice, in vivo B lymphopoiesis is also 
perturbed at the pro-B cell stage onward by blocking IL-7 with a neutralizing anti-IL-7 
monoclonal antibody (Grabstein et al., 1993).  Mice deficient for IL-7Rα, exhibited a 
block at the pre-pro B to pro-B transition, earlier than IL-7–/– mice (Peschon et al., 1994).  
Kikuchi et al. demonstrated that the arrest at the pre-pro-B cell stage in adult IL-7 and IL-
7R deficient mice was because EBF and its target genes were not expressed (Kikuchi, 
Lai, Hsu, & Kondo, 2005). While IL-7 deficiency results in loss of the earliest B cell 
precursors, overexpression or administration of recombinant IL-7 in vivo, expanded early 
B cell subsets and produced a lymphoproliferative disorder in cells bearing the immature 
B cell phenotype (Akdis et al., 2011; Fry & Mackall, 2002).  
Aside from IL-7’s role in B cell differentiation and proliferation, it also regulates 
the survival of early progenitors via the Bcl-2 family of proteins. This function is 
achieved by simultaneously activating the pro-survival members Bcl-2, Bcl-xL and Mcl-
1 (Clark, Mandal, Ochiai, & Singh, 2014; Lu, Chaudhury, & Osmond, 1999; Opferman et 
al., 2003) while repressing the pro-death factors Bax and Bad (Clark et al., 2014; Lu et 
al., 1999). The precise role of IL-7 in the survival of the earliest B cell progenitors 
remains debatable, as others show that IL-7 does not regulate Bcl-2, Bcl-xL and Mcl-1 in 
mouse pre-pro B cells (Kikuchi et al., 2005; Kondo, Akashi, Domen, Sugamura, & 
Weissman, 1997).  
 While critical for murine B cell development, IL-7 is thought to be nonessential 
for human B cell development. Patients with IL-7R defects displayed a T–B+NK+ SCID 
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phenotype with normal to increased numbers of functionally deficient B cells (Giliani et 
al., 2005; Puel, Ziegler, Buckley, & Leonard, 1998; Roifman, Zhang, Chitayat, & Sharfe, 
2000). SCID is characterized by deficiencies in T or B cell and can extend to NK cells. 
Symptoms including pneumonia, meningitis and recurring infections usually occur within 
the first few months of life. Patients with mutations in IL-2RG and its associated kinase, 
Janus Kinase 3 (JAK3), also presented with T–B+NK+ SCID and had normal to elevated 
B cell numbers (Fry & Mackall, 2002).  
Despite the absence of defects in human B cell numbers due to IL-7R mutations, 
there is a growing body of evidence that supports a role for IL-7 in human B 
lymphopoiesis. In vitro cultures of human fetal and adult BM derived B cell progenitors 
demonstrate that they proliferate in response to recombinant IL-7 (Dittel & LeBien, 1995; 
Goodwin et al., 1989; Namikawa, Muench, de Vries, & Roncarolo, 1996). IL-7R was 
expressed at similar levels in pro-B and pre-B cells (Dittel & LeBien, 1995).  Clinical 
trials using recombinant hIL-7 (rhIL-7) to treat malignancy, demonstrated increased 
expansion of pre-B cells in the BM and PB of patients in the study (Sportes et al., 2010). 
Similar to the clinical trial results, patients with above-normal IL-7 levels, as seen in 
advancing HIV, showed an increased frequency of immature B cell in the periphery 
(Malaspina et al., 2006). While fetal B cells differentiated in response to IL-7, Pribyl et 
al. showed that fetal BM CD34+ HSCs were also capable of IL-7 independent B cell 
differentiation (Pribyl & LeBien, 1996).  In addition to the effects on B cell proliferation 
and differentiation, another recently identified function of IL-7 in human B cell 
development is suppression of premature kappa light chain rearrangement in human B 
cell precursors, (Nodland et al., 2011). The possibility that like the mouse, human B cell 
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development is IL-7 independent in the perinatal/neonatal period and IL-7 dependency 
increases with age will be explored in Chapter 2.  
 
Thymic Stromal Lymphopoietin (TSLP)  
TSLP, an IL-7 homologue, was originally identified in the supernatant of the 
murine thymic stromal line, Z210R.1 (Friend et al., 1994).  The mature mouse TSLP 
protein is 121 amino acid (Sims et al., 2000), while the human counterpart is 131 amino 
acids (Quentmeier et al., 2001). Both share 43% amino acid identity (Quentmeier et al., 
2001). Mouse TSLP mRNA was detected in the spleen, thymus, bone marrow and kidney 
(Sims et al., 2000) while human TSLP has a broader range of expression being found in 
the heart, liver, testis, prostate, lung, skeletal muscle, kidney, spleen and colon 
(Quentmeier et al., 2001). Human TSLP is produced by a variety of cells including 
keratinocytes (Soumelis et al., 2002), epithelial cells, endothelial cells, neutrophils, 
macrophages, mast cells (Ying et al., 2005) dendritic cells and fibroblasts (Kashyap, 
Rochman, Spolski, Samsel, & Leonard, 2011).  Recent data identified TSLP as a key 
mediator in allergic and inflammatory conditions, including arthritis, asthma and atopic 
dermatitis (Bleck, Tse, Curotto de Lafaille, Zhang, & Reibman, 2008; Bleck, Tse, 
Gordon, Ahsan, & Reibman, 2010; Koyama et al., 2007; E. B. Lee et al., 2010; Ying et 
al., 2008). TSLP mediates its effects by binding a heterodimeric receptor complex of the 
IL-7R and CRLF2 (cytokine receptor like factor-2, also known as TSLPR) chains 
(Pandey et al., 2000; Park et al., 2000).  Like its cognate cytokine, mouse and human 
CRLF2 share low homology, ~35 % (Tonozuka et al., 2001). The low homology of 
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mouse and human TSLP and CRLF2, suggests that the functions between the species 
may be different 
Initial in vitro experiments showed that TSLP induced proliferation and 
differentiation of murine B cell precursors to the IgM+ stage in fetal liver and long-term 
bone marrow culture (Friend et al., 1994; Ray, Furlonger, Williams, & Paige, 1996), 
unlike IL-7, which induced differentiation to the earlier IgM– stage (Levin et al., 1999). 
While the function of TSLP in in vitro B cell differentiation appears consistent, the in 
vivo data is less so. Vosshenrich et al., supported the in vitro data with in vivo studies 
showing that pro-B cells from fetal liver and pre-B cells from both fetal liver and adult 
BM responded to TSLP (Vosshenrich, Cumano, Muller, Di Santo, & Vieira, 2003). B cell 
precursors from adult BM required pre-BCR expression to respond to TSLP 
(Vosshenrich, Cumano, Muller, Di Santo, & Vieira, 2004). Together these data suggest 
that TSLP may have both ontogeny and tissue specific activities. 
The effects of TSLP in B lymphopoiesis have been evaluated in several transgenic 
models.  In the absence of IL-7, TSLP stimulation increased fetal-derived B cell 
precursors (Vosshenrich et al., 2003) and restored adult B and T lymphopoiesis in 
primary and secondary organs (Chappaz, Flueck, Farr, Rolink, & Finke, 2007). In another 
model, B cells were reduced in the bone marrow but normal numbers were found in the 
spleen (Osborn et al., 2004). The results of TSLP overexpression were not only localized 
to the BM but also systemic. Mice displayed increased immature B cell numbers in the 
periphery (Astrakhan et al., 2007); developed a lethal systemic B lymphoproliferative 
disorder upon B cell restoration (Demehri et al., 2008); developed a systemic 
inflammatory condition (Taneda et al., 2001); exhibited cryoglobulinemia and immune 
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complex disease (Taneda et al., 2001; Tsai et al., 2010) in alternative TSLP transgenic 
models. Increased myelopoiesis often accompanied TSLP overexpression (Osborn et al., 
2004; Tsai et al., 2010). 
 The absence of the TSLP receptor (TSLPR) chain does not appear to impact 
mouse B cell development. TSLPR–/– mice, exhibited no apparent loss of B or T cells 
resulting from the absence of the TSLP receptor-signaling pathway (Carpino et al., 2004). 
In a different TSLPR–/– mouse model, Jensen et al. showed that FL not TSLP was 
responsible for IL-7 independent B lymphopoiesis (Jensen et al., 2008).   
To date, the effects of TSLP on normal human B lymphopoiesis have been limited 
to fetal tissues. Based on the in vitro findings that TSLP promoted B cell development 
from murine fetal sources (Levin et al., 1999; Vosshenrich et al., 2003, 2004), Scheeren 
et al. investigated the role of TSLP in human fetal B cell precursors. They found 
increased B cell differentiation from fetal-liver derived CD34+ HSCs and increased 
proliferation of pro-B and pre-B cells from the fetal liver in response to TSLP (Scheeren 
et al., 2010). Fetal BM pro-B cells also were also TSLP-responsive while pre-B cells 
were not (Scheeren et al., 2010). 
TSLP-induced signals have been implicated in malignant B cell development. 
Firstly, Brown et al. demonstrated that primary pre-B ALL cells increased proliferation 
and viability in vitro when cultured with TSLP (Brown et al., 2007).  Secondly, 
overexpression of CRLF2 on the B cell surface was recently associated with a high-risk 
form of pre-B acute lymphoblastic leukemia (pre-B ALL) (Cario et al., 2010; Mullighan 
et al., 2009; Russell et al., 2009). 
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It remains unknown if the effects of TSLP in human B cell development are 
restricted to fetal tissues. We will explore a role for TSLP in conjunction with IL-7 in the 
development of B cell precursors from postnatal and adult HSC in Chapters 3, 4 and 5. 
 
IL-7 and TSLP Signaling in Mice and Humans  
As demonstrated in Figure 3, the binding of IL-7 to the IL-7 receptor induces 
dimerization of the receptor chains and cross-phosphorylation of the associated JAKs–. 
JAK1 with IL-7R and JAK3 with the common gamma chain. This interaction results in 
the phosphorylation, dimerization and translocation of signal transducer and activator of 
transcription 5a/5b (STAT5a/b) to the nucleus (Isaksen et al., 1999; Johnson, Shah, 
Panoskaltsis-Mortari, & LeBien, 2005). Activation of this pathway is common to B 
lymphopoiesis in mice and humans (Johnson et al., 2005). IL-7 also activates the 
phosphoinositol-3-kinase (PI3K)/AKT pathway in human thymocytes but not in B cell 
precursors (Johnson, Shah, Bajer, & LeBien, 2008) 
Like IL-7, TSLP ligation induces phosphorylation of STAT5 (Isaksen et al., 
1999), but early studies suggested that activation of STAT5 was independent of the 
known JAKs (Isaksen et al., 1999; Ray et al., 1996). Rochman et al. later refined these 
findings, demonstrating that JAK2 associated with CRLF2 and was cross-phosphorylated 
by IL-7R-associated-JAK1 upon TSLP stimulation (Rochman et al., 2010). Unlike IL-7, 
TSLP signaling also activates the PI3K/AKT pathway in B cell precursors (Brown et al., 
2007; Johnson et al., 2008; Tasian et al., 2012).  
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Figure 3. TSLP and IL-7 signaling pathways activated in human B cells. The binding 
of IL-7 to its receptor complex of α and IL2RG, and TSLP to its receptor of IL-7Ra and 
CRLF2, facilitates the cross-phosphorylation of the JAKs-associated with the respective 
chains. Phosphorylated-JAK1 in turn phosphorylates STAT5A/B, which dimerizes and 
translocates to the nucleus.  TSLP also activates the PI3K/AKT/mTOR and together 
with STAT5 they regulate the processes of proliferation, survival and differentiation in 
B cells. 
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Models of B Cell Development 
Several in vitro culture models have been used to explore the stages human of B 
lymphopoiesis and the cytokines that influence these stages. Both stromal cell-dependent 
and stromal-cell independent models have been developed to mimic the BM 
microenvironment by providing intercellular contact and/or proper cytokine stimulation 
for B cell development. The stromal cell-dependent models consist of culturing 
hematopoietic progenitors on mouse or human stromal cell lines, for example, MS-5 
(Berardi et al., 1997; Johnson et al., 2005), S17 (Cumano, Dorshkind, Gillis, & Paige, 
1990; Dorshkind, Johnson, Harrison, & Landreth, 1989; Rawlings et al., 1995) and OP9 
(Scheeren et al., 2010; Vodyanik, Bork, Thomson, & Slukvin, 2005).  These cell lines 
secrete cytokines and in vitro cultures may also be supplemented with recombinant 
cytokines to induce early B cell differentiation. Another method of generating a stromal 
cell-dependent culture model includes the use of primary bone marrow stromal cells 
isolated from human bone marrow (Parrish et al., 2009; Pribyl & LeBien, 1996). Unlike 
their cell line counterparts, these primary stromal cells do not produce high 
concentrations of cytokines (Parrish et al., 2009). This is advantageous because it allows 
the investigator to titrate varying concentrations of exogenous cytokine and evaluate their 
effects on developing B cells without the need for elimination of confounding 
endogenous cytokines. 
As B cells develop, their cytokine requirements change. The high concentration of 
cytokines, like IL-7, that are produced by stromal cell lines and are important for early B 
cell development may hamper the maturation of the early B cell progenitors and 
precursors (Ray et al., 1998). The stromal-cell independent model is an attractive 
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prospect to address this concern because in lieu of stromal cells, the investigator 
administers combinations of recombinant cytokines at different intervals during B cell 
culture (Ichii et al., 2010; Kraus et al., 2014; Yoshikawa et al., 2000). This way the 
effects of the cytokines can be evaluated without intervening stromal cells and the 
uncharacterized proteins that they may secrete.  Together, data from both stromal-cell 
independent and dependent cultures have assisted in characterizing the discreet stages of 
B cell development. 
In vivo mouse models used to study human B cell development, take advantage of 
the severe combined immune-deficient (SCID) mutation that does not affect myeloid 
cells but renders intrinsic B and T cells functionally deficient (Bosma & Carroll, 1991). 
The deficiency is due to a defect in the activity of the DNA repair enzyme, protein kinase 
DNA activated catalytic polypeptide, Prkdc, resulting in incomplete VDJ recombination. 
The antibody- and cellular-mediated immune systems are affected because B and T cell 
do not mature, thus allowing the engraftment of human cells and tissues and the 
reconstitution of human hematopoietic cell lineages. Variations of SCID mice have been 
developed that demonstrate higher engraftment of human cells including the non-obese 
diabetic (NOD)- SCID mice, in which the IL2RG is deleted (NSG mice) or truncated 
(NOG mice) (M. Ito et al., 2002; Shultz et al., 2005). Although there are other strains of 
immune deficient mice that permit the efficient engraftment of human cells (R. Ito, 
Takahashi, Katano, & Ito, 2012), NSG mice rank highest and were thus selected for in 
vivo experiments presented in Chapters 3 and 4.   
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Abstract 
IL-7 is critical for B cell production in adult mice, however its role in human B 
lymphopoiesis is controversial. One challenge was the inability to differentiate human 
cord blood (CB) or adult bone marrow (BM) hematopoietic stem cells (HSCs) without 
murine stroma.  Here, we examine the role of IL-7 in human B cell development using a 
novel, human-only model based on co-culturing human HSCs on primary human BM 
stroma. In this model, IL-7 increases human B cell production by >60-fold from both CB 
and adult BM HSCs. IL-7-induced increases are dose-dependent and specific to CD19+ 
cells. STAT5 phosphorylation and expression of the Ki-67 proliferation antigen, indicate 
that IL-7 acts directly on CD19+ cells to increase proliferation at the CD34+ and CD34– 
pro-B cell stages. Without IL-7, HSCS in CB, but not BM give rise to a small but 
consistent population of CD19LO B lineage cells that express EBF and PAX-5 and 
respond to subsequent IL-7 stimulation. Flt3 ligand, but not thymic stromal-derived 
lymphopoietin (TSLP), was required for the IL-7-independent production of human B 
lineage cells. As compared to CB, adult BM shows a reduction of in vitro generative 
capacity that is progressively more profound in developmentally sequential populations, 
resulting in a ~50-fold reduction in IL-7-dependent B lineage generative capacity. These 
data provide evidence that IL-7 is essential for human B cell production from adult BM 
and that IL-7-induced expansion of the pro-B compartment is increasingly critical for 
human B cell production during the progression of ontogeny. 
  
 36 
Abbreviations 
CB  Umbilical Cord Blood 
BM   Bone Marrow 
HSC   Hematopoietic Stem Cell 
TSLP   Thymic Stromal-Derived Lymphopoietin 
IL-7R   IL-7 Receptor 
LIN–   Lineage Marker Negative  
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Introduction 
Murine studies have provided evidence that B cell development is controlled by a 
network of transcription factors and cytokine signaling that coordinates stage-specific 
expression of B lineage genes (Medina & Singh, 2005; Singh, Pongubala, & Medina, 
2007). In mice, signaling through two cytokine receptors, Flt3 (FMS-like tyrosine kinase 
receptor) and the IL-7R are critical for B cell development. The combined loss of 
signaling through both of these receptors completely blocks fetal and adult B cell 
development (Sitnicka et al., 2003, Vosshenrich, 2003 #856) (Vosshenrich, Cumano, 
Muller, Di Santo, & Vieira, 2003). Flt3 signaling upregulates IL-7R expression (Borge, 
Adolfsson, & Jacobsen, 1999). In adult mice, signaling through the IL-7R upregulates 
expression of Early B cell factor (EBF). EBF in turn regulates expression of a cascade of 
B cell specific genes (Medina & Singh, 2005; Singh et al., 2007) required for the 
transition from the common lymphoid progenitor to pro-B cells (Dias, Silva, Cumano, & 
Vieira, 2005; Kikuchi, Kasai, Watanabe, Lai, & Kondo, 2008; Kikuchi, Lai, Hsu, & 
Kondo, 2005). During fetal and neonatal life, IL-7-independent expression of EBF allows 
early B lineage differentiation, but not proliferation, unless IL-7 is present (Kikuchi & 
Kondo, 2006). 
 Human B cell development is thought to differ from that in mouse with respect to 
the requirement for IL-7. Early evidence for the importance of IL-7 in murine B cell 
production came from in vitro studies showing that B cell precursors derived from adult 
BM increase by approximately 50 fold with the addition of IL-7 (Lee, Namen, Gillis, 
Ellingsworth, & Kincade, 1989). Further evidence came from reports of blocked B cell 
development in the initial in vivo studies that characterized mutant mice with defects in 
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IL-7 (von Freeden-Jeffry et al., 1995), or in components of the IL-7 receptor (IL-7R) 
(DiSanto, Muller, Guy-Grand, Fischer, & Rajewsky, 1995; Peschon et al., 1994). Parallel 
in vitro studies of human B cell development were performed either using fetal 
hematopoietic sources (Dittel & LeBien, 1995; Kurosaka, LeBien, & Pribyl, 1999; 
Moreau, Duvert, Banchereau, & Saeland, 1993; Moreau, Duvert, Caux, et al., 1993; 
Namikawa, Muench, de Vries, & Roncarolo, 1996; Saeland et al., 1991; Wolf, Buckley, 
Goldfarb, Law, & LeBien, 1991) or using hybrid co-cultures with human progenitors and 
murine stromal cell lines (Johnson, Shah, Panoskaltsis-Mortari, & LeBien, 2005; 
Rawlings, Quan, Kato, & Witte, 1995; Taguchi et al., 2007). Inthose experiments IL-7 
either had no effect on B cell production or resulted in IL-7-induced increases that were 
10-fold less than those reported in the mouse. In vivo human data from clinical reports 
indicated that patients having severe-combined-immunodeficiency due to defects in IL-
7/IL-7R signaling lack T cells, but have peripheral blood B cells (Macchi et al., 1995; 
Noguchi et al., 1993; Puel, Ziegler, Buckley, & Leonard, 1998). These data have been 
interpreted to mean that IL-7 is essential for normal murine, but not human, B cell 
development (Bertrand et al., 2000; Espeli et al., 2006; LeBien, 2000; Munfus, Haga, 
Burrows, & Cooper, 2007; Roifman, Zhang, Chitayat, & Sharfe, 2000).  
  More detailed studies in the mouse revealed a dramatic change in B cell precursor 
requirements during ontogeny. IL-7 knockout mice show a block in adult B 
lymphopoiesis, but not in the production of B cells during the fetal or neonatal period 
(Carvalho, Mota-Santos, Cumano, Demengeot, & Vieira, 2001). More recently it has 
been shown that IL-7-independent expression of EBF in the mouse allows B lineage 
differentiation early in ontogeny resulting in a “developmental switch” in murine stem 
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cells with IL-7-independent B cell production occurring during fetal development and 
through the first two weeks of neonatal life, but not in the adult (Kikuchi & Kondo, 
2006).Thus, it is not surprising that in vitro IL-7 effects on fetally-derived human B cell 
precursors (Kurosaka et al., 1999; Moreau, Duvert, Banchereau, et al., 1993; J. R. Pribyl, 
Dittel, & LeBien, 1995; Saeland, Duvert, Moreau, & Banchereau, 1993; Saeland et al., 
1991; Wolf et al., 1991) were minor when compared to those observed for adult B 
lymphopoiesis in the mouse (Lee et al., 1989).Similarly, clinical data from patients with 
IL-7/IL-7R signaling defects was obtained early in life and is consistent with 
observations that fetal/neonatal B cell production is intact in mice with IL-7 defects.   
 It is also possible that residual, low level IL-7R signaling plays a role in B cell 
production in patients with defects in the IL-7R or its signaling pathway. Phosphorylation 
of STAT5 is a signaling event downstream of IL-7R ligation (Lin et al., 1995). Studies 
that compare B cell development in mice that are STAT5 null with that in STAT 
deficient mice that express a truncated form of STAT5 reveal that even low levels of 
residual IL-7R signaling can maintain B cell production in adult mice (Dai et al., 2007; 
Yao et al., 2006). Experiments to assess for IL-7 function in human patients with defects 
in components of the IL-7R signaling pathway are limited by the number, type, and 
quantity of specimens available for study. Thus, in vitro studies of human B cell 
development are essential for determining the role of IL-7 in human B cell development 
and whether humans exhibit the “developmental switch” that results in the loss of IL-7 
independent B cell production observed in the mouse. 
The association between ontogeny and IL-7 requirements has not been rigorously 
examined in humans. In vitro studies that address the role of IL-7 in human B cell 
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production during the neonatal period and through adulthood have been performed using 
hybrid human-mouse co-culture models (Johnson et al., 2005; Rawlings et al., 1995; 
Taguchi et al., 2007).The limitations of this model were highlighted by recent reports 
demonstrating that murine IL-7 can stimulate signaling through the human IL-
7R(Barata et al., 2006; Johnson et al., 2005; Taguchi et al., 2007). Thus, the production 
of murine IL-7 by stroma in hybrid human-mouse co-cultureshas rendered it difficult to 
evaluate the precise contribution of human IL-7, and the magnitude of IL-7-dependent 
effects in human B cell production from HSCs in CB and BM.  
 Here we describe a novel, entirely human model of in vitro B cell development 
that is based on co-culturing human HSCs on primary human BM stroma. Using this 
human-only model we show that human IL-7 increases the production of human B cell 
precursors by more than 60 fold, both from HSCs in adult BM, and from the HSCs in CB 
that give rise to B cells during the neonatal period. IL-7 effects were mediated through 
the direct action of human IL-7 on human CD19+ pro-B cells to increase proliferation at 
both the CD34+ and CD34– stages of B cell development. Adult BM, as compared to 
CB, shows a reduction of in vitro generative capacity that is progressively more profound 
in developmentally sequential populations, resulting in a ~50-fold reduction in B lineage 
generative capacity. In the absence of IL-7, HSCS in CB, but not BM give rise to a small 
but consistent population of CD19LO B lineage cells that express EBF, PAX-5 and 
respond to IL-7 with increased cell size and upregulation of CD19. These data suggest 
that in humans the role of IL-7 in B cell production becomes increasingly critical as 
ontogeny progresses, and that it is an essential factor for B cell production in adults. 
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Materials and Methods 
Cells 
CB was collected according to guidelines approved by the Institutional Review 
Boards at Children’s Hospital Los Angeles and Loma Linda University. Adult human 
BM was purchased from AllCells, LLC, Berkeley, CA; the National Disease Research 
Interchange (NDRI), Philadelphia, PA; or Poietics Cell Systems of Lonza Walkersville, 
Inc., Gaithersburg, MD. The leukopheresis product from a patient with pre-B ALL (> 
90% CD19+ cells) served as a source of primary human pre-B ALL cells. The use of all 
human tissues was reviewed and approved by the Institutional Review Boards at 
Children’s Hospital Los Angeles and/or Loma Linda University. Primary murine BM was 
obtained from normal adult control mice immediately after they were sacrificed as a part 
of other studies approved by the Institutional Animal Care and Use Committees at 
Children’s Hospital Los Angeles or Loma Linda University.  
 Lineage marker negative (Lin–) CD34+ cells were isolated by FACS sorting from 
CD34-enriched CB and BM mononuclear cells as previously described (Payne et al., 
2003). Primary stromal cells from adult human or murine BM were obtained by plating 
whole BM in Dexter’s original medium as described previously (Nolta et al., 2002).Non-
adherent cells were removed on the second day and adherent cells were used through 
passage six.  
 The murine S17 (Collins & Dorshkind, 1987) stromal cell line is a generous gift 
from Dr. Kenneth Dorshkind, University of California Los Angeles and the murine MS-5 
(Ohkawara et al., 1998) stromal cell line is a generous gift from Dr. Kazuhiro Mori.  
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Cultures 
 Human CB and adult BM HSCs  (typically ~10,000 and ~15,000 respectively) 
were seeded onto murine stromal cells pre-plated at 3,500 cells/well (hybrid cultures) or 
onto sublethally irradiated (2000 rads) primary human BM stromal cells plated at 7,000 
cells/well (human-only cultures) in 96-well tissue culture plates in B cell medium: RPMI 
medium (Irvine Scientific, Santa Ana, CA) containing penicillin/streptomycin, L-
glutamine, 50 M 2-mercaptoethanol, and 5% FBS(Omega Scientific, Inc. Tarzana, CA) 
lot tested for ability to support B cell production. Sublethal irradiation assured that 
culture progeny did not arise from residual human HSCs that might be associated with 
the BM-derived stroma. Control cultures were supplemented with IL-3 at 1 ng/ml (first 
week only) and Flt-3 ligand at 1 ng/ml or 50 ng/ml (R&D Systems, Minneapolis, MN) 
two cytokines that have previously been shown to support the production of human B 
lineage cells in vitro (Crooks, Hao, Petersen, Barsky, & Bockstoce, 2000; Miller, 
McCullar, Punzel, Lemischka, & Moore, 1999; Namikawa et al., 1996; Shah, 
Smogorzewska, Hannum, & Crooks, 1996). Additional supplementation with 
recombinant human cytokines and/or antibodies is described in fig. legends or as follows: 
IL-7 at 5 ng/ml, stem cell factor at 25 ng/ml (R&D Systems) neutralizing anti-human IL-
7 antibody, or control antibody at 10 ng/ml (BD Pharmingen, San Diego, CA), 
neutralizing anti-mouse IL-7 antibody (Abcam, Inc. Cambridge, MA) or control antibody 
(Jackson ImmunoResearch, West Grove, PA), neutralizing anti-human TSLP antibody 
(R&D) or control antibody (Jackson ImmunoResearch) at 1 ug/ml,  neutralizing anti-
human Flt-3 ligand or control antibody (R&D) at .6 g/ml. The ND50 for rabbit anti-
mouse IL-7 neutralizing antibody was 0.012 to 0.02 g/ml of antibody for mouse IL-7 at 
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600 pg/ml. The ND50 for rat anti-human IL-7 neutralizing antibody was .0001 to 
.001g/ml of antibody for human IL-7 at 167 pg/ml. The ND50  for sheep anti-human 
TSLP was .05  to .25 g/ml for .5 ng/ml human TSLP. The ND50  for mouse anti-human 
Flt-3 ligand was .02  to .06 g/ml for 5 ng/ml Flt-3 ligand. 
 For cultures described in Figure 4A each well contained 3 antibodies: either the 
neutralizing antibody to Flt-3 ligand, IL-7, and/or TSLP, or the corresponding control 
antibody at an identical concentration as neutralizing antibody.  Wells to which 
exogenous cytokine were added received the appropriated control antibody for that 
cytokine.  This assured that antibody isotypes and concentrations were the same in all 
wells. To simplify, only neutralizing antibodies (and not control antibodies) are indicated 
in the legend to Figure 4A.  
 CD19+ progeny from human-only cultures were enriched for apoptosis assays 
using the Human B cell enrichment kit (StemCell Technologies, Vancouver, BC, Canada) 
and for assays of STAT5 phosphorylation using the Miltenyi Biotech CD19 microbead 
kit (Miltenyi Biotec, Auburn, CA).  
 
FACS-Sorting and Flow Cytometry 
 For flow cytometry cells were surface stained as described previously, (Zhang et 
al., 2005) and resuspended in PBSfor FACS sorting using the FACSVantage or 
FACSAria cell sorter (Becton Dickinson Immunocytometry Systems, [BDIS] San Jose, 
CA) or in PBS or 1% freshly prepared formaldehyde for analysis using the FACSCalibur 
flow cytometer. The following antibodies were used: kappa FITC, lambda FITC, IgM 
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FITC, IgM PE-Cy5 (Cychrome), CD19 APC, CD34 PerCP (BD Pharmingen), and IL-
7RPE (Beckman-Coulter Immunotech). 
 To assess and cytoplasmic mu (c) and Ki-67 expression, cells were first stained 
for surface markers then stained with anti-IgM antibodies to detect intracellular c with 
anti-Ki-67, or with an isotype-matched control antibody (BD Pharmingen) using the Fix 
and Perm Cell Permeabilization Kit (Caltag Laboratories, Burlingame, CA) as per 
manufacturer’s instructions.  
 For phospho STAT5 staining, cells were washed, fixed by incubating for 10 min 
with 1.5% paraformaldehyde at room temperature, pelleted by centrifugation and then 
paraformaldehyde was decanted off. To permeabilize, cells were vortexed, resuspended 
in 100% methanol at 4o C, and incubated for 10 min at 4o C or at -20o C overnight. Cells 
were pelleted by centrifugation, washed in PBS with 10% FBS and .01% sodium azide, 
then incubatedwith anti-phospho STAT5 PE ormouse IgG1 PE isotype control antibody 
(BD Pharmingen) for 30 min at room temperature.Cells were then washed and 
resuspended in staining buffer for flow cytometry. 
 To assess apoptosis, harvested cells were incubated with CD19 APC and the 
apoptosis indicator Annexin V FITC (BD Pharmingen) and prepared for flow cytometry 
according to manufacturers instructions. 
 Fluorescence intensity on all flow cytometry dot plots and histograms is shown on 
a log scale. Forward scatter (FSC) and percent maximum on histograms is shown in a 
linear scale.  
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ELISA 
Primary murine and human BM stromal cells (non-irradiated, 3.5 X 105 cells or 
sublethally irradiated [2000 rads], 7.0 X 105 cells) and murine MS5 and S17 stromal cells 
(non-irradiated, 3.5 X 105 cells) were plated in 200 μl of B cell medium (described above) 
without cytokines in individual wells of a 96-well plate. At weekly intervals 100 l of 
culture medium was harvested, filtered with a 0.2 μm filter, and 100 l of new media 
added to each well. Harvested supernatants were frozen, thawed, and IL-7 levels were 
detected using the Mouse IL-7 or Human IL-7 ELISA kit (R&D Systems). 
 
RT-PCR 
cDNA was prepared as described previously. Reverse-transcription (RT)-PCR to 
detect expression of IL-7 and 2 microglobulin was performed as described previously 
(Payne et al., 2003). Intron-spanning PCR primers for mouse and human IL-7 and 2 
microglobulin were as follows: human 2 microglobulin, 5’–CTC GCG CTA CTC TCT 
CTT TC–3’ and 5’ –CAT GTC TCG ATC CCA CTT AAC–3’ (330 base product); 
human IL-7, 5’–CTC CCC TGA TCC TTG TTC TG–3’ and 5’–TCA TTA TTC AGG 
CAA TTG CTA CC–3’ (151 base product); mouse2 microglobulin, 5’–TGC TAT CCA 
GAA AAC CCC TC–3’ and 5’–GGC ATG CTT AAC TCT GCA GG –3’ (259 base 
product); and mouse IL-7,5’ –TGG AAT TCC TCC ACT GAT CC–3’and 5’ –TGG 
TTC ATT ATT CGG GCA AT–3’ (160 base product): (Invitrogen Life Technologies, 
Paisley, PA). PCR conditions for human IL-7 and B2 were as follows: 10 min 94° C (1 
cycle); 94° C for 1 min, 50° C for 45 s, 72° C for 1 min and 15 s (5 cycles); 94° C for 1 
min, 55° C for 30 s, 72° C for 1 min and 15 s (29 cycles); 72° C for 5 min (1 cycle). PCR 
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conditions for mouse IL-7 and B2 were as follows: 15 min 95° C (1 cycle); 94° C for 30 
s, 55° C for 30 s, 72° C for 30 s (35 cycles); 72° C for 10 min (1 cycle). 
  cDNA was amplified for detection of CD19, EBF, Pax-5, and GAPDH 
(housekeeping gene) using the LightCycler 1.0 system real-time thermal cycler and the 
LightCycler FastStart DNA MasterPLUS SYBR Green kit (Roche Applied Science, 
Indianapolis, IN).  The small numbers of B lineage cells produced in the absence of IL-7 
activity precluded quantitative or semi-quantitative assessment of mRNA levels. The 
assessment of samples as positive for expression was based on 1) observing reproducible 
CT values in 2 replicates of the target gene where the GAPDH housekeeping gene 
showing a CT value of <30 cycles and 2) melting curve analysis showing superimposable 
melting curves across samples (including pre-B ALL cells as a positive control) and 
replicates for a given target gene in the absence of a superimposable product in negative 
control samples. Gene specific primer pairs were designed to span introns using Roche's 
Assay Design Center at www.roche-applied-science.com. Primers were as follows: 
GAPDH left 5'- GAG TCC ACT GGC GTC TTC AC; GAPDH right 5'- GTT CAC ACC 
CAT GAC GAA CA; CD19 left 5'- TCC ACC TGG AGA TCA CTG CT; CD19 
right  5'- GAC CTT CCA GCC ACC AGT C; Pax5 left   5'-  GTC CCA GCT TCC AGT 
CAC AG; Pax5 right  5'- GTG CTC ACC GAG GAC ACC; EBF left  5'-AGC TGC 
CAA CTC CCC CTA T; EBF right Lower  5' GGG AGG CTT GTG GAG GAG. Cycling 
parameters for all products: initial denaturation of 15 min at 95 degrees followed by 50 
cycles of 10 s at 95°C (denaturing); 5 s at 60°C (annealing); 15 s at 72°C (elongation). 
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Statistics and Data Analysis 
 In flow cytometry analysis, CD19+ B lineage cells and CD34+ HSC and 
progenitor populations were identified based on light scatter within a 
lymphocyte/progenitor light scatter gate and by expression of indicated surface markers.  
CD19–CD34– non-B lineage cells were identified based on light scatter within a living 
cell light scatter gate. Gates for determining percentages of cells positive for surface or 
intracellular markers were set on similarly gated CD19+ B lineage and CD19– cells in 
samples co-stained for CD19 and isotype-matched control antibodies. 
 Absolute numbers of culture progeny were determined by multiplying the fraction 
of cells within a particular subset (gated based on surface immunophenotype: CD19–, 
CD19+, CD19+CD34+IL-7R+, etc.) as a percentage of the cells within living cell light 
scatter (assessed by flow cytometry) by the total count of living cells generated in the 
culture (determined by hemocytometer count of cells negative for trypan blue staining or 
by flow cytometry using Caltag Counting Beads, [Caltag Laboratories]). Relative 
numbers of cells were determined by dividing the absolute number of cells of a particular 
type generated in each experimental condition by the absolute numbers of the same type 
of cells generated under control conditions (Figure 1, 2) or under control conditions plus 
anti-human IL-7 neutralizing antibodies (Figure 3, 8) in each independent experiment.  
 Each independent co-culture experiment represents an independent FACS sort of 
Lin–CD34+ BM or CB cells. In most cases adult BM in independent experiments is from 
different donors and in all cases CB in each independent experiment is pooled from 
multiple different donors. The hematopoietic cells for all conditions in each independent 
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experiment are aliquoted from a pool of cells FACS sorted at the same time from the 
same donor(s).  
 Flow cytometry analysis was performed using FlowJo software (Tree Star, Inc. 
Ashland, OR). Statistical analysis was performed using InStat3 software (GraphPad 
Software, Inc., San Diego, CA).  
 
Results 
Human-Only Co-Cultures Support In Vitro Human B Lymphopoiesis 
We developed a novel, human-only in vitro model of B cell development based 
on co-culturing nonfetal human hematopoietic progenitors with primary human stroma 
from adult BM (Figure 1A). Initial experiments used CB as a source of HSCs. While CB 
contains fetally-generated B cells, the stem cells present in CB are of interest because 
they give rise to B cells in the neonatal period and are increasingly used clinically as a 
source of HSCs for transplant. 
 B cell production in human-only cultures was compared to that in an established 
hybrid co-culture model (Crooks et al., 2000; Fluckiger et al., 1998; Hao, Smogorzewska, 
Barsky, & Crooks, 1998; Rawlings et al., 1997) consisting of human HSCs and murine 
S17 stroma. (Figure 1A).The emergence of human B lineage cells in human-only 
cultures paralleled that observed in hybrid cultures with murine S17 stroma. CD19+ B 
lineage cells were undetectable at one week and rare at two weeks (data not shown). At 
three weeks, CD19+ B lineage cells were detectable in both human-only and hybrid S17 
cultures under control conditions. However the frequency of B lineage cells was low in 
human-only cultures (Figure 1B, middle panel). With the addition of human IL-7, 
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human-only cultures produced a substantial population of CD19+ cells (Figure 1C, 
middle panel). At 3 weeks, the CD19+ B lineage cells present in human-only cultures, 
like those in hybrid cultures, were B cell precursors that did not express the cytoplasmic 
mu (c) Ig heavy chain (Figure 1B, C, middle and left panels) or surface immunoglobulin 
(Ig) as evidenced by the absence of kappa and lambda Ig light chains (data not shown). 
At 5 weeks, surface IgM+ cells were observed in both human-only (Figure 1B, C, right 
panels) and hybrid co-cultures (data not shown), and while the production of c+ and 
IgM+ B cells in human-only cultures was inefficient (~11 to 16% of CD19+ cells), it was 
consistently higher than that observed in hybrid co-cultures (~3% of CD19+ cells). These 
data provide evidence that co-cultures with primary human BM stromal cells support the 
production of human B cells and establish human-only cultures as an in vitro model for 
studying early stages of human B lymphopoiesis.  
 
Exogenous IL-7 Increases B Cell Production in Human-Only, but not Hybrid Co-
Cultures with Murine Stromal Cell Lines 
Using human-only and hybrid S17 cultures we characterized the effect of IL-7 on 
the production of human B cell precursors from CB HSCs. The addition of IL-7 to 
human-only, but not hybrid S17 cultures, significantly increased the production of 
CD19+ B lineage cells as compared to cultures without IL-7 (Figure 1B, C, D).Stem cell 
factor (SCF) had no significant effect on human B cell production, either alone or in 
combination with IL-7 in human-only or hybrid S17 cultures (Figure 1D). Thus, human-
only cultures revealed specific, IL-7 effects on human B cell production.  
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 A titration of IL-7 into human-only cultures showed that IL-7-induced increases 
in the production of B lineage cells were dose-dependent and specific to CD19+ cells, 
achieving maximal effects (43-fold) at 10 ng/ml of IL-7 (Figure 1E). In contrast, IL-7-
induced increases observed in hybrid S17 cultures at 3 weeks never averaged more than 
3-fold at any concentration of IL-7 (Figure 1E). These data provide evidence that IL-7 
induces a lineage-specific increase in the in vitro production of human B cell precursors 
that is not detectable in hybrid cultures with the murine S17 stromal cell line. 
 To determine if the inability to support IL-7-induced increases in human B cell 
production is specific to murine S17 stroma,we examined IL-7 effects in hybrid cultures 
with the MS-5 murine stromal cell line, another established model (Berardi et al., 1997; 
Nishihara et al., 1998; Ohkawara et al., 1998) for in vitro human B lymphopoiesis. As 
with S17 stroma, the addition of IL-7 did not significantly increase the production of 
human B cell precursors in hybrid MS-5 cultures (data not shown). However, substantial 
numbers of human B lineage cells were produced in the absence of exogenous IL-7 in 
hybrid cultures with murine S17 and MS-5 stroma (Figure 1B and data not shown) 
suggesting that another factor replaces human IL-7 in hybrid human-mouse co-cultures.  
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Figure 1 (Figure 4). Exogenous IL-7 increases B cell production in human-only, but 
not hybrid human-mouse co-cultures with murine stromal cell lines. (A) CB CD34+ 
cells that were negative for lineage markers (Lin–CD34+) were FACS-sorted and placed 
in co-culture with murine S17 stroma (left panels) or with sub-lethally irradiated, 
primary stroma from adult human BM (middle and right panels). Co-cultures were 
supplemented with IL-3 (first week only) and Flt3 ligand (3, F; control conditions), with 
or without the addition of IL-7 (5 ng/ml). Cells generated in cultures without IL-7 (B) 
or with IL-7 (C) were harvested at 3  or 5 weeks and stained for flow cytometry to assess 
for surface expression of the B lineage marker, CD19, and the presence of Ig heavy 
chain protein (c in the cytoplasm or surface IgM as indicated. Plots are gated on 
lymphocyte light scatter (gates not shown). CD19+ B lineage cells, as a percentage of 
the total cells in living cell light scatter (mean + SEM) for 4 independent experiments 
(see “Materials and Methods”) are given in left and middle panels. Percentages of IgM+ 
cells (mean + SEM) among total CD19+ cells at 5 weeks are given in right panels (8 
independent experiments). (D) Hybrid S17 (left panel) and human-only cultures (right 
panel) established under control conditions (3, F) as described above were 
supplemented with stem cell factor (S), with IL-7 (7) or with a combination of IL-7 and 
SCF and harvested at 3 weeks. Relative numbers of CD19+ and CD19– progeny were 
determined as described in “Materials and Methods”. Data shown are the means + SEM 
of 6 independent experiments. (* p = .012, ANOVA) (E) Hybrid S17 (left panel) and 
human-only cultures (right panel) initiated as described above were supplemented with 
increasing amounts of IL-7 as indicated. At 3 weeks culture progeny were harvested and 
relative numbers of CD19– and CD19+ cells were determined. Data shown are the 
means + SEM of 3 independent experiments with the exception of IL-7 at 100 ng/ml for 
which n=2. 
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IL-7 Activity is Critical for B Cell Production in Hybrid S17  
and MS-5 Cultures 
While early studies suggested that mouse IL-7 does not act on human cells 
(Goodwin et al., 1989; Kroemer, Kroncke, Gerdes, & Richards, 1998), more recent 
reports indicate that this is not the case (Barata et al., 2006; Johnson et al., 2005). A 
titration of anti-mouse IL-7 neutralizing antibodies, but not control antibodies, into 
hybrid cultures with murine stroma gave a dose-dependent reduction in human B cell 
production. At the highest concentrations, anti-mouse IL-7 neutralizing antibodies 
decreased B cell production from CB HSCs in hybrid S17 and MS-5 cultures by 10 and 
17 fold, respectively, as compared to co-cultures with no neutralizing antibody (Figure 
2A). The production of non-B lineage (CD19–) cells was not affected by anti-mouse IL-7 
neutralizing antibodies (Figure 2B). These data provide evidence that endogenously 
produced murine IL-7 is critical for the production of human B cell precursors in hybrid 
co-cultures with murine S17 and MS-5 stroma. 
 
Production of IL-7 by Primary Human and Murine BM Stroma 
To determine if stromal cells can serve as a source of IL-7 for in vivo human B 
cell development we examined the ability of primary human BM stroma to produce IL-7. 
IL-7 mRNA was detected in primary adult human BM stroma as well as primary murine 
BM stroma and murine stromal cell lines (Figure 2C). Next we compared the levels of 
IL-7 protein produced by murine and human stroma grown as in co-cultures. Weekly 
assessment of IL-7 by ELISA showed that primary adult human BM stroma produce low 
levels of IL-7 in vitro (ranging from .15 to 1.02 pg/ml during a five week culture period) 
 54 
and that IL-7 production is not affected by sub-lethal irradiation prior to plating for co-
culture.In contrast, the murine S17 and MS-5 stromal cell lines produced levels of IL-7 
that were at least 40 fold higher than that of primary human BM stroma (Figure 2D). 
However, in vitro IL-7 production by primary adult murine BM stroma, either with or 
without sub-lethal irradiation, was below the threshold of detection by the ELISA for 
mouse IL-7.Thus, the high level of in vitro IL-7 production by murine S17 and MS-5 
murine stromal cell lines does not reflect that of primary murine BM stroma that support 
in vivo IL-7-dependent B cell development in the mouse.  
 While the production of IL-7 from primary adult human BM stroma was 
detectable with the much more sensitive ELISA assay for human IL-7, those levels would 
have been below the sensitivity of the mouse IL-7 ELISA assay. These data provide 
evidence that primary human adult BM stroma produce IL-7 and that the level of in vitro 
IL-7 production by these cells is consistent with that observed for mouse, an animal 
model where the physiological relevance of IL-7 in B cell development has been 
demonstrated in vivo (Carvalho et al., 2001; von Freeden-Jeffry et al., 1995) 
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Figure 2 (Figure 5). B cell production in hybrid human-mouse co-cultures is dependent 
on murine IL-7 activity.FACS-sorted Lin–CD34+ CB cells were placed in hybrid co-
cultures with the murine S17 or MS-5 stromal cell lines and grown under control 
conditions (3, F) or control conditions supplemented with increasing amounts of anti-
mouse IL-7 neutralizing antibody or appropriate control antibody. Culture progeny were 
harvested at 3 weeks and absolute numbers of CD19+ and CD19– cells were determined 
as described in “Materials and Methods”. Absolute numbers of (A) CD19+ and (B) 
CD19– progeny generated under increasing control and anti-IL-7 antibody 
concentrations were compared to absolute numbers of CD19+ and CD19– cells 
generated under control conditions with no antibody. Relative numbers of CD19+ and 
CD19– cells (as compared to control conditions with no antibodies) are graphed. Data 
shown are the means + SEM for 3 independent experiments. (C) RT-PCR analysis using 
primers to detect IL-7 and 2 microglobulin (2m, ubiquitously expressed in nucleated 
cells). Analyses from three different adult mice (age range 6-12 weeks), from the murine 
S17 and MS-5 stromal cell lines (n=2) and from three different adult donors (age range 
20-30) are shown. (D) ELISA assessment of in vitro IL-7 production from indicated 
stromal cell lines (murine MS-5 and S17) or primary stroma. Stroma were plated under 
conditions similar to those used for co-cultures (3,5000 non-irradiated MS-5 or S17 cells 
per well and 7,000 sublethally irradiated primary human stroma per well in 96 well 
plates).For comparison, non-irradiated primary human stroma were also plated at 
3,500 cells per well. Media was harvested at weekly time points and assessed for IL-7 
by ELISA. Note the difference in threshold for sensitivity of mouse and human IL-7 
ELISA assays (murine: 3.5 - 8.3 pg/mL and human: <0.1 pg/ml). Primary adult murine 
BM stroma was also assessed for IL-7 production, however data is not shown as the 
levels of IL-7 production for both irradiated and non-irradiated primary adult murine 
BM stroma were below the sensitivity of the murine IL-7 ELISA. 
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IL-7 is Essential for the Production of B Lineage Cells from HSCs in Adult BM, 
but not from HSCs in CB 
To determine the extent to which B cell production is dependent on IL-7 and how 
this might change during ontogeny, we compared the production of B cell precursors 
from CB and adult BM HSCs in human-only cultures supplemented with anti-human IL-
7 neutralizing antibodies or with IL-7 (Figure 3A).A small population of CD19+ B 
lineage cells were generated from CB HSCs in cultures where IL-7 activity was 
neutralized. In contrast, B lineage cells derived from adult human BM were almost totally 
absent from cultures with anti-IL-7 antibodies, (Figure 3A). These data suggest that 
HSCs in CB but not adult BM have the potential for IL-7-independent human B 
lymphopoiesis.  
A comparison of human-only cultures initiated with CB and adult BM HSCs 
showed that IL-7-induced increases in both cases were similar in magnitude and specific 
to CD19+ cells (Figure 3B). However, the fraction of culture progeny comprised of B 
lineage cells was significantly less in cultures with HSCs from adult BM (Figure 3A). 
Therefore, we compared the generative capacities of CB and BM HSCs with respect to B 
lymphoid (CD19+) and non-B lymphoid (CD19–) progeny and the effects of IL-7 on 
these capacities (Figure 3C). For each Lin–CD34+ CB cell plated at culture initiation, an 
average of 5.7 CD19+ cells were generated at 3 weeks in human-only cultures with IL-7. 
Surprisingly, the average B lymphoid generative capacity of adult BM HSCs in identical 
conditions was only .11 CD19+ cells/HSC plated. The capacities of CB and adult BM 
HSCs to generate CD19– progeny were not significantly different and were unaffected by 
IL-7. Thus, the in vitro B lymphoid generative capacity of adult BM HSCs is more than 
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50 fold less thanthat of CB HSCs and this decreased generative capacity is specific to 
CD19+ cells. These data suggest thatIL-7 is more critical in maintaining human B cell 
production during adult life than during the neonatal period and that this may be due in 
part to a selective decrease in the B lymphoid generative capacity of HSCs in adult BM 
as compared to CB. 
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Figure 3 (Figure 6). B cell production from adult BM HSCs is profoundly dependent 
on IL-7. Human-only cultures were initiated with FACS-sorted Lin–CD34+ HSCs from 
CB or BM under control (3, F) culture conditions (see Figure 1) supplemented with 
exogenous human IL-7 or with neutralizing anti-human IL-7 antibodies as indicated. 
At 3 weeks culture progeny were harvested, counted, and stained for flow cytometry to 
detect expression of the B lineage marker, CD19.(A) Plots shown are gated on 
lymphocyte light scatter (gates not shown) and display equal numbers of cells. CD19+ 
B lineage cells, as a percentage of the total cells in living cell light scatter (mean + SEM) 
for 6 independent experiments are given. (B) Relative numbers of CD19+ and CD19– 
culture progeny at three weeks were determined as described in “Materials and 
Methods”.Data graphed are the increases in relative numbers of CD19+ and CD19– 
cells in cultures supplemented with exogenous IL-7 as compared to cultures 
supplemented with anti-IL-7 neutralizing antibodies (* p < .05, two-tailed paired t test). 
(C) Shown are CD19+ and CD19– generative capacities of CB and adult BM (donor 
age 20-30) HSCs under indicated conditions. Generative capacity was determined by 
dividing the absolute numbers of CD19+ or CD19– progeny generated at 3 weeks by 
the number of Lin–CD34+ HSCs plated at culture initiation. Data shown in panel C are 
the means + SEM of 6 independent experiments (** p < .01, two-tailed Mann-Whitney 
test). 
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Flt3 Ligand, but not TSLP is Required for the IL-7-Independent Production of B 
Lineage Cells from CB HSCs 
Studies of mouse B cell development suggest that TSLP, a cytokine that signals 
through the IL-7R and/or Flt3 ligand support the production of fetal/neonatal B cells in 
the absence of IL-7 (Jensen et al., 2008; Vosshenrich et al., 2003). Therefore we 
examined the extent to which the IL-7-independent production of B lineage cells from 
CB HSCs in our human-only cultures (Figure 3A, left panel) is dependent on Flt3 ligand 
and TSLP. The production of CD19+ cells from CB HSCs in human-only cultures 
supplemented with Flt-ligand and anti-IL-7 was compared to that observed with 
neutralizing anti-Flt-ligand, neutralizing anti-TSLP, or both.  As shown in Figure 4A, the 
addition of anti-TSLP antibodies had no effect on IL-7 independent production of B 
lineage cells, while CD19+ B lineage cells were essentially absent in cultures that 
contained anti-Flt3 ligand. These data show that Flt3 ligand, but not TSLP, is required for 
the IL-7-independent production of B lineage cells from CB HSCs that we observed in 
human-only cultures. 
 
B Lineage Cells Produced in the Absence of IL-7 are Capable of  
Subsequent IL-7 Responses 
IL-7 has been reported to increase the expression of CD19 on fetally-derived 
human B cell precursors (Wolf, Weng, Stieglbauer, Shah, & LeBien, 1993) and in the 
presence of IL-7, IL-7R+ B cell precursors are larger in size than B cell precursors that 
lack the IL-7R (Johnson et al., 2005). Consistent with this report, flow cytometry 
analysis showed that the B lineage cells generated from CB and BM HSCs in human-only 
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cultures expressed high levels of CD19 in the presence of IL-7, while cultures 
supplemented with anti-IL-7 neutralizing antibodies expressed much lower levels of 
CD19 (Fig 3A). Human-only cultures supplemented with IL-7 also showed higher 
frequencies of B cells that were larger (as indicated by increased forward scatter (FSC) in 
flow cytometry analysis) as compared to those produced in cultures with anti-IL-7 
neutralizing anti-bodies (see below).   
 To determine if the B lineage cells generated in the absence of IL-7 were capable 
of responding to IL-7 by upregulating CD19 and exhibiting increased cells size 
characteristic of cycling cells, we switched the culture progeny produced from CB HSCs 
in human-only cultures supplemented with anti-IL-7 neutralizing antibodies to human 
stromal cell cultures with IL-7 (anti-IL-7 to IL-7 switch cultures). After 3 days, anti-IL-7 
to IL-7 switch cultures were compared to cultures that had been switched to human 
stroma and anti-IL-7 (anti-IL-7 to anti-IL-7 switch cultures) or to human-only cultures 
that had been both initiated with and switched to IL-7 supplementation (IL-7 to IL-7 
switch cultures). The percentage of cells expressing high levels of CD19 (CD19HI) was 
increased in anti-IL-7 to IL-7 switch cultures (Figure 4B, middle panel), as compared to 
anti-IL-7 to anti-IL-7 switch cultures (Fig 4B, top panel), however, the percentages were 
not as high as those observed among B lineage cells that were produced under continuous 
exposure to IL-7 (Fig 4B, bottom panel, and Fig 4D). Cultures with B cell precursors that 
were never exposed to IL-7 (anti-IL-7 to anti-IL-7 switch cultures) showed a low 
frequency of cells with the high levels of FSC characteristic of cycling cells. The switch 
from anti-IL-7 to IL-7 resulted in a significant increase in the frequency of cells that were 
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FSCHI and an FSC histogram profile that was similar to that seen for IL-7 to IL-7 switch 
cultures.  
 IL-7R-signaling, partially via upregulation of EBF, has been reported to be a 
regulator of the transcription factor network that controls B cell development in the 
mouse (Singh et al., 2007). Expression of EBF in the absence of IL-7 in fetal and 
neonatal mice allows IL-7-indepdent B cell differentiation at early points in ontogeny 
(Kikuchi & Kondo, 2006). Therefore we were interested in examining expression of EBF 
and its downstream target PAX-5 (O'Riordan & Grosschedl, 1999) in the early B lineage 
cells generated in our human-only cultures. CD19+ cells generated in switch cultures 
were FACS-sorted for RT-PCR. Real time RT-PCR showed that B lineage cells 
generated in all three switch culture conditions expressed mRNA for CD19, PAX-5, and 
EBF, (Supplemental Data) however the small number of cells generated in cultures 
initiated with anti-IL-7 precluded a quantitative comparison of mRNA levels.  Taken 
together these data provide evidence that the CD19LO cells generated from CB HSCs in 
the absence of IL-7 are B lineage cells and have the capacity to respond to subsequent IL-
7 stimulation.  
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Figure 4 (Figure 7). IL-7-independent production of human B lineage cells is 
dependent on Flt3 ligand and produces CD19+ B lineage cells that can respond to IL-7. 
(A) Human-only cultures were initiated with FACS-sorted Lin–CD34+ HSCs from CB 
and grown with indicated cytokines (+), with cytokine-specific neutralizing antibodies 
(anti-) or without the indicated cytokine or its neutralizing antibody (-----). 
Corresponding isotype control antibodies were added to all wells in which a specific 
neutralizing antibody was not used but are not indicated in the graph—see “Materials 
and Methods”. At 3 weeks, culture progeny were harvested, counted, stained for CD19 
expression and the CD19+ generative capacity was determined as described in Figure 3 
legend. Data in panel A are the means + SEM of 2 independent experiments with 3 
replicates per experiment, (ANOVA, *** p < .001 for Bonferroni multiple comparisons 
post test) (B, C) Human-only cultures were initiated with FACS-sorted Lin–CD34+ 
HSCs from CB under control (3, F) culture conditions and supplemented with 
exogenous human IL-7 or with neutralizing anti-human IL-7 antibodies. After 3 weeks, 
culture progeny were harvested and then switched to a second human-only culture for 
3 days under indicated culture conditions  (IL-7 to IL-7, anti-IL-7 to anti-IL-7, or anti-
IL-7 to IL-7). After 3 days, switch cultures were harvested, stained to detect CD19, and 
the level of CD19 expression (panel B) and the size (as indicated by FSC, panel C) of 
gated CD19+ B lineage cells was determined by flow cytometry analysis. Histograms 
depicting CD19HI and FSCHI gates from a representative experiment are shown. D) 
Graphed are the percentages of total CD19+ cells that fall within CD19HI and FSCHI 
gates (mean + SEM for 6 independent experiments; * = p > .05, ** = p > .01, *** = p > 
.001, two-tailed paired t test 
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Supplemental Data (Figure 8).  Expression of B cell-specific transcripts by CD19+ 
cells produced in human-only cultures. Culture progeny generated in switch cultures as 
described in Figure 4B (IL-7 to IL-7, anti-IL-7 to anti-IL-7, or anti-IL-7 to IL-7) were 
harvested, stained for flow cytometry, and CD19+ B lineage cells were FACs-sorted. 
cDNA was prepared from sorted cells and from primary pre-B ALL cells (pos. ctrl.). 
Real time PCR to detect GAPDH (housekeeping gene), CD19, Pax-5, and EBF was 
performed as described in “Materials and Methods.” (A) Shown are the CT values for 
2 replicates of real time PCR amplification of indicated cDNAs from Pre-B ALL cells 
and from B lineage cells generated in indicated switch cultures. (B) Melting curves for 
final round (cycle 50) PCR products generated using primers to detect GAPDH,, CD19, 
PAX-5, EBF as indicated above each plot.  Each plot shows the superimposed melting 
curves (multiple colors) for PCR products from Pre-B ALL (2 replicates), for FACS-
sorted B lineage cells generated in each of the switch culture conditions (2 replicates 
each), and for a negative control that contained water and no cDNA (1 replicate, color 
as indicated). Note that all melting curves peak at or near 86 to 88 degrees C as expected 
for these primers. (C) Shown are additional replicates from independent experiments of 
positive (Pre-B ALL) and negative control (water) samples using the PAX-5 primer pair 
which consistently generated a primer artifact peak. The melting curve of the primer 
artifact showed a consistent peak (~80 degrees C) that was easily distinguishable from 
the melting curve peak observed in the positive control (~86 degree C) and in CD19+ 
cells generated in all culture conditions as shown in the lower left plot in panel B. 
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IL-7 Directly Targets B Cell Precursors in Human-Only Cultures 
To identify the cellular targets of IL-7 we used flow cytometry to examine IL-
7R expression among cells present during in vitro B lymphopoiesis (Figure 5A). IL-
7R was not detectable on primary human BM stromal cells used in co-cultures (Figure 
5B).Approximately 35% of CD19+ B cell precursors produced in co-culture expressed 
the IL-7R, regardless of whether they arose from HSCs in CB or adult BM or whether 
IL-7 was present (Figure 5C and Figure 5D, right panel).  We gated CD19– cells into a 
CD34– subset that included more mature non B-lineage cells and into a CD34+ subset 
that included HSCs and progenitors present in the 3-week human-only cultures. Of the 
CD19–CD34– non B lineage cells generated from CB and BM HSCs in human-only 
cultures, 3-12 % expressed the IL-7R (Figure 5C, left panel) while 4-14% of the of the 
CD19–CD34+ HSC and progenitor subset was IL-7R+ (Figure 5C, middle panel). The 
percentage of cells in each subset that expressed IL-7R was not significantly different in 
cultures initiated with CB and BM HSCs, and the presence or absence of IL-7 activity 
had no significant impact on the percentage of cells expressing the IL-7R in any of the 
subsets (Figure 5D). These data show that CD19+ B cell precursors represent the major 
IL-7R+ population in human-only cultures and are therefore a potential IL-7 target 
during in vitro B cell development.  
 To determine if IL-7 acts directly on B cell precursors we used flow cytometry to 
assess phosphorylation of STAT5, an event downstream of IL-7R signaling (Lin et al., 
1995). CD19+ B cell precursors were isolated from human-only cultures and assessed by 
flow cytometry for purity (based on CD19 expression) and for IL-7Rexpression (Figure 
5E, left panel) and then for STAT5 phosphorylation following incubation with or without 
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IL-7 (Figure 5E, right panel). Phosphorylated STAT5 was detected in B cell precursors 
incubated with IL-7, but not in B cell precursors cultured without IL-7 (Figure 5E, right 
panel).The percentage of B cell precursors positive for phosphorylated STAT5 following 
incubation with IL-7 was virtually identical to the percentage of cells expressing IL-7R 
(Figure 5E, compare left and right panels). These data provide evidence that B cell 
precursors are directly targeted by IL-7 in human-only cultures.  
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Figure 5 (Figure 9). IL-7 directly targets B lineage cells.  (A) Human-only cultures were 
initiated with FACS-sorted Lin–CD34+ HSCs from CB or BM under controlconditions 
(3, F) and supplemented with anti-IL-7 neutralizing antibodies or exogenous human IL-7. 
At 3 weeks culture progeny were harvested and stained for flow cytometry to detect co-
expression of CD19, IL-7R and CD34. Cells were gated into CD19+, CD19–CD34– and 
CD19–CD34– subsets as indicated. Plot shown is from a CB culture with IL-7. (B) Flow 
cytometry analysis of IL-7R expression among primary human BM stromal cells used in 
human-only cultures. Data is representative of flow cytometry analysis of stroma from 
three different donors. (C) Flow cytometry analysis showing IL-7R vs. CD19 expression 
for human-only cultures of CB or BM HSCs supplemented with IL-7. Insets show isotype 
antibody control vs. CD19 staining. Plots are gated on lymphocyte light scatter (gates not 
shown) and display equal numbers of cells. (D) The percentages of cells in indicated 
subsets (gated as shown in panel A) that express IL-7R are graphed. Data are from 3-
week, human-only cultures of CB and BM HSCs supplemented with anti-IL-7 or IL-7 as 
indicated. Percentages are the means + SEM of 5 (CB) or 3 (BM) independent experiments 
with 8 and 6 total replicates, respectively. (E) Human-only cultures were initiated with 
CD34+ HSCs from CB under control conditions supplemented with exogenous human IL-
7. At 3 weeks, culture progeny were harvested and CD19+ B lineage cells were isolated by 
magnetic separation. Aliquots of purified B cell precursors were co-stained for expression 
of CD19 and IL-7R or with isotype-matched control antibodies (left panel). Plots shown 
are gated on events falling within lymphocyte light scatter. Quadrants were set based on 
isotype control staining (inset) and percentages of cells in each quadrant are shown. The 
remaining purified precursors, after a minimum of 3 hours removal from IL-7, were 
incubated with or without exogenous human IL-7 for 1 hour and then stained for flow 
cytometry with an antibody to detect phosphorylated STAT5 or an isotype-matched control 
antibody as describe in “Materials and Methods”. The percentage of cells positive for 
phospho-STAT5 staining, based on isotype control staining (overlay) are shown (right 
panel). Data shown is representative of two independent experiments. 
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IL-7-Induced Increases in B Cell Production are Mediated Through  
Increased Proliferation of B Cell Precursors 
To determine if increased cell survival is involved in the IL-7-induced increases 
observed in our co-cultures, we examined the effect of IL-7 on apoptosis among culture-
generated human B cell precursors. Human-only cultures initiated with CB HSCs were 
harvested at 3 weeks and CD19+ cells (either enriched or unseparated from CD19– cells) 
were placed in co-culture with fresh human stroma and supplemented with anti-IL-7 
neutralizing antibodies, control antibodies, or IL-7.Cells were harvested at daily time 
points and flow cytometric analysis of staining with the Annexin V apoptosis indicator 
was used to determine the percentages of CD19+ B cell precursors undergoing apoptosis. 
IL-7 had no effect on the percentages of CD19+ that were Annexin V+, whether they 
were in co-culture alone or together with CD19– cells (data not shown). Similarly IL-7 
had no effect on apoptosis among in vivo-generated B cell precursors (CD19+K/L–) that 
were FACS sorted from adult BM and assessed in identical assays (data not shown). 
These results suggest that IL-7 does not mediate protection from apoptosis and that 
increased survival of CD19+ B cell precursors is unlikely to be a major mechanism by 
which IL-7 increases human B cell production.  
 To determine if increased proliferation is a mechanism for IL-7-induced increases 
in human B cell production, we used flow cytometry to examine expression of the Ki-67 
proliferation antigen in cells harvested from human-only cultures supplemented with IL-7 
or with anti-IL-7 neutralizing antibodies (Figure 6A). IL-7 did not change the percentage 
of CD19– cells that were Ki-67+ in cultures of CB or BM HSCs (Figure 6A, B). In 
contrast, in 
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CB cultures the percentage of CD19+ cells expressing the Ki-67 was significantly higher 
with IL-7 supplementation (Figure 6B). Cultures of BM HSCs generated too few B cell 
precursors to be assessed for Ki-67 when anti-IL-7 antibodies were added. However, the 
percentage of B cell precursors expressing Ki-67 was the same in CB and BM cultures 
with IL-7 (Figure 6 A, B). 
 To verify that the increases in proliferation observed in cultures supplemented 
with IL-7 were due to the direct action of IL-7 on B cell precursors, we compared Ki-67 
expression (Figure 6C) and size (indicated by FSC, Figure 6D) in IL-7R+ and IL-7R– 
B cell precursors generated in cultures with IL-7. For both CB and BM cultures, average 
cell size and the percentages of cells expressing Ki-67 was significantly higher for IL-
7R+ than for IL-7R– B cell precursors. These data provide further evidence that IL-7 
increases the production of human B lineage cells through increased proliferation due to 
direct targeting of B cell precursors by IL-7. 
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Figure 6 (Figure 10). IL-7-induced increases in the production of B lineage cells are 
mediated through increased proliferation. Human-only cultures were initiated with 
FACS-sorted Lin–CD34+ HSCs from CB or BM under control conditions (3, F) and 
supplemented with anti-human IL-7 neutralizing antibodies or with exogenous human 
IL-7. At 3 weeks, culture progeny were harvested, counted, and stained for surface 
expression of IL-7R and/or the B lineage marker, CD19. Surface-stained cells were 
fixed, permeabilized and stained with an antibody specific to the Ki-67 proliferation 
antigen or an isotype-matched control antibody. (A) The plots shown are gated on living 
cell light scatter and display equal numbers of cells. Gates shown were set based on 
isotype control staining among CD19+ and CD19– cells (insets). (B) Graphed are the 
percentages of CD19– (left panel) and CD19+ cells (right panel) positive for the Ki-67 
proliferation antigen (mean + SEM) for n=5 (BM) and n=8 (CB) experiments. In co-
cultures with BM HSCs and with anti-IL-7 neutralizing antibodies, too few B cells were 
generated to assess Ki-67 expression (ND, not done). (C, D) At 3 weeks co-cultures 
supplemented with IL-7 were harvested, counted, and stained for surface expression of 
IL-7R and/or the B lineage marker, CD19. Surface stained cells were fixed, 
permeabilized and stained with an antibody specific to the Ki-67 proliferation antigen 
or an isotype-matched control antibody. (C) The expression of Ki-67+ among gated 
CD19+IL-7R– and CD19+IL-7R+ cells (gates not shown) are plotted in histograms (left 
panels) and graphed (right panel). (D) The forward scatter (FSC, an indicator of cell 
size) of gated (gates not shown) CD19+IL-7R– (shaded) and CD19+IL-7R+ (overlay) 
cells are plotted in histograms (left panels). The relative forward scatter of CD19+IL-
7R+ cells as compared to CD19+IL-7R– cells  is graphed in the panel at right. Data 
shown in panels C and D are the mean + SEM for 5(CB) or 3 (BM) independent 
experiments. (* p < .05;*** p < .001, paired t test). 
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Expression of the IL-7R in Context of Human B Cell 
 Development In Vivo 
To determine whether the IL-7 targets that we identified in our human-only 
cultures are reflective of human B cell development in vivo, we examined the expression 
of IL-7R in early B lineage cells that were generated in vivo in adult human bone 
marrow. The average frequency of IL-7R+ cells among in vivo-generated B cell 
precursors (CD19+K/L–) in adult human BM (Figure 7A, Table 1) was similar (32%) to 
that observed for B cell precursors generated in vitro (35%) from HSCs in CB and adult 
BM in human-only cultures (Figure 5C, D). The percentages of in vivo-generated 
CD19+K/L– B cell precursors that we assessed in human subjects (Table 1) exhibited a 
broad range in the percentage of cells that were IL-7R+ (17%-56%) and showed no 
obvious correlation with age, gender, or race, suggesting that there is substantial natural 
variation among adult individuals. Thus, the IL-7R+ population of B cell precursors 
observed in human-only cultures is reflective of in vivo B cell development in adult 
human BM and suggests a physiological role for IL-7 in human B cell development.  
 A substantial portion of the B cell precursors generated in human-only cultures 
initiated with CB and BM HSCs were IL-7R–. This was also the case for CD19+K/L– 
cells in adult BM. To determine if the expression of IL-7R correlated with the 
expression of developmental markers during in vivo B cell differentiation we examined 
IL-7R expression among developmental subsets of CD19+ K/L– B cell precursors 
identified based on expression of CD34+ or cFigure 7B). The percentages of IL-7R+ 
cells were similar for all developmental subsets (c+, c–, CD34–, and CD34+) of 
CD19+K/L– cells.  Thus, the expression of IL-7Ramong B cell precursors produced in 
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vivo does not appear to correlate with particular stages of development that can be 
identified based on expression of CD34 or with successful rearrangement of the Ig heavy 
chain as indicated by the expression of c (Figure 7B).  
 
 
 
 
.  
Figure 7 (Figure 11). The distribution of IL-7R+ cells in adult human B cell precursor 
populations produced in vivo. (A) Primary adult human BM mononuclear cells, either 
fresh or frozen and then thawed, were stained for flow cytometry to assess co-expression 
of CD19, the kappa and lambda light chains, IL-7Rand either CD34 or the 
cytoplasmic mu (c) Ig heavy chain. CD19+ B lineage cells falling within lymphocyte 
light scatter (gates not shown) that were negative for the kappa and lambda light chains 
(CD19+K/L–) were gated as shown (left panel) and the percentage of cells expressing 
of IL-7R was determined (right panel, n=10).CD19+K/L– cells were gated into a 
CD34+ and CD34– subsets (n=7) or into c– and c+ subsets (n=2). Percentages of 
total CD19+K/L– or of the cells in each subset that were IL-7R are graphed. 
Percentages are the mean + SD from the indicated (n) numbers of donors 
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Table 1. Expression of IL-7R by in vivo-generated CD19+ K/L– B cell precursors 
  Donor Information 
Donor % IL-7R+ Age Gender Race 
1 27.9 ------ ------ ----------- 
2 24.1 ------ ------ ----------- 
3 38.6 49 Female Caucasian 
4 56.5 25 Male Caucasian 
5 26.4 25 Male Caucasian 
6 50.6 22 Female African American 
7 23.2 25 Male Caucasian 
8 22.6 22 Male African American 
9 17.4 20 Male African American 
10 32.8 19 Female Caucasian 
Avg 32.0    
 
Precursor Populations Targeted by IL-7-Induced Expansion 
 in Human-Only Cultures 
In the mouse, IL-7R signaling has been associated with distinct differentiation and 
proliferation signals. Thus, while the expression of IL-7R may not correlate with 
markers of development in CD19+ B cell precursors, it is possible that IL-7 may directly 
target distinct developmental populations of IL-7R+ B lineage precursors for 
proliferation or for differentiation. To identify the developmental targets of IL-7-induced 
proliferation we examined IL-7-induced increases and expression of the Ki-67 
proliferation antigen in four subsets that include developmentally sequential populations 
of B cell precursors. FACS analysis of the cells present at 3 weeks in human-only 
cultures was used to identify four populations (Figure 8A): 1) The most primitive IL-7R– 
HSCs and progenitors (HSC) through which IL-7 effects might be indirectly mediated, 2) 
IL-7R+ progenitors (IL-7R+ P) that would include the earliest CD19– lymphoid-
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committed progenitors that express the IL-7R(Hao et al., 2001)  (Ryan et al., 1997)  ; 3) 
CD34+ pro-B cells (CD34+ B) and 4) CD34– pro-B cells (CD34– B).  
 Human-only cultures initiated with Lin–CD34+ cells from CB and BM and 
supplemented with IL-7 showed significantly increased numbers of cells in the CD34+ B 
and CD34– B subsets at three weeks when compared to cultures with anti-IL-7. The 
relative numbers of CD34+ B cells increased by only 5 to 14-fold (CB and BM cultures 
respectively) when IL-7 was present while CD34– B cells went up by 194 to 90-fold (CB 
and BM cultures respectively).  In contrast, the relative numbers of HSCs, and IL-7R+ P 
were not significantly increased in cultures with IL-7 (Figure 8B).  Consistent with the 
IL-7 effects that we observed on cell numbers, CB cultures supplemented with IL-7 
showed significantly higher percentages of Ki-67+ cells among the CD34+ B and CD34– 
B, but not among the HSC or IL-7R+ P subsets (Figure 8C).  The percentage of Ki-67+ B 
cells among CD34– B cells in BM cultures was similar to that observed in CB cultures, 
however there were too few CD19+ cells to assess in Ki-67 expression in any BM 
cultures with anti-IL-7 or in the CD34+ B cells in BM cultures where IL-7 was present 
(Figure 8C, right panel). Taken together these data provide evidence that IL-7 targets 
both CD34+ and CD34– pro-B cells for increased proliferation. In contrast, in our culture 
model we were unable to detect any significant changes in proliferation due to IL-7 
effects among developmental subsets that would include CD19– B cell precursors.  
 In Figure 3 we showed that IL-7 is particularly critical for the production of B 
lineage cells from adult BM because the capacity of adult BM to generate B lineage cells 
is greatly reduced as compared to CB. To get a better understanding of the dynamics and 
potential mechanisms that might be responsible for the changes in B cell development 
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that occur during ontogeny, we compared the ability of CB and adult BM to generate the 
developmental subsets observed in vitro in human-only cultures. In cultures with adult 
BM the HSC generative capacity was about half, and the IL-7R+ P generative capacity 
about 10 fold less than that observed for CB cultures (Figure 8D, Note the 10X scale 
reduction in the right panel).  In cultures with IL-7, the adult BM generative capacities 
for cells in the CD34+ B and CD34– B subsets were ~40-fold and ~50-fold less, 
respectively than those observed for CB. While BM cultures generated detectable CD19– 
subsets, and the capacity to generate these cells was unaffected by IL-7, B lineage 
precursors that reached the CD19+ stage of development were essentially absent in 
cultures with anti-IL-7. These data suggest that there is a progressive loss of generative 
capacity during the course of B lineage differentiation in adult BM, as compared to CB 
and that as a consequence of this reduced B lineage generative capacity, IL-7 is more 
critical for B cell development from HSCs in adult B and that as a consequence of this 
reduced B lineage generative capacity, IL-7 is more critical for B cell development from 
HSCs in adult BM.
 80 
 
 
 
 81 
 
Figure 8 (Figure 12). Precursor populations targeted by IL-7-induced expansion. A) 
Flow cytometry analysis of human-only cultures was used to identify four subsets of 
cells that include developmentally sequential precursors to mature B cells: HSCs and 
IL-7R– Progenitors (HSC), IL-7R+ progenitors (IL-7R+ P), CD34+ pro-B cells 
(CD34+B), and CD34– pro-B cells (CD34–B). Surface immunophenotypes used to 
identify each population in human-only cultures are indicated at the bottom of the panel. 
Human-only cultures initiated with Lin–CD34+ cells from CB and BM and 
supplemented with anti-IL-7 or with exogenous IL-7 were harvested at 3 weeks, and 
counted and stained for flow cytometry to detect surface CD19, CD34, IL-7R and an 
additional surface or intracellular marker. Cells in each subset were gated as shown in 
Figure 5A, C and based on isotype control staining. (B) Relative numbers of cells in 
each subset were determined as described in “Materials and Methods”. Data graphed 
are the increases in relative numbers of cells in each subset in cultures supplemented 
with exogenous IL-7 as compared to cultures supplemented with anti-IL-7 neutralizing 
antibodies. Data shown are from 3 independent experiments and 6 total replicates. (C) 
The percentage of cells in each gated subset that are positive for expression of the Ki-
67 proliferation antigen are graphed. Data shown are the means + SEM obtained from 
3-7 independent experiments (D) The ability of CB and BM Lin–CD34+ cells to 
generate cells in each subset under indicated conditions was determined by dividing the 
absolute numbers of progeny in each subset, generated at 3 weeks, by the number of 
Lin–CD34+ HSCs plated at culture initiation.  Data shown were obtained from 3 
independent experiments and 6 total replicates (HSC, IL-7R+ P) or from 6 independent 
experiments (CD34+ B and CD34– B). (* p < .05, ** p <. 01, *** p < .001, **** p < 
.0001, two-tailed paired t test). 
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Discussion 
Defining the role of IL-7 in human B cell development has been difficult for 
several reasons. First, most early studies of IL-7 and human B cell development used 
fetal hematopoietic sources. This is particularly relevant as subsequent murine studies 
revealed that IL-7-dependent B lymphopoiesis is linked with ontogeny–only in the adult 
mouse does B cell development become dependent on IL-7. Thus, differences in fetal and 
adult B cell development have been interpreted as fundamental differences in mouse and 
human B lymphopoiesis. Second, studies of humans that are defective in components of 
the IL-7R signaling pathway are hampered by limitations in the number, type, and 
quantity of specimens available for assessment of IL-7 function. Third, studies of 
nonfetal B lymphopoiesis were hampered by the lack of an in vitro model of human B 
cell development that reconstitutes the human BM stroma microenvironment without the 
confounding factors introduced by murine stromal cell lines. Here we describe a novel 
human-only model of in vitro B cell development based on co-culturing HSCs on 
primary human BM stroma. We used this model to examine the role of IL-7 in human B 
lymphopoiesis from HSCs in adult BM and from the HSCs in CB that give rise to B cells 
during the neonatal period.  
 Using the human-only culture model we show that IL-7 increases the production 
of human B cell precursors from HSCs in CB and adult BM by more than 60-fold as 
compared to cultures with anti-IL-7 neutralizing antibodies (Figure 3). IL-7-induced 
increases were dose-dependent (Figure 1E), specific to CD19+ cells (Figure 1E and 5), 
and mediated through increased proliferation (Figure 6), but not increased cell survival 
(data not shown). Expression of the IL-7Rand the induction of STAT5 phosphorylation 
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following stimulation with IL-7 (Figure 5) indicate that IL-7 acts directly on CD19+c– 
cells present in 3-week human-only cultures (Figure 1) to expand both the CD34+ and 
CD34– pro-B cell compartments (Figure 8).  
 The IL-7-induced increases in B cell precursors that we observed in human-only 
cultures were not detectable in hybrid cultures where human HSCs were co-cultured on 
murine S17 or MS-5 stromal cell lines (Figure 1, 2). The absence of IL-7 effects that we 
and others (Rawlings et al., 1995) (Nishihara et al., 1998) have observed in hybrid 
cultures is likely due to high IL-7 production by MS-5 and S17 stromal cell lines (>40-
fold that of primary human or murine BM stroma [Figure 2]) since human B cell 
production was reduced up to 17 fold (Figure 2A) by high levels of anti-mouse IL-7 
neutralizing antibodies. Thus, the human-only model revealed IL-7 effects on human B 
cell development that were not easily detectable in hybrid human-mouse co-cultures.  
 A critical role for IL-7 in adult B cell development has been demonstrated in vivo 
in the mouse model (von Freeden-Jeffry et al., 1995)-(DiSanto et al., 1995; Peschon et 
al., 1994).  IL-7 expression by primary murine BM stroma (Figure 2) and the level of IL-
7 that elicits in vitro B cell precursor responses (1 ng/ml) in the mouse (Medina & 
Kincade, 1994) are consistent with what we see during in vitro human B cell 
development (Figure 1, 2). The expression of IL-7R by B cell precursors (Figure 7) and 
of IL-7by stromal cells (Figure 5) in primary human BM suggests that the IL-7 effects 
we observe in vitro are physiologically relevant for in vivo human B cell development. 
Indirect evidence for the in vivo role of IL-7 in human B cell development comes from 
patients with T cell lymphopenia in whom endogenous IL-7 is upregulated and expansion 
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of the immature B cell pool correlates with increased serum levels of IL-7 (Malaspina, 
Moir, Ho, et al., 2006), (Malaspina, Moir, Chaitt, et al., 2006). 
Data obtained using our human-only culture model provide the first evidence that 
human B cell production from HSCs in adult BM is dependent on IL-7. Robust IL-7-
independent B cell production has been reported in human fetal BM (J. A. Pribyl & 
LeBien, 1996). In the absence of IL-7, we observed that HSCS in CB, but not BM 
consistently give rise to a small population of CD19LO B lineage cells (Figure 3) that 
express EBF and PAX-5 at three weeks and differentiate to generate very small numbers 
of IgM+ B cells at 5 weeks (Figure 1). When switched to IL-7 at 3 weeks, CD19LO cells 
generated in the absence of IL-7 respond by upregulating CD19 and exhibiting increased 
cell size that is characteristic of cycling cells (Figure 4B-D). Studies of B cell 
development in the mouse model suggest that IL-7-independent expression of EBF 
allows early B lineage differentiation (but not expansion unless IL-7 is present) during 
the fetal and neonatal period.  This results in what has been described as a 
“developmental switch” in stem cells with IL-7-independent B cell production occurring 
through the first two weeks of neonatal life, but not in the adult (Kikuchi & Kondo, 
2006). Our data showing that human B cell development from HSCs in adult BM is IL-7-
dependent, coupled with our characterization of B lineage cells generated from CB in the 
absence of IL-7, provide the first evidence that that such a “developmental switch” may 
also occur in human B lymphopoiesis.  
We found that adult BM, as compared to CB, shows a reduction of in vitro 
generative capacity that is progressively more profound in developmentally sequential 
populations (Figure 3, 8). The ability of adult BM to generate HSCs, IL-7R+ progenitors, 
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and pro-B cells after 3 weeks in human-only cultures with IL-7 was reduced by half, 10- 
and 50-fold, respectively, of that observed for CB (Figure 8D). Indeed the CD19+ 
generative capacity of BM HSCs in the presence of IL-7 was similar to that of CB HSCs 
in the absence of IL-7 activity (Figure 3). The B lymphoid-specific decrease in generative 
capacity that we observed for human HSCs in adult BM, as compared to CB, is consistent 
with a selective loss of B lymphoid generative capacity observed in xenograft transplant 
models and in the clinical transplant setting (Arakawa-Hoyt et al., 1999; Inoue et al., 
2003).  
The decline in IL-7-dependent B lymphoid generative capacity that we have 
observed in adult versus fetal B cell development suggests, that a mechanism other than 
the “developmental switch” observed in the mouse model may contribute to the decline 
in IL-7-independent B cell production that occurs during the progression to adulthood. It 
is possible that IL-7-induced expansion of the pro-B compartment (absent in the IL-7-
indepdent B cell production observed by Kikuchi et al.) is essential for B lymphopoiesis 
from adult HSCs because of their reduced generative capacity. Further studies will be 
needed to determine the extent to which the decline in B cell generative capacity 
contributes to the loss of IL-7-independent B lymphopoiesis in adult humans and mice 
and whether B cells arising from IL-7-dependent and IL-7-independent pathways in 
humans are functionally distinct.  
In summary, data obtained using our human-only culture model provide the first 
evidence that B cell development from HSCs in adult BM is dependent on IL-7 and 
characterize the progressive decline in developmentally sequential populations of B cell 
precursors that correlates with B cell production that is the dependent on IL-7. These 
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studies have implications for immune reconstitution following stem cell transplant with 
CB versus BM in the clinical setting. 
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Abstract  
The cytokine, TSLP, stimulates in vitro proliferation of human fetal B cell precursors, 
however, its in vivo role during normal human B lymphopoiesis is unknown. Genetic alterations 
that cause overexpression of the TSLP receptor component, CRLF2, lead to B cell acute 
lymphoblastic leukemia (CRLF2 B-ALL), implicating the TSLP-CRLF2 pathway in 
leukemogenesis. The utility of classic patient-derived xenografts (PDX) for in vivo studies of the 
TSLP-CRLF2 pathway in normal and malignant human B lymphopoiesis are limited because 
available data suggest that mouse TSLP does not activate human CRLF2-mediated signals. First, 
we show that mouse TSLP does not induce activation of CRLF-2 downstream pathways 
(JAK/STAT5 and PI3K/AKT/mTOR) that are activated by human TSLP (hTSLP) in CRLF2 B-
ALL cells. Next, we engineered xenograft mice to produce hTSLP (+T mice) by injection with 
stromal cells transduced to express hTSLP. Control (–T) mice were produced using stroma 
transduced with control vector. Normal serum levels of hTSLP were achieved in +T mice, while 
hTSLP was undetectable in –T mice. PDX generated from +T as compared to –T mice showed a 
3-6 fold increase in normal human B cell precursors that was maintained through later stages of B 
cell development. Gene expression profiles in CRLF2 B-ALL from +T PDX indicate increased 
mTOR pathway activation and are more similar to the original patient sample than those from –T 
PDX. The novel +T/–T xenograft model developed here provides a preclinical model for 
understanding the TSLP-CRLF2 pathway in B lymphopoiesis and identifying treatments for 
CRLF2 B-ALL.  
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Introduction  
TSLP is an IL-7-like cytokine that plays key roles at several points in normal 
hematopoietic cell development and function.(Ito et al., 2005; Siracusa et al., 2011; Ying et al., 
2005; Zhou et al., 2005) The role of TSLP in B lymphopoiesis has been evaluated almost 
exclusively in mice.(Osborn et al., 2004; Ray, Furlonger, Williams, & Paige, 1996; Reche et al., 
2001; Sims et al., 2000) Knowledge of TSLP in normal human B-cell development is limited to a 
single in vitro study showing that TSLP increases production of fetal B cell precursors.(Scheeren 
et al., 2010) Genetic alterations that cause overexpression of the TSLP receptor component, 
CRLF2, have been linked to B cell acute lymphoblastic leukemia (ALL), thus implicating the 
TSLP pathway in leukemogenesis (Cario et al., 2010; Chapiro et al., 2010; Russell et al., 2009; 
Yoda et al., 2010). The low homologies of murine and human TSLP and CRLF2 
(~40%)(Quentmeier et al., 2001; Tonozuka et al., 2001) suggest the need for novel models to 
study the in vivo role of TSLP in normal and malignant human B lymphopoiesis.  
ALL is the most common childhood malignancy and primarily involves the B-lineage (B-
ALL). Although cure rates approach 90%, approximately 10-20% of patients still relapse.(Hunger 
et al., 2012; Raetz & Bhatla, 2012) Genomic profiling has identified several high-risk B-ALL 
subtypes that are chemo-resistant. (Chen et al., 2012; Mullighan, 2011; Mullighan et al., 2009; 
Mullighan et al., 2007) Included is CRLF2 B-ALL, a leukemia with genetic alterations causing 
over-expression of the CRLF2 protein on the surface of B-ALL cells.(Cario et al., 2010; Chapiro 
et al., 2010; Russell et al., 2009; Yoda et al., 2010) CRLF2 and the IL-7 receptor alpha chain (IL-
7R) together form the TSLP receptor signaling complex (Figure 1A).(Park et al., 2000; Reche et 
al., 2001) Binding of TSLP induces CRLF2 and IL-7R dimerization leading to activation of the 
JAK-STAT5(Rochman et al., 2010; Wohlmann, Sebastian, Borowski, Krause, & Friedrich, 2010) 
and the PIK3/AKT/mTOR pathways, (Zhong et al., 2012; Zhong et al., 2014) as demonstrated in 
CRLF2 B-ALL. (Tasian et al., 2012) The finding that JAK kinases are mutated in CRLF2 B-
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ALL(Harvey et al., 2010) suggested that CRLF2 and mutated JAK cooperate to induce 
constitutive STAT5 activation in CRLF2 B-ALL.(Malin et al., 2010; Roll & Reuther, 2010) 
However, approximately half of CRLF2 B-ALL, lack JAK mutations. Thus, the role of TSLP in 
the leukemogenesis of CRLF2 B-ALL remains unclear and the mechanisms for its contribution to 
chemoresistance are unknown. 
The genetic landscape produced by inherited germline variations contributes to 
leukemogenesis and disease outcome (Moriyama, Relling, & Yang, 2015) and is a biological 
component that contributes to racial, ethnic and other health disparities in ALL (Lim, Bhatia, 
Robison, & Yang, 2014). This is particularly relevant in CRLF2 B-ALL which occurs five times 
more often in Hispanic children than others (Harvey et al., 2010) and comprises more than half of 
the ALL cases in children with Down Syndrome (Hertzberg et al., 2010; Mullighan et al., 2009; 
Russell et al., 2009). Patient-derived xenograft (PDX) models produced by injecting human cells 
into immune deficient mice provide in vivo preclinical models for understanding disease 
mechanisms and identifying effective therapies in context of the range of genetic landscapes 
present in the human population. However, engineered cellular models (Reche et al., 2001) 
suggest that mouse TSLP (mTSLP) is species-specific and unlikely to stimulate CRLF2-mediated 
signaling in human cells (Park et al., 2000; Reche et al., 2001). Given the role of TSLP in 
activating the CRLF2 pathway (Tasian et al., 2012) and the identification of CRLF2 as a 
biological component of health disparities in CRLF2 B-ALL (Harvey et al., 2010; Hertzberg et 
al., 2010; Mullighan et al., 2009; Russell et al., 2009), it is important that studies to identify 
disease mechanisms and potential therapies for this leukemia be performed in preclinical models 
that provide human TSLP (hTSLP).  
Our goal was to develop and validate a xenograft model that can be used to study the role 
of hTSLP in normal and malignant B-lymphopoiesis. Here we describe the development of a 
novel xenograft model system comprised of mice that provide hTSLP (+T mice) and mice that do 
not (–T mice). PDX generated from +T mice show functional in vivo hTSLP effects, expanding 
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the production of normal B cell precursors from hematopoietic stem cells (HSCs) and inducing 
changes in mTOR-regulated gene expression in primary CRLF2 B-ALL cells. These data validate 
the +T/–T xenograft model system as an important new preclinical model for understanding the 
role of hTSLP in normal and malignant B lymphopoiesis and for identifying therapies to treat 
CRLF2 B-ALL.  
 
Materials and Methods  
Additional details are available in the Online Supplementary Methods. 
 
Human Samples and Cell Lines  
Human CRLF2 B-ALL cell lines MUTZ5 and MHH-CALL4 were from DSMZ 
(Braunschweig, Germany) and the human stroma line HS-27a (HS27) from ATCC, (Manassas, 
VA). Primary human CRLF2 B-ALL cells (Online Supplementary Table 1 and) and umbilical 
cord blood (CB) were obtained in accordance with protocols approved by the Loma Linda 
University Institutional Review Board (IRB) and with the Helsinki Declaration of 1975, as 
revised in 2008. Details of HS27 stroma characteristics, CB CD34+ cell isolation, and culture 
media are described in the Supplementary Methods. 
 
Mice 
Studies were performed using NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice (Jackson 
Laboratory) housed under pathogen-free conditions at Loma Linda University Animal Care 
Facility. Studies were conducted in accordance with Loma Linda University Institutional Animal 
Care and Use Committee (IACUC) approved protocols.  
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Flow Cytometry 
Cells were prepared for flow cytometry using specific antibody clones as described in 
Supplementary Methods. Flow cytometry analysis was performed using a MACSQuant analyzer 
(Miltenyi Biotec, Inc, Auburn, CA) and FlowJo analysis software (FlowJo, Ashland, OR).  
 
Stromal Cell Transduction  
Human HS27 stromal cells were transduced to express hTSLP (+T stroma) or with 
control vector (–T stroma) at a multiplicity of infection of 0.5-5/cell overnight. After 
transduction, cells were washed, expanded in culture, and frozen in aliquots. For the generation of 
+T and –T mice, stromal cells were thawed, cultured, and injected into mice within 15 passages 
after thawing. Details of lentiviral vector production and ELISAs to determine hTSLP levels are 
available in Supplementary Methods.  
 
Xenograft Transplantation  
HS27 stroma transduced to be +T or –T were injected intraperitoneally into NSG mice at 
doses of 5 or 10x106 cells at time points described in Results section. Mice were sub-lethally 
irradiated with 225 cGy, then transplanted by tail vein injection with freshly thawed human 
umbilical CB CD34+ cells (1x105) or primary CRLF2 B-ALL cells (5x105 Patient 1 and 1.5 x106 
Patient 2). 
 
Gene Expression Analysis in CRLF2 B-ALL Cells 
Microarray analyses were performed by Miltenyi Biotec’s Genomic Services (Miltenyi 
Biotec GmbH, Bergisch Gladbach) using Agilent Whole Human Genome Oligo Microarrays 
(Design ID 039494, 8x60K v2). Libraries for RNA sequencing were prepared and sequenced by 
the UCLA Clinical Microarray Core. Data discussed in this publication are deposited in NCBI's 
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Gene Expression Omnibus (GEO).(Edgar, Domrachev, & Lash, 2002) Microarray and RNA 
sequencing data are available through accession numbers GSE65274 and GSE74339 respectively 
at (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc= GSExxx). Gene Set Enrichment 
Analysis (GSEA) was performed by Novogenix Laboratories, LLC (Los Angeles, CA). Details of 
microarray, RNA sequencing, data processing, differential gene expression analysis, GSEA, and 
quantitative RT-PCR analysis are in the Supplementary Methods. 
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Cells and Cell Culture Media 
The human stromal cell line HS-27a (HS27) was selected for use in our model 
because 1) HS27 is one of a limited number of human bone marrow-derived stromal cell 
lines; 2) HS27 secretes low levels of growth factors that do not support proliferation of 
isolated progenitor cells in cocultures1; and 3) our laboratory has found that HS27 grow 
robustly in culture. HS27 stroma were maintained in RPMI 1640 medium (Irvine 
Scientific) supplemented with penicillin/streptomycin, L-glutamine, 50 μM 2-ME and 
10% FBS (Omega Scientific). MUTZ5 and MHH-CALL4 were maintained in RPMI 
1640 medium (Irvine Scientific, Santa Ana, CA) supplemented with 
penicillin/streptomycin, L-glutamine, 50 μM 2-ME and 20% FBS (Omega Scientific, 
Tarzana, CA). This media was also used for in vitro cultures with and without TSLP 
(both for phosphoflow assays and for gene expression profiling in response to TSLP). 
 
Flow Cytometry 
For detection of surface antigens, cells were stained using standard flow 
cytometry protocols, followed by fixation and permeabilization as described below to 
detect intracellular antigens. To assess intracellular IgM, the Fix & Perm® cell fixation 
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and permeabilization kit (Life Technologies, Grand Island, NY)) was used according to 
manufacturer’s instructions. To discriminate living from dying cells, in some 
experiments, cells were stained with fixable viability dyes (eBioscience, San Diego, CA), 
per manufacturer’s instructions. All antibodies were monoclonal, anti-human antibodies, 
unless otherwise stated. Specific antibody clones and conjugates are shown below.  
Antibody Clone Manufacturer 
Ig κ light chain FITC G20-193 BD Pharmingen  
(San Jose, CA) Ig λ light chain FITC JDC-12 
CD66b FITC G10F5 
CD34 APC 8G12 BD Biosciences  
(San Jose, CA CD56 PE MY31 
CD79a PE HM47  
IgM PE.Cy-5  G20-127 
Anti-Phospho AKT (pS473) Alexa Fluor 488 M89-61 
Anti-phospho STAT5 (pY694) PE 47/Stat5 (pY694) 
Anti-Phospho S6 (pS235/S236) Alexa Fluor 488 N7-548 
CD10 APC.Cy7 HI10A BioLegend  
(San Diego, CA) CD14 APC M5E2 
CD19 APC HIB19 
CD19 Pacific Blue HIB19 
CD34 PerCP 581 
CD38 Brilliant Violet 421 HIT2 
Ig κ light chain Pacific Blue MHK-49 
Ig λ light chain Pacific Blue MHL-38 
IgD PE IA6-2 
TSLPR APC 1B4 
CD19 APC HIB19 eBioscience  
(San Diego, CA) CD19 PE.Cy7  SJ25C1 
CD45 PE.Cy7  HI30 
Ig κ light chain eFluor 450 TB28-2 
Ig λ light chain eFluor 450 1-155-2 
CD19 APC LT19 Miltenyi Biotec 
(Auburn, CA) CD29 PE TS2/16 
CD90 APC DG3 
CD127 PE (IL-7Ra) MB15-18C9 
Anti-Mouse CD45 FITC 30F11 
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Statistical Analysis 
Statistical analysis was performed using Students t test and data expressed as 
mean ± SEM. Statistical significance was defined as p<0.05. 
 
Phospho-Flow Cytometry Staining 
Human CRLF2 B-ALL cell lines were harvested from continuous culture and 
primary CRLF2 B-ALL cells were obtained as BM from patient-derived xenografts. Cells 
were rested in culture without cytokines for 2 hrs, and then cultured with mTSLP, hTSLP 
or no cytokine for 30 mins (S6 and AKT) or 1 hour (STAT5). Cells were then harvested 
and stained with antibody to phosphorylated STAT5 (pSTAT5), AKT (pAKT) or S6 
(pS6) as previously described for STAT5 (Parrish et al., 2009). Primary CRLF2 B-ALL 
patient-derived samples were also stained with CD19 APC prior to fixation and 
permeabilization for detection of phospho proteins and CD19+ cells were gated for 
phospho-flow cytometry plots.  
 
ELISA Assays of TSLP  
Concentrations of hTSLP in the supernatant of transduced HS27 stromal culture 
and in sera collected from NSG mice injected with transduced stroma were measured 
using the Human TSLP ELISA MAX Kit (BioLegend, San Diego, CA). Stromal cell 
supernatants were harvested from confluent flasks when stromal cells were passaged 
(typically two times per week) and sera was obtained from mice at weekly time points at 
the time of weekly stromal cell injection. Data was collected using the uQuant microplate 
spectrophotometer (BioTek Instruments Inc., Winooski, VT) and analyzed using the KC 
Junior, version 1.6 (BioTek Instruments, Inc., Winooski, VT) 
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Lentivirus Vector and TSLP-Expressing Human Stromal Cells 
TSLP vector was generated using standard molecular cloning techniques with 
complementary DNA encoding human TSLP (purchased from Thermo Scientific Open 
Biosystems). In this vector, the EF-1α promoter was used to drive TSLP expression. A 
control vector with GFP was also generated. The lentiviral vector packaging and titering 
were performed as previously described (Meng et al., 2012). In brief, VSV-G–
pseudotyped lentiviral vectors were prepared by calcium phosphate–mediated 3-plasmid 
transfection of 293T cells. Briefly, 27 µg transfer vector construct, 17.5 µg second-
generation gag-pol packaging construct pCMV.R8.74, and 9.5 µg VSV-G expression 
construct pMD2.G were used for transfection of 12x106 293T cells overnight in 25 ml 
DMEM with 10% fetal bovine serum. The cells were treated with 10 mM sodium 
butyrate during the first of three 12-hour vector supernatant collections. The supernatant 
was filtered through 0.22-µm-pore-size filters and concentrated 100-fold by 
ultracentrifugation before freezing and storing at –80° C. All vector stocks were titered 
by transducing HT1080 cells with analysis for GFP expression by flow cytometry or real-
time PCR.  
 
 103 
Processing of Samples from Xenograft Mice 
Flow cytometry analysis of peripheral blood (PB) was used to establish 
chimerism with human cells prior to euthanasia. PB was collected using tail-tip excision 
(tail nick) and placed into a microtainer serum separator tube (BD Gold, 200/cs). Samples 
were centrifuged at 1500 rpm for 15 mins. Serum was removed for ELISA analysis. 
Blood cells were subjected to red blood cell lysis (Kang et al., 2002) and remaining white 
blood cells were stained for human surface markers. NSG mice were euthanized 5-7 
weeks after CB CD34+ transplantation or 12 weeks after CRLF2 B-ALL transplantation. 
On the day of euthanasia fresh bone marrow (BM), spleen and PB were harvested. Single 
cell suspensions were obtained from the BM by using 26g syringe and PBS to flush the 
femora and humeri and by filtering cells with a 70 micron cell strainer (BD Biosciences, 
San Jose, CA). Cells obtained from all tissues were stained immediately for flow 
cytometry analysis or were frozen for future use. 
 
Microarray Analysis of Gene Expression in CRLF2 B-ALL Cells 
 Mice engineered to be +T and –T by stromal cell injection were transplanted with 
primary CRLF2 B-ALL cells from a Hispanic pediatric patient. Following transplant, 
mice received weekly intraperitoneal injection of 5X106 +T or –T stroma from 
Transduction 1 (see Results section). Nine weeks post transplant, BM was harvested and 
frozen for later use. For microarray to evaluate in vivo TSLP-induced changes in gene 
expression, xenograft BM was thawed and human B-ALL cells were isolated by 
magnetic separation using the Human CD19 microbead kit (Miltenyi Biotec, Inc., San 
Diego, CA) according to manufacturer’s protocol and rapidly frozen on dry ice (Samples 
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E1-E3 and F1-F3 described below).  For microarray to evaluate in vitro TSLP-induced 
changes in gene expression (Fig. 4), xenograft BM was thawed and cultured in vitro for 3 
days with TSLP at 15ng/ml or without TSLP and with neutralizing anti-TSLP antibody 
(R&D Systems, Minneapolis, MN) or control antibody (Jackson ImmunoResearch). 
Following culture, cells were harvested and thawed and human B-ALL cells were 
isolated by magnetic separation using the Human CD19 Microbead Kit according to 
manufacturer’s protocol and rapidly frozen on dry ice (samples A1-A3, B1-B3, C1-C3 
and D1-D3 as described below). Frozen cells were shipped to Miltenyi Biotec (Miltenyi 
Genomic Services) for RNA isolation, sample preparation, whole genome microarray, 
and discriminatory gene analysis (DGA) as follows:  
 
Total RNA Isolation 
Human total RNA was isolated using the NucleoSpin® RNA kit (Macherey-
Nagel, Bethlehem, PA). RNA quality and integrity were determined using the Agilent 
RNA 6000 Nano Kit on the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa 
Clara, CA). RNA was quantified by measuring A260nm on the ND-1000 
Spectrophotometer (NanoDrop Technologies, Wilmington, DE). 
 
RNA Amplification and Labelling 
  Sample labelling was performed as detailed in the “One-Color Microarray-Based 
Gene Expression Analysis protocol (version 6.6, part number G4140-90040). Briefly, 50 
ng RNA for the samples from groups A, B, E and F, 10 ng RNA for the samples of group 
C and D, and the complete available amount of RNA for the samples C3 and D1 was 
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used for the amplification and labelling step using the Agilent Low Input Quick Amp 
Labelling Kit (Agilent Technologies). Yields of cRNA and the dye-incorporation rate 
were measured with the ND-1000 Spectrophotometer (NanoDrop Technologies).  
Microarray Sample Key 
 
Sample Source of Cells 
E1, E2, E3 CRLF2 B-ALL cells from +T mice 
F1, F2, F3 CRLF2 B-ALL cells from –T mice 
 
Hybridization of Agilent Whole Human Genome Oligo Microarrays 
  The hybridization procedure was performed according to the “One-Color 
Microarray-Based Gene Expression Analysis protocol (version 6.6, part number G4140-
90040) using the Agilent Gene Expression Hybridization Kit (Agilent Technologies). 
Briefly, 0.6 µg Cy3-labeled fragmented cRNA in hybridization buffer was hybridized 
overnight (17 hours, 65 °C) to Agilent Whole Human Genome Oligo Microarrays 8x60K 
v2 (AMADID 039494) using Agilent’s recommended hybridization chamber and oven. 
Following hybridization, the microarrays were washed once with the Agilent Gene 
Expression Wash Buffer 1 for 1 min at room temperature followed by a second wash 
with preheated Agilent Gene Expression Wash Buffer 2 (37 °C) for 1 min.  
 
Scanning and Data Analysis 
Fluorescence signals of the hybridized Agilent Microarrays were detected using 
Agilent’s Microarray Scanner System G2505C (Agilent Technologies). The Agilent 
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Feature Extraction Software (FES) 10.7.3.1 was used to read out and process the 
microarray image files. 
 
Gene Set Enrichment Analysis 
  Microarray data was evaluated at the level of gene sets to define and quantitate 
trends in gene expression similar to published data. Ranked gene lists were created and 
submitted to the online public repository provided by the BROAD Institute for Gene Set 
Enrichment Analysis (GSEA) (Mootha et al., 2003; Subramanian et al., 2005) to evaluate 
Oncogenic Signatures that are enriched in CRLF2 B-ALL cells expanded in +T as 
compared to –T mice (www.broadinstitute.org/gsea).  
 
Discriminatory Gene Expression Analysis 
 After probe summarization, quantile normalization and log2 transformation, 
differentially expressed genes were identified by a combination of effect size and 
statistical significance. For the analysis of the individual comparisons, only reporters with 
an at least two-fold median up- or downregulation in +T samples compared to –T 
samples and an adjusted p-value (Student’s t-test, two-tailed, equal variance, Benjamini-
Hochberg correction for multiple testing) p≤0.05 were considered relevant. In an 
additional filtering step, only Agilent reporters with signal intensity values significantly 
above local background (p<0.01 as calculated by the Rosetta Resolver® gene expression 
data analysis system) in at least two samples of the group with higher median expression 
were selected (Weng et al., 2006). All microarray data reported in this publication were 
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deposited in the NCBI’s Gene Expression Omnibus at National Center for Biotechnology 
Information and are accessible via the GEO series accession number GSE65274. 
 
Real Time Quantitative RT-PCR 
Expression of select genes observed in microarray results was validated using 
quantitative reverse transcriptase - polymerase chain reaction (qRT-PCR) using primers 
shown below.  Total RNA (2.0μg) was reverse transcribed using poly d(T)20 primers and 
SuperScript II reverse transcriptase (Life Technologies, Grand Island, NY). The resulting 
cDNAs were used for qRT-PCR analysis of their mRNA levels on a StepOne Plus 7500 
Real-time PCR system (Applied Bioscience Inc., Foster City, CA) using specific primers 
for each gene (see supplemental table 2 for primer sequences) following the 
manufacturer's instructions. The fluorescence threshold value was calculated and 
normalized to the values of 18s rRNA. The fold change in mRNA expression of genes 
between the TSLP-treated W31 cell group versus untreated group was achieved by the 
ratio of fluorescence threshold value in the treated groups versus that of the untreated 
group. The fold change for each gene was paired with that of microarray analysis.  Linear 
regression analysis of the fold change versus that of microarray was performed with 
Origin 6.0. The graph shows the best-fit line, the formula for the best-fit line (Y = a + 
bX), its correlation coefficient (r), and the probability (P) that the r value is a false 
positive. 
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Gene Forward Primer Reverse Primer 
BIVM 5’-GGCCAGAGGCAATGCAAAG                                     5’-TGAGGTCTAATACTTTCCGCTGT 
PTH2 5’-CTGGTTCTCCACAGGTGATG                                    5’-CATGTACGAGTTCAGCCACT 
FOSL2 5’-AACACCCTGTTTCCTCTCCG                                   5’-ATCTACCCGGAATTTCTGCGG 
RAMP1 5’-GCAGGACCATCAGGAGCTACA                              5’-GCCTACACAATGCCCTCAGTG 
SLC4A8 5’-TGGGTCCAGTAGGGAAAGGT                               5’-ACCGTCACCTGGTCTAGGAA 
NR4A2 5’-GTAACTCGGCTGAAGCCATGC 5’-GTCGTAGCCTGTGCTGTAGTT 
KCNH8 5’- GCAAGATCAATTTGCATCCACTAT                        5’- AAGGCAGGGCAGCGATTA 
THSD7A 5’- CCATCTCGAGTCTTTGTTCACATT 5’- CATTTGGGAATTGTGCTTCTCA 
RAB26 5’-CCAGGCCCTTCTGACTTTGT 5’-CTGCTTGTTGGGACTGTTGC 
RGS1 5’-CTCCCTGGGTGAACAGCTTG 5’-GCTTCTTCAACTCTGCGCCT 
NELL1 5’-GATATGAAGCCACCCGTGTT 5’-CTGAAGGTCAGGGTCCATCC 
MDF1 5’-GAAGTTGCAGACACACCCATCTC 5’-GTCCAGGACGATGTTGCACAG 
KREMEN2 5’-TGAGGACCCAGAGGCCC 5’-CAGACAGCTCCCCCAATCG 
CPNE8 5’-CGCCTCCTCCCAATATGGAC                                 5’-ATTTCTGCAGGACACGGACA 
 
 
 
RNA Sequencing and Analysis of Gene Expression in  
CRLF2 B-ALL Cells 
RNA libraries were prepared for sequencing by the UCLA Clinical Microarray 
Core using TruSeq kits (Illumina). Libraries were sequenced on a HiSeq 2000/2500 at 1 
X 50 bp. Transcript levels were estimated using RNA-Seq by Expectation Maximization  
(Li & Dewey, 2011); Reads were mapped to the human genome (hg19) using 
RefSeq annotation. Pairwise differential expression assessments were performed using 
the method EBSeq(Leng et al., 2013); genes were considered to be differentially 
expressed based on a False Discovery Rate of less than 5% (Posterior Probability of 
being Differentially Expressed < 0.05). Gene Ontology (GO) analysis was performed 
using DAVID. Gene Set Enrichment Analysis (GSEA) was performed using MSigDB. 
Ranked lists of genes having a fold change of greater than 1.5 were used as input for 
GSEA. The transcript per million (TPM) values from respective samples were clustered 
using hierarchical clustering with R. Spearman rank correlation was used as the distance 
metric followed by average linkage clustering.  
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Results  
Mouse TSLP does not Activate the Human TSLP Receptor Complex 
Activation of the human TSLP receptor complex can be induced by hTSLP, but 
not by mTSLP, in murine Ba/F3 cells transduced to express human CRLF2 and IL-7R 
(Reche et al., 2001). However, the ability of mTSLP to activate CRLF2-signaling in 
human cells, particularly those expressing high levels of CRLF2 observed in CRLF2 B-
ALL, has not been reported. To determine if mTSLP can induce CRLF2-mediated signals 
we tested its ability to activate downstream pathways in human CRLF2 B-ALL cells. 
First, we verified that the CRLF2 B-ALL cell lines and primary CRLF2 B-ALL cells 
used in our studies express the TSLP receptor components. Expression of IL-7R
well as high levels of CRLF2, was observed in both CRLF2 B-ALL cell lines and in the 
two primary CRLF2 B-ALL samples used in studies described here (Figure 1B).   
Next we used phospho-flow cytometry to determine whether mTSLP can activate 
the JAK-STAT5 and PI3K/AKT/mTOR pathways activated by hTSLP in CRLF2 B-ALL 
cells (Tasian et al., 2012). hTSLP induced robust increases in phosphorylated STAT5 
(pSTAT5) and S6 (pS6, activated downstream of mTOR) and more modest increases in 
phosphorylated AKT (pAKT) in CRLF2 B-ALL cell lines and primary CRLF2 B-ALL 
cells (Figure 1C-E). In contrast, stimulation of CRLF2 B-ALL cells with mTSLP showed 
no effect (Figure 1C-E)(Dann, Selvaraj, & Thomas, 2007) These data show that mTSLP 
fails to induce the STAT5, AKT, or S6 phosphorylation that are characteristic of CRLF2-
mediated signals induced by hTSLP in human CRLF2 B-ALL cells. Thus, TSLP 
produced in the existing mouse xenograft models does not induce human CRLF2-
mediated signals. 
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Figure 1 (Figure 13). Mouse TSLP does not activate the human TSLP receptor 
complex. A) Pathways activated downstream of TSLP receptor signaling in human 
cells. B) CRLF2 B-ALL cell lines (MUTZ5, MHH-CALL4) and primary CRLF2 B-
ALL cells used to produce patient-derived xenografts (PDX) used in the studies 
described here were stained for flow cytometry to detect the TSLP receptor components 
(IL-7Rα and CRLF2). Plotted in red are CRLF2 B-ALL cells within living cell light 
scatter. Quadrants shown are set based on unstained controls (blue overlay) C-E) 
CRLF2 B-ALL cell lines and CRLF2 B-ALL cells from a PDX generated from the 
primary cells in panel C were stimulated with human TSLP (hTSLP), mouse TSLP 
(mTSLP), or no cytokine and evaluated for phosphorylated STAT5 (pSTAT5), AKT 
(pAKT), and S6 (pS6) by phospho-flow cytometry. 
 112 
Engineering Xenograft Mice to Express Normal Serum Levels  
of Human TSLP 
We developed a strategy for engineering xenograft mice that provide hTSLP to 
activate CRLF2-mediated signals (Figure 2A) by building on a previous cytokine 
delivery approach (Dao, Pepper, & Nolta, 1997). Our goal was to produce stable, 
sustained serum levels of hTSLP, similar to normal levels reported in children (range 13-
32 pg/ml(Lee et al., 2010)) by intraperitoneal injection of stromal cells transduced to 
express high levels of hTSLP (+T mice, Figure 2A). Control mice (–T mice) were 
produced by injecting stroma transduced with empty vector. Because the only difference 
between +T and –T mice is the presence of hTSLP in +T mice, this model would allow 
us to identify the in vivo effects of hTSLP by comparing hematopoiesis in +T and –T 
PDX generated from these mice.  
Human HS27 stromal cells (Graf, Iwata, & Torok-Storb, 2002) were transduced 
with lentiviral vector containing hTSLP (+T stroma) or with control vector (–T stroma). 
Culture supernatant collected from stroma after the initial transduction showed hTSLP 
levels of ~500 pg/ml (Figure 2B, Transduction 1). The ability of +T stroma to generate 
measureable serum levels of hTSLP in vivo was evaluated. NSG mice receiving weekly 
intraperitoneal injections of 5X106 +T stroma showed serum hTSLP levels that were low 
but detectable (4-10 pg/ml; data not shown). To achieve higher levels of sustained hTSLP 
expression NSG mice were injected with 3 doses of 1X107 +T or –T stroma over a 1 
week period (loading dose) followed by weekly injections of 1X107 stromal cells. Serum 
collected at weekly time points showed serum hTSLP levels of ~80 pg/ml following the 
initial 3 doses of +T stroma but quickly dropped to 15-20 pg/ml with +T stroma 
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injections (Figure 2C, left panel). hTSLP was not detectable in the sera of mice 
transplanted with –T stroma (Figure 2C). These data show that +T stroma can generate 
normal serum levels of hTSLP and that serum levels of hTSLP correspond to the number 
of stromal cells injected during the previous 1-2 week period. These data suggested that 
stable, sustained hTSLP production might be more likely with weekly injections of 
stroma that could deliver slightly higher doses of hTSLP. 
A second stromal cell transduction produced hTSLP levels averaging ~900 pg/ml 
in culture supernatants harvested at early, mid and late passages from +T stroma across 
multiple thaws of frozen aliquots (Figure 2B, transduction 2). hTSLP was undetectable in 
supernatant from similarly passaged –T stroma (Figure 2B, Transduction 2). NSG mice 
transplanted at weekly time points with 5X106 stroma from transduction 2 showed serum 
hTSLP levels of approximately 20 pg/ml that were stable up to 11 weeks (Figure 2D, and 
data not shown). Evaluation of BM and spleen of +T and –T mice by flow cytometry 
showed that HS27 stroma (CD29+CD90+) were not detectable in the either the spleen or 
BM of PDX mice (Online Supplementary Figure S1). These data provide evidence that 
the HS27 +T stroma in the peritoneal cavity give rise to normal serum levels of hTSLP in 
PDX mice.  
To verify that the hTSLP produced in our model induces CRLF2-mediated 
signals, CRLF2 B-ALL cell lines were assessed for activation of the JAK/STAT5 and 
PI3K/AKT/mTOR pathways. Supernatant from +T stroma induced robust pSTAT5 and 
pS6 and minimal pAKT (Figure 2E-G). In contrast, CRLF2 B-ALL cells stimulated with 
supernatant from –T stroma showed background levels of pSTAT5, pAKT, and pS6, 
similar to cells incubated with medium alone (Figure 2E-G). These data show that +T 
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stroma, but not –T stroma, used in our model produce hTSLP that can activate signaling 
in human CRLF2 B-ALL cells.  
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Figure 2 (Figure 14). Engineering xenograft mice to express normal serum levels of 
human TSLP. (A) Strategy for developing the –/+hTSLP xenograft model. (B) Culture 
supernatant from HS27 +T and HS27 –T stromal cells was collected after multiple 
passages following the initial transduction (Transduction 1) and assessed by ELISA for 
hTSLP protein production. Supernatant from Transduction 2 was collected at early 
(passage 1-5), mid (passages 6-10) and late (passages 11-15) post thaw passages and 
hTSLP levels were evaluated by ELISA. C-D) Serum levels of hTSLP in blood collected 
at indicated time points from +T or –T mice injected with stroma as determined by 
ELISA were as follows: (C) loading dose (3 doses of 1X107 in first week) followed by 
weekly doses of 1X107 stromal cells (Transduction 1), graphed are the means ± SEM of 
n = 2-7 mice at each time point. (D) injection of 5X106 stromal cells (Transduction 2) 
at weekly intervals; graphed are the means ± SEM n ≥ 24 mice at each time point. (E-
G) CRLF2 B-ALL cell lines were stimulated with stromal cell supernatant 
(Transduction 2) and levels of pSTAT5, pAKT and pS6 were measured by phospho-
flow cytometry.  
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Supplementary Figure 1 (Figure 15). HS27 stroma are not detectable in bone marrow 
or spleen of xenograft mice. (A) Flow cytometry plots showing human CD29 and CD90 
expression on HS27 stromal cells transduced to express human TSLP (+T HS27 
stroma). Similar staining was observed for HS27 stroma transduced with empty vector 
(–T HS27 stroma). +T or –T HS27 stroma were injected at weekly time points into 
sublethally irradiated NSG mice for 13 weeks. Mice were euthanized and bone marrow 
(BM) and spleen were harvested and stained for flow cytometry to detect human CD29 
and CD90 co-expression as a means of identifying HS27 stroma in these tissues. Plotted 
are 25,000 events from (B) BM and (C) spleen of +T mice showing that CD29+CD90+ 
HS27 stroma are not detectable in BM or spleen of +T NSG mice.  Similar data were 
obtained in –T NSG mice. Data shown are representative of n=5 +T mice and n=4 –T 
mice. 
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hTSLP Produced in Xenograft Mice Exerts In Vivo Functional Effects on 
Normal Human B Lineage Cells  
We evaluated the ability of hTSLP in +T PDX to induce in vivo functional effects 
on human B lineage cells. hTSLP has been shown to increase the in vitro production of 
normal human B cell precursors(Scheeren et al., 2010) despite their low levels of 
CRLF2 expression (Online Supplementary Figure S2). Thus, expansion of normal human 
B cell precursors provides a sensitive in vivo functional test of the hTSLP produced in 
our xenograft model. We compared normal B cell production in +T and –T NSG mice 
transplanted with umbilical CB CD34+ cells from 3 different donors (Figure 3A, S3A 
and S4A). Five weeks post-transplant mice were euthanized and bone marrow (BM) 
harvested for flow cytometry to evaluate the production of B lineage and other 
hematopoietic cells. Mouse and human cells were identified based on expression of 
mouse CD45 (mCD45) or human CD45 (hCD45), respectively (Figure 3B, S3B and 
S4B). Flow cytometry analysis of hCD19 expression on gated human cells showed an 
increase in the percentage of B lineage cells in +T as compared to –T PDX mice 
generated from all 3 CB donors (Figure 3C, S3C and S4C). Pooled data comparing BM 
cellularity in all three experiments showed that the total number of human cells 
(hCD45+) was increased by 3-4 fold in +T as compared to –T PDX and this was due to 
significant increases in CD19+ (B lineage) cells but not CD19– cells (Figure 3D). These 
data suggest that hTSLP in +T PDX selectively expands human B lineage cells rather 
than exerting global effects on hematopoiesis. 
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Supplementary Figure 2 (Figure 16). Expression of CRLF2 and IL-7R on normal 
human B cell precursors and CRLF2 B-ALL harvested from xenograft mice. (A) Bone 
marrow was harvested from xenograft mice transplanted with human CD34+ cord blood 
cells and stained for flow cytometry. Plotted is CRLF2 and IL-7Ra expression on B cell 
precursors (hCD19+ and Ig kappa & lambda–). (B) Bone marrow was harvested from a 
patient-derived xenograft generated using Patient 1 CRLF2 B-ALL cells. Plotted is the 
CRLF2 and IL-7R staining on human CRLF2 B-ALL (hCD19+) cells. Gates were set 
based on isotype control staining. 
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Figure 3 (Figure 17). hTSLP produced in xenograft mice exerts in vivo functional 
effects on normal human B lineage cells. (A) –T and +T NSG mice were transplanted 
with 1X105 CD34+ human cord blood (CB) cells and injected with weekly doses of 
5X105 stromal cells (Transduction 2 stroma). (B) Five weeks post-transplant, mice were 
euthanized, BM harvested and cells were stained for flow cytometry to detect mouse 
CD45 (mCD45), human CD45 (hCD45), and hCD19. Total living cells were gated and 
mCD45 vs. hCD45 is plotted with gates to identify mouse and human leukocytes 
respectively, in the BM. (C) hCD45+ cells were gated and hCD19 expression is shown 
by histogram. Percentages are mean + SEM. Data shown in A-C were obtained from 
CB2, n=2 –T PDX and n= 4 +T PDX; data from two additional CB samples (CB1 and 
CB3) are shown in Online Supplementary Figures S3-S4. (D) Graphed are the fold 
change in total human cells (hCD45+), human B lineage cells (CD19+), and human 
non-B lineage cells (CD19–). Fold change was obtained by normalizing cell numbers 
in +T animals to the average cell numbers in –T animals for each experiment. Data 
shown in Panel D are pooled from 3 different experiments performed with CB samples 
1-3. Total n=9 –T PDX mice and n=14 +T PDX mice. Statistical significance was 
calculated using a 2-tailed, unpaired t-test (* P ≤ 0.05; ** P ≤ 0.05). 
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Supplementary Figure 3 (Figure 18). Functional effects of hTSLP produced in +T 
xenograft mice on normal human B lineage cells generated from CB 1. (A) –T and +T 
NSG mice were transplanted with 1X105 CD34+ human cord blood cells (CB 1) and 
injected with weekly doses of 1X107 stromal cells (transduction 1 stroma). (B) Five 
weeks post-transplant, mice were euthanized, BM harvested and cells were stained for 
flow cytometry to detect mouse CD45 (mCD45), human CD45 (hCD45), and hCD19. 
Total living cells were gated and mCD45 vs. hCD45 is plotted with gates to identify 
mouse and human leukocytes respectively, in the BM. (C) hCD45+ cells were gated and 
hCD19 expression is shown by histogram. Percentages are mean + SEM. Data shown 
in A-C were obtained from CB 1, n=3 –T PDX and n= 5 +T PDX. 
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Supplementary Figure 4 (Figure 19). Functional effects of hTSLP produced in +T 
xenograft mice on normal human B lineage cells generated from CB 3. A) –T and +T NSG 
mice were transplanted with 1X105 CD34+ human cord blood cells (CB 3) and injected 
with weekly doses of 5X106 stromal cells (transduction 2 stroma). B) Five weeks post-
transplant, mice were euthanized, BM harvested and cells were stained for flow cytometry 
to detect mouse CD45 (mCD45), human CD45 (hCD45), and hCD19. Total living cells 
were gated and mCD45 vs. hCD45 is plotted with gates to identify mouse and human 
leukocytes respectively, in the BM. C) hCD45+ cells were gated and hCD19 expression is 
shown by histogram. Percentages are mean + SEM. Data shown in A-C were obtained from 
CB 3, n=4 –T PDX and n= 5 +T PDX.  
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B Cell Precursor Production is Increased in +T PDX Mice  
 To confirm that normal human B cell precursors are expanded in +T PDX, we 
compared the production of human B cell subsets (Figure 4A) and non B-cell lineages in 
–T and +T PDX. Staining of PDX BM for markers of human non-B cells showed that 
human CD19– cells are comprised primarily of monocytes (CD14+), but also include 
granulocytes (CD66B+), NK cells (CD56+), and CD34+ cells. The number of cells in 
each non-B lineage was similar (data not shown) in the BM from –T and +T PDX, 
indicating that the production of these cells is not skewed. However, the production of B 
cell precursors was increased 3-6 fold at each stage of B cell development in +T PDX as 
compared to –T PDX, beginning with the earliest CD34+ pro-B cells (Figure 4B). This 
increase was maintained through the mature B cell stage in BM and spleen (Figure 4B) 
with no skewing of B cell subsets in the BM (Figure 4C) or spleen (data not shown). 
These data provide evidence that hTSLP produced in vivo in +T PDX has a functional 
effect on normal human B cell precursors that express low levels of CRLF2. 
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Figure 4 (Figure 20). B cell precursor production is increased in +T PDX. BM and spleen 
were harvested from –T and +T PDX mice generated by from three different CB samples 
as shown in Figure 3, and in Online Supplementary Figures S3-S4. (A) Harvested cells 
were counted by hemocytometer and were stained for flow cytometry and to identify 
progenitors and B cell subsets in the BM and spleen based on the indicated 
immunophenotypes. (B) Total living cell counts and percentages of living cells in each 
subset were used to calculate the number of cells in each subset. Graphed is the fold 
changed in each subset obtained by normalizing cell numbers in +T animals to the average 
cell numbers in –T animals for each experiment. (C) Graphed is the frequency of each 
subset within the total CD19+ B lineage pool. Data shown are pooled from experiments 
performed using PDX generated from CB 1-3. n=9 –T PDX mice and n =15 +T PDX mice. 
Statistical significance was calculated using a 2-tailed, unpaired t-test (** P ≤ 0.01; *** P 
≤0.001). 
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hTSLP  in Xenograft Mice Induces mTOR-Regulated Genes in 
 Primary CRLF2 B-ALL 
To determine the ability of hTSLP in +T xenografts to activate CRLF2 
downstream pathways in CRLF2-B-ALL cells we used primary samples obtained two 
different Hispanic pediatric patients. (Patient characteristics shown in Online 
Supplementary Table S1.) First, we evaluated the ability of NSG mice transplanted with 
HS27 stroma to support engraftment of primary CRLF2 B-ALL cells. PDX from Patient 
1 were generated using NSG mice injected with +T stroma from transduction 1 (stroma 
injection schedule, Figure 5A). Serum levels of hTSLP produced in these mice were 
detectable but below normal levels (4-10 pg/ml) and therefore provided a sensitive test of 
in vivo hTSLP activity in +T PDX. +T and –T NSG mice were transplanted with primary 
CRLF2 B-ALL cells (Figure 1B, right panel) from Patient 1. Mice were euthanized at 9 
weeks when peripheral blood chimerism reached 80%. BM was harvested and stained for 
mCD45 and human-specific markers (CRLF2 and CD19) to identify CRLF2 B-ALL cells 
(Figure 5B). Flow cytometry analysis showed BM chimerism of human CRLF2 B-ALL 
cells was >90% in +T and –T PDX (Figure 5B). These data show that NSG mice support 
engraftment of primary B-ALL cells when injected with –T or with +T stroma.  
The leukemia cell burden in the BM of –T and +T PDX generated from Patient 1 
and from Patient 2 showed no consistent differences (Online Supplementary Figure S6). 
Thus, our next question was whether hTSLP in +T animals induces gene expression 
profiles associated with pathway activation downstream of CRLF2-mediated signaling in 
primary CRLF2 B-ALL cells. Human CRLF2 B-ALL cells were isolated from the BM of 
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+T and –T PDX generated from Patient 1 by magnetic separation. Gene expression was 
compared by whole genome microarray performed in triplicate. Differential gene  
expression analysis identified 280 gene reporters that were upregulated and 281 gene 
reporters that were downregulated at least 2 fold (Figure 5C). Microarray was validated 
by quantitative RT-PCR (qRT-PCR) analysis of selected differentially expressed genes 
(Table S2). Changes in gene expression by microarray and qRT-PCR were strongly 
correlated as indicated by linear regression (Figure 5D). GSEA(Mootha et al., 2003; 
Subramanian et al., 2005) of whole genome microarray data showed a strong enrichment 
for genes regulated downstream of mTOR activation in CRLF2 B-ALL cells from +T 
PDX as compared to –T PDX (FDR q-value = 0.022, Figure 5E). These data provide 
evidence that the hTSLP in +T PDX, even when present at low levels, acts on CRLF2 B-
ALL cells to increase mTOR pathway activation downstream of CRLF2.
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Supplementary Table 1 (Table 2). CRLF2 B-ALL Patient Characteristics. 
Patient 
Designation 
 
Gender 
 
Age 
 
Immunophenotypic 
Markers  
CRLF2 and 
IKZF1 
Status 
Ethnicity 
 
Patient 1 M 10 
years 
CD10+ 
CD19+ 
CD20+ 
CD22 surface, dim 
CD22 cytoplasmic, 
dim 
CD34 partial 
CD38 partial 
CD45 dim 
CD58 dim 
CD79a+ 
HLA-DR+ 
CRLF2 
High 
No IKZF1 
deletion 
Hispanic 
 
Patient 2 M 18 
years 
CD9+ 
CD10 partial 
CD19+ 
CD20 partial 
CD22 surface, dim 
CD22 cytoplasmic, 
dim 
CD34 partial 
CD38+ 
CD45 dim 
CD79a+ 
HLA-DR+ 
TdT+ 
CD3 cytyoplasmic– 
Kappa– 
Lambda– 
MPO– 
CRLF2 
High 
IKZF1 
deletion 
 
Hispanic 
 
IKZF1 deletion = deletion of one allele of IKZF1 (Ikaros) was determine as described10.  
Both patients expressed high levels of CRLF2 as assessed by flow cytometry in Figure 1. 
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Figure 5 (Figure 21). hTSLP in +T xenograft mice induces mTOR-regulated genes in 
primary CRLF2 B-ALL. (A) –T and +T NSG mice were transplanted with primary 
CRLF2 B-ALL cells from Patient 1 and injected weekly with 5X106 stromal cells 
(transduction 1). (B) 9 weeks post-transplant, mice were euthanized, BM was harvested 
and cells were stained with mCD45 and hCD19 to identify human B-ALL cells. CRLF2 
staining (black overlay) on gated hCD19+ cells is shown in bottom panels. Isotype 
control is shown in gray. (C) Human hCD19+ B-ALL cells were isolated by magnetic 
separation and analyzed using whole genome microarray to identify genes that are 
differentially regulated in +T as compared to –T PDX. Graphed are the numbers of 
Agilent gene reporters up or downregulated (≥2 fold, p≤ .05) in CRLF2 B-ALL cells 
from +T as compared to –T PDX. (D) qRT-PCR validation of whole genome 
microarray. Regression analysis of fold changes measured by microarray versus fold 
changes measured by qRT-PCR. (E) Gene Set Enrichment Analysis (GSEA) of whole 
genome microarray data shows that CRLF2 B-ALL cells harvested from +T PDX 
exhibit an increase in expression of genes regulated downstream of mTOR signaling as 
compared to cells from –T PDX. The top half of the GSEA enrichment plot shows the 
enrichment score for each gene and the bottom half shows the values of the ranking 
metric moving down the list of the ranked genes 
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Supplementary Figure S6 (Figure 22). CRLF2 B-ALL leukemia cell burden in BM 
of –T and +T PDX. Bone marrow cells from +T and –T PDX generated from Patient 1 
and Patient 2 and shown in Figure 5 and 6 were harvested, counted by hemocytometer, 
and stained for flow cytometry to identify living CRLF2 B-ALL cells. Total living cell 
counts and percentages of living CRLF2 B-ALL cells within the total living cells were 
used to calculate the number of CRLF2 B-ALL cells per PDX. Graphed is the fold 
change in living leukemia cells in +T PDX as compare to –T PDX obtained by 
normalizing CRLF2 B-ALL cell numbers in +T animals to the cell numbers in –T 
animals for each experiment. 
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Supplementary Table 2 (Table 3). qRT-PCR validation of genes that are differentially 
regulated in CRLF2 B-ALL cells expanded in +T as compared to –T xenograft mice.  
Gene Microarray  
(fold change) 
qRT-PCR  
(fold change) 
BIVM 4.440 6.907 
PTH2 3.477 2.784 
FOSL2 2.793 1.843 
RAMP1 2.725 2.227 
SLC4A8 2.628 6.417 
NR4A2 2.138 3.548 
KCNH8 2.154 2.355 
   
THSD7A –3.628 –6.648 
RAB26 –2.727 –2.726 
RGS1 –2.749 –2.498 
NELL1 –3.586 –3.143 
MDF1 –2.168 –7.621 
KREMEN2 –2.336 –2.003 
CPNE8 –3.008 –4.695 
The table shows the list of genes that were selected from the microarray dataset for 
validation by qRT-PCR analysis and their respective fold changes as determined by 
microarray and by qRT-PCR.  
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+T PDX Show Gene Expression Profiles that are More Similar to the Original 
Patient Sample  
Next we performed experiments to determine whether +T PDX provide an in vivo 
environment more like the patient than –T PDX and if this could be achieved with short 
term in vivo hTSLP exposure. PDX were established using CRLF2 B-ALL cells from 
Patient 2. Injection of stromal cells from transduction 2 were not initiated until two weeks 
prior to euthanasia (Figure 6A). At euthanasia BM was harvested and stained for flow 
cytometry to verify CRLF2 B-ALL engraftment (Figure 6B). Human leukemia cells were 
isolated from the BM of +T and –T PDX by magnetic separation for RNA sequencing. 
Differential gene expression analysis identified 503 genes that were upregulated and 117 
that were downregulated at least 2-fold in CRLF2 B-ALL cells from +T as compared to –
T PDX (Figure 6C). Similar to what we observed with Patient 1, GSEA analysis of RNA 
sequencing data showed an enrichment for genes regulated downstream of mTOR in 
CRLF2 B-ALL cells from +T as compared to –T PDX (FDR q-value = 0.00048, Figure 
6D). A comparison of +T PDX to –T PDX showed similar immunophenotypes to each 
other and to that reported for the respective original Patient 1 and Patient 2 samples 
(Online Supplementary Table 1 and Figure S7), indicating that the differences in mTOR-
regulated gene expression are unlikely due to selective survival of different clones. These 
data demonstrate that in vivo hTSLP-induced changes in mTOR regulated gene 
expression can be observed after short term stimulation and validate our model in a 
second primary CRLF2 B-ALL patient sample.  
To determine whether +T PDX provide an in vivo environment that is more 
similar to the patient than –T PDX, we compared gene expression profiles of +T and –T 
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PDX to the original ex vivo CRLF2 B-ALL patient sample. Human leukemia cells were 
isolated from the BM of +T and –T PDX generated from Patient 2, and from the original 
primary Patient 2 sample by magnetic separation. RNA sequencing was performed to 
determine whole genome expression. Analysis of gene expression by unsupervised 
clustering and Spearman rank correlation show that gene expression in +T PDX, as 
compared to –T PDX, is significantly more closely correlated to the original patient 
sample (Figure 6E). These data validate the use of +T/–T xenograft mice as an in vivo 
preclinical model system for studies to understand the role of hTSLP in normal human B 
cell production and in the development and progression of CRLF2 B-ALL.  
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Figure 6 (Figure 23). +T PDX show gene expression profiles that are more similar to 
the original patient sample. (A) –T and +T NSG mice were transplanted with primary 
CRLF2 B-ALL cells from Patient 2. Beginning at ten weeks after leukemia transplant 
mice received two injections with 5X106 stromal cells (transduction 2 stroma) one week 
apart. (B) Twelve weeks post-transplant, mice were euthanized, BM was harvested and 
cells were stained with mCD45 and hCD19 to identify human B-ALL cells. CRLF2 
staining (black overlay) on gated hCD19+ cells is shown in bottom panels. Isotype 
control is shown in gray. (C) Human hCD19+ B-ALL cells were isolated by magnetic 
separation and RNA sequencing with differential gene expression analysis was 
performed to identify genes that are differentially regulated in +T as compared to –T 
PDX. Graphed are the numbers of significantly up or down-regulated gene (≥2 fold, p≤ 
.05) in CRLF2 B-ALL cells from +T as compared to –T PDX. (D) GSEA of RNA 
sequencing data shows that CRLF2 B-ALL cells harvested from +T PDX exhibit an 
increase in expression of genes regulated downstream of mTOR signaling as compared 
to cells from –T PDX. The top half of the GSEA enrichment plot shows the enrichment 
score for each gene and the bottom half shows the values of the ranking metric moving 
down the list of the ranked genes. (E) RNA sequencing was performed on CRLF2 B-
ALL cells isolated by magnetic separation from 2 +T PDX mice (+T PDX M1 and M2) 
and 2 –T PDX mice (–T PDX M1 and M2) and from the original Patient 2 primary 
sample used to generate them. Graphed is a dendrogram of unsupervised hierarchical 
clustering and heatmap of Spearman rank correlation values showing that gene 
expression in +T PDX is significantly more closely correlated to the original sample 
than is –T PDX. p<.0001. Spearman rank coefficients are shown in Online 
Supplementary Figure S5. Significance of differences in correlation coefficients was 
determined using Fisher’s r-to-z transformation. 
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Supplementary Figure S5 (Figure 24). Spearman rank coefficients for comparisons of 
gene expression in +T and –T PDX to original patient sample. A) CRLF2 B-ALL cells 
from Patient 2 were used to generated –T and +T PDX mice as described in Figure 6. RNA 
sequencing was performed on CRLF2 B-ALL cells isolated from 2 +T mice (+T PDX M1 
and M2) and 2 –T PDX mice (–T PDX M1 and M2) and from the original Patient 2 primary 
sample used to generate them. Spearman rank coefficients are shown for comparison of 
gene expression in +T and –T PDX and in the primary patient sample. The comparisons 
between +T and –T PDX and the primary patient sample are highlighted to match the 
heatmap in Figure 6E.  
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Supplemental Figure S7 (Figure 25). Surface immunophenotype CRLF2 B-ALL 
from –T and +T PDX. +T and –T PDX were stained for flow cytometry to determine 
immunophenotype with respect to marker expression on the original primary CRLF2 
B-ALL patient sample (see Online Supplementary Table 1). Plotted is expression of 
indicated markers on gated living human CD19+ leukemia cells in –T and +T PDX 
samples from Patient 1 and Patient 2 
 137 
Discussion  
PDX provide a critical complement to other models in understanding normal and 
malignant human B lymphopoiesis in context of the broad background of human genetic 
variation. A limitation of PDX is the reduced cross-species activity of some cytokines. 
Classic immune deficient mice, including NSG mice, selectively support B lineage 
differentiation. This is because IL-7, a cytokine important for human B cell production 
(Parrish et al., 2009) shows high species cross reactivity (Johnson, Shah, Panoskaltsis-
Mortari, & LeBien, 2005) while myeloid supportive cytokines do not. Here we show that 
mTSLP does not induce the increases in STAT5 and PI3K/AKT/mTOR phosphorylation 
induced by hTSLP in CRLF2 B-ALL cells (Figure 1). CRLF2 B-ALL cells express 
abundant IL-7R and CRLF2 as compared to normal B cell precursors (Figure 1 and S1) 
and thus provide a sensitive test for mTSLP activity. These data establish that the classic 
mouse xenograft models do not provide cross-species activation of the human TSLP 
receptor.  
The goals of the studies described here were to develop a xenograft model that 
expresses hTSLP and to validate the effects of hTSLP produced in the model on normal 
and malignant B cell precursors. We engineered NSG mice that express normal serum 
levels of hTSLP (+T mice) or that lack hTSLP (–T mice) (Figure 2) by intraperitoneal 
injection with stroma transduced to express hTSLP (+T stroma) or with a control vector 
(–T stroma) (Figure 2). hTSLP produced by +T stroma induced in vitro STAT5 and 
PI3K/AKT/mTOR pathway activation (Figure 2) and showed in vivo functional effects as 
indicated by selective expansion of normal B cell precursors (Figure 3-4, S3, S4) and 
upregulation of the mTOR pathway in primary CRLF2 B-ALL cells (Figure 5-6). The 
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studies described here establish and validate a novel hTSLP+/– xenograft model system 
while providing the first data on the in vivo impact of hTSLP on normal B cell 
development and primary CRLF2+ B-ALL cells. 
Normal serum levels of hTSLP were achieved in our model, however, a novel 
aspect of our model is the ability to modulate serum levels of hTSLP based on the timing 
and number of stromal cells injected intraperitoneally. The ability to vary hTSLP levels 
or initiate hTSLP at time points after transplant of hematopoietic cells offers advantages 
for experimental design. The ability to modulate serum levels of hTSLP is also 
biologically relevant because TSLP production is increased by environmental factors 
such as pollutants and allergens and is upregulated in some autoimmune diseases and 
solid tumors (Ziegler et al., 2013). TSLP is primarily produced by cells residing outside 
the BM (immune cells, smooth muscle cells, gut and skin epithelial cells),(Takai, 2012) 
although human BM stroma do produce hTSLP (Allakhverdi et al., 2013). Thus, the 
major source of hTSLP that acts on normal and malignant B cells in vivo in patients is 
likely to be produced outside the marrow as it is in our model.  
Little is known about cellular mechanisms that contribute to the initiation, 
progression and maintenance of CRLF2 B-ALL or the biological factors that contribute 
to the health disparities associated with this disease. Studies of the relationship between 
inherited genetic variation and susceptibility to ALL provide some clues to the 
relationship of ALL to ethnicity (Xu et al., 2013). Patient-derived xenograft (PDX) 
models are particularly critical for health disparities diseases where inherited genetic 
variation or alterations such as Down Syndrome are likely to play a role in disease 
progression (Liem et al., 2004; Lock, Liem, & Papa, 2005). The ability to generate PDX 
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mice that provide hTSLP make it possible to study the initiation, progression and 
maintenance of CRLF2 B-ALL from normal human progenitors transduced to 
overexpress CRLF2 on a range of genetic backgrounds.  
The +T and –T PDX generated in the studies described here did not show 
consistent differences in the leukemia cell burden (Online Supplementary Figure S6). 
However, changes in gene expression that contribute to chemoresistance would not 
necessarily be expected to impact leukemia burden in untreated PDX, but would instead 
be revealed following chemotherapy. CRLF2 B-ALL is a leukemia at high risk for 
relapse and the mTOR pathway is known to play a role in chemoresistance in multiple 
malignancies (Jiang & Liu, 2008). The ability of +T PDX to model TSLP-induced mTOR 
activation makes this an important model for understanding and identifying therapeutic 
strategies for overcoming chemoresistance in CRLF2 B-ALL. Our finding that gene 
expression +T PDX is significantly more like the original patient sample than –T PDX 
(Figure 6E, S5) support the use of +T PDX mice as a preclinical model of CRLF2 B-
ALL. PDX generated from +T and –T mice and CRLF2 B-ALL samples obtained from 
Hispanic or Down Syndrome pediatric patients will allow us to study disease mechanisms 
1) in context of a genetic background associated with CRLF2 B-ALL health disparities 
and 2) in context of TSLP-CRLF2 mediated signals present in vivo in the patient.  
The model developed here provides an important new tool for understanding the 
mechanisms of TSLP activity in normal and malignant B lymphopoiesis. It also provides 
a preclinical model for identifying therapies to effectively treat CRLF2 B-ALL in an 
environment that can induce the TSLP-mediated signals present in vivo in patients and in 
context of the genetic background that leads to health disparities in this disease.  
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CHAPTER FOUR 
TSLP OR IL-7 PROVIDE AN IL-7R SIGNAL THAT IS CRITICAL FOR 
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Abstract 
Thymic stromal lymphopoietin (TSLP) and IL-7 are cytokines that signal via the 
IL-7 receptor alpha (IL-7R) to exert both overlapping and unique functions during early 
stages of mouse B cell development. In human B lymphopoiesis the requirement for IL-
7RΑ the roles of IL-7 and TSLP are less clear. Here we 
evaluated human B cell production using novel in vitro and xenograft models of human B 
cell development that provide selective IL-7 and human TSLP (hTSLP) stimulation.  We 
show that in vitro human B cell production is almost completely blocked in the absence 
of IL-7RΑ -7 can provide a signal critical for the 
production and proliferation of human CD19+ PAX5+ pro-B cells. Analysis of primary 
human bone marrow (BM) stromal cells show that they express both IL-7 and TSLP 
providing an in vivo source of these cytokines. Using novel xenograft models we show 
that the in vivo production of human pro-B cells under the influence of mouse IL-7 is 
reduced by anti-IL-7 neutralizing antibodies, and this loss can be restored by hTSLP at 
physiological levels. These data establish the importance of IL-7R-mediated signals for 
normal human B cell production. 
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Abbreviations  
BM   Bone Marrow  
CB   Umbilical Cord Blood 
FMO   Fluorescence Minus One 
hTSLP   Human Thymic Stromal Lymphopoietin 
IL-7R  IL-7 Receptor Alpha 
TSLP   Thymic Stromal Lymphopoietin 
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Introduction  
IL-7R
cell production is IL-7RΑ-independent (von Freeden-Jeffry et al., 1995). IL-7R
component of two distinct cytokine receptor complexes with different secondary chains, 
one activated by IL-7 and the other by TSLP (Zhang et al., 2001). In adult mice where 
IL-7 is knocked out, there is a block in B cell precursor production that can be restored by 
TSLP, but only at the supra-physiological levels achieved in TSLP transgenic mice 
(Chappaz, Flueck, Farr, Rolink, & Finke, 2007).  
The role of IL-7R signals in human B cell development is controversial (Corfe 
& Paige, 2012; Sportes, Gress, & Mackall, 2009). Patients with defective IL-7R signaling 
exhibit severe combined immunodeficiency (SCID) characterized by a loss of T cells 
(Macchi et al., 1995; Noguchi et al., 1993; Puel, Ziegler, Buckley, & Leonard, 1998; 
Russell et al., 1995). Although B cell function may be compromised in these patients, B 
cell numbers are normal (Giliani et al., 2005), suggesting that human B lymphopoiesis 
differs from that in mice with respect to the requirement for IL-7R-mediated signals. 
However, these data are obtained during the first year of life consistent with fetal B cell 
production through an IL-7R-independent process similar to mouse. Early in vitro 
studies also suggested that human B cell production is IL-7-independent, however, these 
were often performed using fetal hematopoietic sources or culture models that produced 
mouse IL-7 which was later shown to activate human IL-7R (Johnson, Shah, 
Panoskaltsis-Mortari, & LeBien, 2005). Although fetal B cell production is not dependent 
on IL-7 or TSLP, both of these cytokines can stimulate in vitro proliferation of human 
fetal B cell precursors (Scheeren et al., 2010). 
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Our previous in vitro studies, performed using a human-only co-culture model, 
showed that human B cell production beyond the fetal period is increasingly dependent 
on a signal that can be provided by IL-7 (Parrish et al., 2009). The ability of TSLP to 
replace IL-7 in providing this signal is unknown and the importance of IL-7R–IL-
7R n for in vivo human B lymphopoiesis has not been demonstrated. 
Recently we developed a novel xenograft model and it showed that physiological levels 
of human TSLP (hTSLP) increase human B cell production, in vivo, in context of IL-7 
(Francis et al., 2015). Here we use novel in vitro and xenograft models, engineered to 
provide selective IL-7 and hTSLP stimulation, to evaluate the requirement for IL-7R IL-
7R signals in post-fetal human B cell production and the ability of hTSLP to induce 
these signals at physiological levels.  
 
Results and Discussion 
TSLP or IL-7 can Provide a Signal Critical for the In Vitro Production of Human 
B Cell Precursors 
To investigate the role of IL-7R signals induced by TSLP and IL-7 in early 
stages of human B cell production, we developed a human-only co-culture model that 
supports the production of human pro-B cells and provides selective IL-7 or TSLP 
stimulation. Human umbilical cord blood (CB) CD34+ cells were cultured with primary 
human bone marrow (BM) stromal cells in media supplemented with human serum. 
Selective cytokine stimulation was achieved with combinations of exogenous human IL-7 
or TSLP and with neutralizing antibodies to counter activity of endogenously produced 
IL-7 and TSLP (Fig 1A). CB CD34+ cells were grown under selective cytokine 
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conditions for 3 weeks. Culture progeny were harvested and stained for flow cytometry to 
identify CD19+ PAX5+ B lineage cells. Control cultures that lacked TSLP or IL-7 
produced small numbers of B lineage cells (Fig 1B). In contrast, TSLP and IL-7 cultures 
showed robust production of CD19+ PAX5+ B lineage cells (Fig 1B). Cultures with 
TSLP or IL-7 produced similar numbers of B cell precursors (Fig 1C).   
To determine if TSLP-induced proliferation contributes to the increased 
production of human B cell precursors from CB CD34+ cells, we compared BrdU 
incorporation in cells generated under selective cytokine conditions (Fig 1D). 
Proliferation in TSLP cultures was significantly increased as compared to control cultures 
lacking IL-7R -7 (Fig 1E). These data 
demonstrate that TSLP can replace IL-7 in providing signals critical for in vitro 
production and proliferation of human CD19+ PAX5+ pro-B cells and that human B cell 
production is almost completely blocked in the absence of IL-7R stimulation. 
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Figure 1 (Figure 26). TSLP can replace IL-7 in supporting the in vitro production 
and proliferation of human CD19+ PAX5+ B cell precursors. (A) Human-only 
cultures were produced by plating primary human CB CD34+ cells on primary human 
BM stroma. Selective cytokine stimulation was achieved by supplementing cultures 
with exogenous IL-7 or TSLP or neutralizing antibodies to TSLP (anti-T) or IL-7 
(anti-7) as indicated. Cultures without a particular neutralizing antibody were 
supplemented, as a control, with non-specific isotype-matched antibodies (ctrl Ig). All 
culture conditions included IL-3 and Flt-3 ligand. Cultures were maintained for 3 
weeks, then harvested and stained for flow cytometry. (B) Dot plots of CD19 vs. 
PAX5 staining in each culture condition are shown (representative of n=3 independent 
experiments). PAX5 fluorescence minus one (FMO) control is displayed in inset. (C) 
Graphed are the relative numbers of CD19+ cells (mean± SEM) generated in vitro 
under indicated conditions at three weeks (n=14). D) Representative dot plots of CD19 
vs BrdU staining in indicated conditions. BrdU FMO control is displayed in the inset 
of the Ctrl dot plot. (E) Graphed is the percent BrdU+ cells (mean± SEM) in the total 
CD19+ population generated under indicated conditions at three weeks (n=8). 
Statistical analysis was performed using one-tailed, t-test, *p<0.05, **p<0.001. Error 
bars represent mean ± SEM. 
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Human Bone Marrow Stromal Cells Express TSLP, as well as IL-7 
 To determine if the BM provides an in vivo source of TSLP we evaluated the 
ability of primary human BM stroma to produce TSLP. For comparison we evaluated IL-
7, which we have previously shown to be expressed by human BM stroma (Parrish et al., 
2009). RT-PCR analysis of stromal cells cultured from healthy donors showed TSLP and 
IL-7 transcripts (Fig 2A) that resulted in protein production as evidenced by TSLP and 
IL-7 in supernatants harvested from cultured cells (Fig 2B). These data demonstrate that 
human BM stroma provide an in vivo source of both cytokines in the normal human BM 
microenvironment where B cell precursors are generated. 
 
 
  
Figure 2 (Figure 27). IL-7 and TSLP are produced by human BM stroma. (A) RT-
PCR, was used to detect TSLP, IL-7 or beta-2 microglobulin (2M, control) transcripts 
in primary human BM stromal cells from different human donors – pediatric (BM #1 
and BM #2) and adult (BM #3) or culture medium as a negative control. Each patient 
sample was assessed in two or more different PCR reactions. (B) Supernatant from 
confluent BM stromal cell cultures were assessed by ELISA for TSLP and IL-7 
protein production. Data are expressed as mean ± SEM of triplicate values for TSLP, 
and duplicate values for IL-7. Dashed lines (---) represent ELISA threshold of 
detection.  
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IL-7R Signals Induced by TSLP or IL-7 Increase the In Vivo 
Production of Human B Cell Precursors 
Next we evaluated the in vivo role of IL-7R-mediated signals in human B cell 
development and the ability of physiological levels of TSLP to replace IL-7 in the 
induction of these signals. Mouse TSLP does not show cross-species activity on human 
cells (Francis et al., 2015) although IL-7 does (Barata et al., 2006; Johnson et al., 2005). 
Thus, classic xenografts provide IL-7, but not TSLP that can stimulate IL-7R signals. 
We used a novel human-mouse xenograft that provides normal serum levels of hTSLP 
(+T mice) and control (–T mice) that lack hTSLP (Francis et al., 2015) as an in vivo 
system for human B cell precursor production. To study in vivo human B cell precursor 
production under selective IL-7 and hTSLP stimulation, we established +T and –T 
xenografts with CB CD34+ cells and treated for two weeks with antibodies that 
neutralize mouse and human IL-7 (Grabstein et al., 1993) (Fig 3A). This allowed us to 
compare B lymphopoiesis in mice with 1) no hTSLP and reduced IL-7 (–T–7 mice); 2) 
no hTSLP and normal IL-7 (–T+7 mice); and 3) physiological hTSLP and reduced IL-7 
(+T–7 mice).  
Human progenitors and B cell subsets in the bone marrow of xenograft mice were 
identified by flow cytometry (Fig S1 in online Supporting Information) and cell numbers 
were compared (Fig 3). No differences in numbers of human hematopoietic stem cells or 
multi-potential progenitors was observed, including the earliest IL-7R+ progenitors 
(CD19–CD34+IL-7R+) (Fig 3B). In contrast, mice with normal IL-7 or with 
physiological levels of hTSLP showed a human pro-B compartment that was increased 
by 2-3 fold as compared to that observed in –T–7 mice (Fig 3C). Increases observed with 
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physiological hTSLP extended to the pre-B cell stage, although significant increases in 
pre-B cells were not achieved in –T+7 mice (Fig 3C). Later stages of B cell development 
were not impacted, which was not surprising, given the short anti-IL-7 treatment period 
(Fig 3C). No significant differences were detected in the numbers of non-B cells 
generated in mice with hTSLP or IL-7 as compared to –T–7 xenografts (Fig 3D). T 
lineage cells are not generated in xenograft mice at this time point and so were not a part 
of the non-B lineage compartment. These data show that the in vivo production of human 
pro-B cells under the influence of IL-7 is reduced by anti-IL-7 neutralizing antibodies, 
and this loss can be restored by hTSLP at physiological levels.  
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Figure 3  (Figure 28). IL-7 and TSLP increase the in vivo production of human B cell 
precursors in human-mouse xenografts. (A) Immune deficient NSG mice were 
engineered to express physiological levels of hTSLP (+T mice) or without hTSLP (–T 
mice) as described (Francis et al., 2015).  CB CD34+ cells were injected by tail vein 
into –T and +T mice. Five weeks later, –T mice and +T mice were treated for two weeks 
with anti-human/mouse IL-7 antibody or isotype-matched control antibody to generate 
–T–7 mice (no hTSLP and reduced IL-7), –T+7 mice (no hTSLP and normal IL-7), and 
+T–7 mice (physiological hTSLP and reduced IL-7). At 7 weeks post-transplant, mice 
were euthanized and BM harvested and stained for human specific markers to identify 
hematopoietic subsets (for gating see Fig S1 in online Supporting Information.) 
Graphed are the absolute numbers of cells in (B) progenitor populations, (C) B cell 
subsets, and (D) non-B cells in the BM of xenograft mice. Data shown were obtained 
from two different CB donors with a total of four mice per group. Statistical analysis 
was performed using one-tailed, unpaired t-test, *p<0.05 compared to –T–7 mice. Error 
bars represent mean ± SEM. 
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Supplemental Figure S1 (Figure 29). Flow cytometry to identify hematopoietic subsets 
in xenografts with selective IL-7 and hTSLP stimulation. Human CB CD34+ cells were 
injected by tail vein into mice engineered to express hTSLP (+T mice) or that lacked 
hTSLP (–T mice) as described in methods and previously reported (Francis, et al 2015). 
Beginning 5 weeks after injection of CD34+ cells, mice were treated for two weeks with 
neutralizing anti-human/mouse IL-7 antibody or isotype-matched control antibody to 
generate mice with no hTSLP and reduced IL-7 stimulation (–T–7 mice); mice with no 
hTSLP and normal IL-7 (–T+7 mice); and mice with physiological hTSLP and reduced 
IL-7 (+T–7 mice). Mice were euthanized seven weeks post-transplant and BM harvested 
and stained for human specific markers to identify progenitors, developmentally sequential 
B cell subsets and non-B cells in the BM of indicated xenograft groups. (A) Surface 
immunophenotypes used to identify indicated hematopoietic subsets in xenograft mice. (B-
D) Flow cytometry plots showing gating and representative data from n=4 xenografts in 
each group (B) –T–7 xenografts (C) –T+7 xenografts and (D) +T–7 xenografts. Gates were 
set based on isotype controls. 
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Concluding Remarks 
In summary, we used in vitro selective cytokine cultures to show that the 
production of human B lineage cells beyond the fetal period is dependent on an IL-7R-
mediated signal that can be provided by either TSLP or IL-7. We demonstrate that both 
of these cytokines are produced by normal human BM stroma. The validity of these 
findings for in vivo B lymphopoiesis is supported by the reduction in human B cell 
precursors observed following treatment with IL-7 neutralizing antibodies in xenografts 
and the ability of hTSLP to restore this loss.  
These studies provide in vivo evidence that IL-7R signals are required for 
normal human B cell production and proliferation beyond the fetal period and suggest 
that TSLP can replace IL-7 in providing these signals. Our data provide a potential 
explanation for the recent report that B lineage commitment is not blocked in SCID 
patients who have defects in IL-7 signaling components (common gamma chain and 
JAK3), but have an intact TSLP receptor signaling pathway (Kohn et al., 2014). Our 
studies suggest that therapies to stimulate or block IL-7- and TSLP-mediated IL-7R 
signals are likely to impact B cell production. Consistent with this, data from clinical 
trials showing that the administration of recombinant human IL-7 can increase newly 
formed B cells in the periphery and expand the bone marrow lymphoid compartment 
(Mackall, Fry, & Gress, 2011). 
 
Materials and Methods  
Additional details are available in the online Supporting Information.  
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Human Samples 
Umbilical CB and BM were obtained in accord with Loma Linda University 
Institutional Review Board (IRB) protocols and the Helsinki Declaration of 1975, as 
revised in 2008. Isolation of CB CD34+ cells and detection of TSLP production in BM 
stroma are described in online supplementary methods.  
 
Selective-Cytokine Co-Cultures  
CB CD34+ cells were seeded on primary human BM stroma and maintained as 
described (Parrish et al., 2009) with media containing 5% human AB serum (Omega 
Scientific, Tarzana, CA). All cultures, including control, were supplemented with IL-3 
and Flt-3 Ligand. For selective cytokine stimulation, hTSLP and/or IL-7 (R&D Systems 
Inc., Minneapolis, MN) were added. If neither TSLP nor IL-7 was added, cultures were 
further supplemented with neutralizing antibodies to counter activity of endogenously 
produced TSLP and/or IL-7. Cultures without cytokine-specific neutralizing antibody 
were supplemented with an isotype-matched control. Co-cultures were harvested at 3 
weeks. BrdU (Sigma-Aldrich, St. Louis, MO) was added for the final 24 hours in some 
cultures. 
 
Animal Studies  
Studies were performed using NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice 
(Jackson Laboratory) under protocols approved by the Loma Linda University 
Institutional Animal Care and Use Committee (IACUC). Mice were engineered by 
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intraperitoneal injection with stroma transduced to express hTSLP (+T mice) or with 
control vector (–T mice) as described (Francis et al., 2015). +T and –T mice were 
transplanted with CD34+ cells by tail vein injection, after sub-lethal irradiation. Five 
weeks after CB transplantation, anti-mouse/human IL-7 neutralizing antibody or isotype-
matched control (BioXCell, West Lebanon, NH) was injected as described in previous 
studies that used this anti-IL-7 antibody to inhibit in vivo mouse B lymphopoiesis 
(Grabstein et al., 1993).  
 
Supplementary Methods 
Human Samples 
Umbilical cord blood (CB) and bone marrow (BM) were obtained in accordance 
with protocols approved by the Loma Linda University Institutional Review Board (IRB) 
and with the Helsinki Declaration of 1975, as revised in 2008. Umbilical cord blood (CB) 
was obtained from placentas after caesarean section delivery of full-term neonates at 
Loma Linda University Medical Center. Mononuclear cells were isolated using Ficoll-
Paque Plus (GE Healthcare Bio-Sciences, AB) or by red blood cell (RBC) lysis (Kang et 
al., 2002). CD34+ cells were isolated by magnetic separation with CD34+ microbeads 
(Miltenyi Biotec, Auburn, CA) and stored in liquid nitrogen for subsequent use. Pediatric 
BM samples were obtained as waste samples remaining after clinical procedures under an 
LLU Institutional Review Board (IRB)-approved protocol. Adult BM and stromal cells 
were purchased from Lonza Inc. (Walkersville, MD). Stromal cells were isolated from 
pediatric and adult BM as previously described (Nolta et al., 2002) and maintained in 
IMDM medium supplemented with 15% horse serum, 15% FBS, hydrocortisone, 2-
mercaptoethanol, penicillin-streptomycin and L-glutamine.  
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In Vitro Co-Cultures  
Human-only in vitro co-cultures were initiated as previously described (Parrish et 
al., 2009) which primarily yield pro-B cells. Briefly, CB CD34+ cells were seeded onto 
pre-plated primary human BM stromal cells, at 10,000 to 20,000 cells per well in 96-well 
plates. For some experiments, numbers were scaled up to give equivalent cell densities in 
6-well and 12-well plates. Cultures were maintained in RPMI 1640 medium (Irvine 
Scientific, Santa Ana, CA) supplemented with penicillin/streptomycin, L-glutamine, 50 
uM 2-mercaptoethanol and 5% human AB serum lot tested to support human B cell 
production (Omega Scientific, Tarzana, CA). All cultures, including control, were 
supplemented with IL-3 (1 ng/ml; first week only) and Flt-3 Ligand (1 ng/ml, 
continuously), two cytokines that support early lymphoid progenitors (Crooks, Hao, 
Petersen, Barsky, & Bockstoce, 2000; Shah, Smogorzewska, Hannum, & Crooks, 1996). 
For selective cytokine stimulation human TSLP (10 ng/ml) or human IL-7 (5 ng/ml) or 
no cytokines (control cultures) were added. All cytokines were from R&D Systems Inc. 
(Minneapolis, MN). If TSLP or IL-7 was not added, cultures were further supplemented 
with an anti-human neutralizing antibody to counter activity of any endogenously 
produced TSLP or IL-7. Cultures without a specific neutralizing antibody (anti-IL-7 or 
anti-TSLP) were supplemented with an isotype-matched control for the neutralizing 
antibody. Anti-human neutralizing or control antibody for IL-7 was used at 10 ng/ml (BD 
Pharmingen, Franklin Lakes, NJ). Anti-human neutralizing or control antibody for TSLP 
was used at 1 ug/ml (R&D Systems and Jackson ImmunoResearch, West Grove, PA). 
Media, cytokines, and antibodies were replenished weekly. Cultures were maintained for 
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three weeks, and then harvested. For BrdU incorporation, selective cytokine cultures 
-Aldrich, St. Louis, MO) for the final 24 hours of 
culture. 
 
Flow Cytometry 
For detection of surface antigens, cells were stained using standard flow 
cytometry protocols, followed by fixation and permeabilization as described below to 
detect intracellular antigens. To discriminate living from dying cells, in some 
experiments, cells were stained with fixable viability dyes (eBioscience, San Diego, CA), 
per manufacturer’s instructions.  
To assess intracellular IgM, the Fix & Perm® cell fixation and permeabilization 
kit (Life Technologies, Grand Island, NY)) was used according to manufacturer’s 
instructions. All antibodies were monoclonal, anti-human antibodies, unless otherwise 
stated. Intranuclear detection of BrdU was performed using BrdU Flow Kit option no. 2 
(BD Pharmingen) according to manufacturer’s instructions. Briefly, cells were harvested, 
surface stained, washed then fixed with BD cytofix/cytoperm buffer (BD Biosciences) for 
15-30 minutes at room temperature. Cell suspensions were washed, then stored overnight 
in freezing medium (90% FBS and 10% DMSO) at –80ºC. The following day, thawed 
cells were washed, re-fixed in BD cytofix/cytoperm buffer and washed with BD 
perm/wash buffer. Cells were treated with DNase (300 ug/ml, Sigma-Aldrich) for 1 hour 
at 37ºC, washed then stained with anti-BrdU FITC or isotype-matched control for 20 
minutes at room temperature. Cells were washed then resuspended in 1% PFA for 
acquisition. To assess intracellular PAX-5, cells were first surface stained for viability 
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and surface markers, then fixed and permeabilized with FoxP3 fix/perm buffer 
(eBioscience) for 30-60 minutes at 4ºC in the dark. Cells were washed, resuspended in 
permeabilization buffer and stained with PAX-5 PE or isotype-matched controls for 30 
minutes at room temperature. Cells were washed then resuspended in 1% PFA for 
acquisition. In some experiments, cells were simultaneously stained for PAX-5 and 
BrdU. In these experiments cells were first stained for PAX-5 according to 
manufacturer’s directions, followed by BrdU staining according to manufacturer’s 
instructions. 
Antibody Clone Manufacturer 
BrdU FITC B44 BD Biosciences (San Jose, CA) 
Ig κ light chain FITC G20-193 
Ig λ light chain FITC JDC-12 
IgM PE Cy-5  G20-127 
CD19 APC HIB19 
CD34 PerCP 8G12 
CD34 APC 8G12 
CD34 APC.Cy7 581 Biolegend (San Diego, CA) 
IgD PE IA6-2 
CD19 APC HIB19 eBioScience (San Diego, CA) 
CD19 PE.Cy7  SJ25C1 
CD45 PE.Cy7  HI30 
CD127 PE eBioRDR5 
Ig κ light chain eFluor 450 TB28-2 
Ig λ light chain eFluor 450 1-155-2 
PAX-5 PE 1H9  
Anti-Mouse CD45 FITC 30F11 Miltenyi Biotec (Auburn, CA) 
CD19 APC LT19 
CD34 APC AC136 
CD127 PE MB15-18C9 
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Polymerase Chain Reaction 
Total RNA was extracted from 8 to 9 x 105 human stromal cells with RNA-STAT 
60 reagent (Tel-Test Inc., Friendswood, TX). cDNA was synthesized using Omniscript 
Reverse Transcriptase (Qiagen, Valencia, CA). The expression of TSLP, IL- -2 
microglobulin as a control, were assessed by touch down PCR. The primers used were: 
TSLP forward 5’-TCG TAA ACT TTG CCG CCT AT-3’ and reverse 5’-TGG TGC TGT 
GAA ATA TGA CCA-3’ (324 bp); IL-7 forward 5’- CTC CCC TGA TCC TTG TTC TG 
and reverse 5’- TCA TTA TTC AGG CAA TTG CTA CC- -2 
microglobulin forward 5’-CTC GCG CTA CTC TCT CTT TC-3’ and reverse 5’-CAT 
GTC TCG ATC CCA CTT AAC-3’ primers. 
 Touch-down PCR conditions for TSLP were as follows: 95°C for 5 min (1 cycle); 
95°C for 1 min, 61°C for 30 sec. 72°C for 1 min (2 cycles); 95°C for 1 min, 59°C for 30 
sec. 72°C for 1 min (2 cycles); 95°C for 1 min, 57°C for 30 sec. 72°C for 1 min (2 
cycles); 95°C for 1 min, 55°C for 30 sec. 72°C for 1 min (2 cycles); 95°C for 1 min, 53°C 
for 30 sec. 72°C for 1 min (2 cycles); 95°C for 1 min, 51°C for 30 sec. 72°C for 1 min 
(30 cycles); 72°C for 10 min (1 cycle); and final hold step of 4°C.  
Touchdown PCR conditions for IL-7 were as follows: 95°C for 5 min (1 cycle); 
95°C for 1 min, 63°C for 45 sec. 72°C for 1 min (2 cycles); 95°C for 1 min, 61°C for 45 
sec. 72°C for 1 min (2 cycles); 95°C for 1 min, 59°C for 45 sec, 72°C for 1 min (2 
cycles); 95°C for 1 min, 57°C for 30 sec. 72°C for 1 min (2 cycles); 95°C for 1 min, 55°C 
for 45 sec. 72°C for 1 min (2 cycles); 95°C for 1 min, 53°C for 45 sec. 72°C for 1 min 
(30 cycles); 72°C for 10 min (1 cycle); and final hold step of 4°C.  
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Amplified PCR products were visualized with a 2.2% FlashGel (Lonza, 
Walkerswood, MD). PCR products were purified with QIAquick PCR purification kit 
(Qiagen, Valencia, CA) and sequenced at the Genomics Core (University of California, 
Riverside, CA). 
Animal Studies 
Studies were performed using NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice 
(Jackson Laboratory). Mice were housed under specific pathogen-free conditions in the 
Loma Linda University animal facility and studied in accordance with an Institutional 
Animal Care and Use Committee (IACUC) approved protocols. Mice were engineered by 
intraperitoneal injection with HS-27 stromal cells (ATCC, Manassas, VA) that had been 
transduced to express human TSLP (+T mice) or transduced with empty vector (–T mice) 
as previously described (Francis et al., 2015). Transduction of stroma and injection of 
stromal cells were performed as described (Francis et al., 2015). Mice were transplanted 
by tail vein injection with freshly thawed,  CB CD34+  cells after sub-lethal irradiation at 
225 cGy. Five weeks after CB transplant, 3 mg MAb anti-mouse/human IL-7 (clone: 
M25) or IgG2b isotype-matched control (clone: MPC-11, BioXCell, West Lebanon, NH) 
was injected, i.p. every 3–4 days for 2 weeks as described in previous studies that used 
this anti-IL-7 antibody to inhibit in vivo mouse B lymphopoiesis (Grabstein et al., 1993). 
NSG mice were euthanized by CO2 asphyxiation, seven weeks after CB CD34+ 
transplantation and BM was harvested and frozen for flow cytometry analysis. 
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CHAPTER FIVE 
UNPUBLISHED DATA: EFFECTS OF TSLP ON B CELL DIFFERENTIATION 
FROM HUMAN ADULT BONE MARROW HAEMATOPOIETIC STEM CELLS 
 
Abstract 
Studies from mice suggest that during ontogeny, B cell progenitors respond 
differently to TSLP. The ability of TSLP to expand B cell production from adult bone 
marrow HSCs has not been evaluated in humans. Using an innovative human selective 
cytokine co-culture, we demonstrate that in the absence of IL-7, TSLP does not increase 
the production of B cell progenitors. This data suggests that TSLP may not be as 
important for adult lymphopoiesis. 
 
Introduction 
 In mice and men, the bone marrow (BM) is the primary organ of post-natal B 
lymphopoiesis and identifying the cytokines that drive the differentiation and growth of B 
cell progenitors in this organ has been a major topic of study. TSLP and IL-7, members 
of the same cytokine family (Sims et al., 2000), were initially found to have overlapping 
yet distinct functions in promoting B cell development in mice. In culture, both mouse 
TSLP and IL-7 stimulated the proliferation of B cell precursors. TSLP facilitated 
differentiation to the IgM+ stage, while IL-7 supported differentiation to an earlier IgM– 
stage (Levin et al., 1999).  In addition to that difference, data from other studies suggest 
that TSLP may play a role at different points in mouse ontogeny. B cell progenitors from 
fetal liver were TSLP-responsive, while those from the BM were responsive only after 
the pre-B cell receptor was expressed (Vosshenrich, Cumano, Muller, Di Santo, & Vieira, 
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2003, 2004). Furthermore, in the absence of IL-7, intrinsic TSLP levels were unable to 
sustain B cell production in the bone marrow of these (Vosshenrich et al., 2003). 
However when overexpressed, TSLP restored the B cell compartment in adult IL-7 
deficient mice (Chappaz, Flueck, Farr, Rolink, & Finke, 2007). 
 While the ability of TSLP to replace IL-7 has been evaluated in the mouse, little is 
known about its role in modulating human B cell differentiation from HSCs. To date, a 
single study exists, which examined human TSLP in fetal B lymphopoiesis. Like the 
mouse, human fetal B cell precursors, proliferated in response to human TSLP (Scheeren 
et al., 2010). Our group recently found that human TSLP increased the numbers of B cell 
precursors generated in in vivo (Chapter 3) (Francis et al., 2015) and in vitro (Chapter 4) 
models of CB lymphopoiesis. Here we set out to determine if human TSLP also 
promoted the growth and differentiation of B cell progenitors from adult bone marrow 
HSCs, similarly to fetal HSCs. These preliminary findings suggest that TSLP may not be 
a major player in human adult B cell development. 
 
Materials and Methods 
Cell Sources 
Human adult BM and stromal cells were purchased from Lonza Inc. 
(Walkersville, MD) and mononuclear cells were isolated by density-gradient 
centrifugation using Ficoll-Paque Plus (GE Healthcare Bio-Sciences, AB) or by red blood 
cell (RBC) lysis buffer (Kang et al., 2002). The adult BM mononuclear cells were 
enriched for CD34+ hematopoietic stem cells (typically >80% purity as determined by 
post isolation flow cytometry analysis) using a direct CD34+ cell isolation kit (Miltenyi 
Biotec, Auburn, CA). CD34+ cells were frozen and stored in liquid nitrogen until further 
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use. Adult BM stromal cells were isolated from total BM as previously described (Nolta 
et al., 2002). The stromal cells were maintained in IMDM medium supplemented with 
15% horse serum, 15% FBS, hydrocortisone, 2-mercaptoethanol, penicillin-streptomycin 
and L-glutamine. All cells were used in accordance with the Institutional Review Board 
(IRB) guidelines of Loma Linda University. 
 
In Vitro Co-Cultures  
Human only co-cultures were initiated as previously described (Parrish et al., 
2009). Briefly, adult BM CD34+ cells were seeded unto pre-plated primary human BM 
stromal cells, at 20,000 to 32,000 cells per well in 96-well plates. For some experiments 
numbers were scaled up to give equivalent cell densities in 6-well and 12-well plate. 
Cultures were maintained in B cell medium [RPMI 1640 medium (Irvine Scientific), 
penicillin/streptomycin, L-glutamine, 50 uM 2-ME and 5 % human AB serum lot tested 
to support B cell production (Omega Scientific)]. Cultures were supplemented with 1 
ng/ml IL-3 during the first week only and 1 ng/ml Flt-3 Ligand, 10 ng/ml TSLP and/ or 5 
ng/ml IL-7. All cytokines were from R&D Systems Inc. (Minneapolis, MN). Cultures 
were further supplemented with anti-human neutralizing or control antibody for Flt3-
Ligand at 0.05 ug/ml (R&D Systems); anti-human neutralizing or control antibody for 
IL-7 at 10 ng/ml (BD Pharmingen); or anti-human neutralizing or control antibody for 
TSLP at 1 ug/ml (R&D Systems and Jackson ImmunoResearch, respectively). Each 
week, half of the old medium was removed and replaced with fresh medium 
supplemented in the same way. Neutralizing antibodies were added at saturating 
concentration. Cultures were maintained for three weeks then harvested.  
 173 
Flow Cytometry 
In vitro cultures were harvested, surface stained then resuspended in 1% PFA as 
previously described (Zhang et al., 2005). Data were acquired on either a FACSCalibur 
(BD Immunocytometry Systems) or MACSQuant® (Miltenyi Biotec), and then analyzed 
with FlowJo software v8 or v9 (FlowJo, Ashland, OR). All antibodies are monoclonal, 
anti-human antibodies unless otherwise stated. Clones are included in parentheses. From 
BD Biosciences (San Jose, CA): CD19 APC (HIB19), CD24 FITC (ML5), CD34 PerCP 
(8G12), and IgM PE.Cy5  (G20-127). From Biolegend (San Diego, CA): CD19 Pacific 
Blue (HIB19), CD24 PE.Cy7 (ML5) and CD34 APC.Cy7 (581). From eBioscience (San 
Diego, CA): CD19 APC (HIB19), CD127 Alexa-Fluor 647 (eBioRDR5) and CD127 PE 
(eBioRDR5). From Miltenyi Biotec (Auburn, CA): CD19 APC (LT19) and CD127 PE 
(MB15-18C9). 
 
Statistics 
Statistical analysis was performed using GraphPad Prism 6 (GraphPad Software, 
Inc., La Jolla, CA). 
 
Results and Discussion 
It is not known if TSLP-induced effects on human B cell development extend to 
the adult bone marrow or if they are restricted to HSCs from fetal and post-fetal sources. 
To evaluate the effects of TSLP in adult B cell development, BM CD34+ cells were 
enriched by magnetic separation and cultured on primary human BM stroma as 
previously described (Parrish et al., 2009). As shown in Figure 30A, four culture 
conditions were created from combinations of IL-3, Flt-3 ligand, TSLP and/or IL-7. In 
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control conditions with IL-3 and Flt-3 ligand, a few B cell progenitors were produced 
(Figure 30B and C). While the size of this B cell progenitor population significantly 
increased with the addition of IL-7, TSLP supplementation did not increase the number 
of B cell precursors above control conditions (Figure 30B and C). Conditions with both 
TSLP and IL-7 stimulation generated similar numbers of B cell precursors to the IL-7 
only condition (Figure 30B and C). Allakhverdi et al. demonstrated that human CD34+ 
progenitors express both IL-7R and TSLPR chains and are responsive to TSLP in an 
allergy model (Allakhverdi et al., 2009). Therefore we do not attribute the failure to 
impact B cell production on the absence of the receptor components. 
As TSLP has been shown to promote the differentiation of adult mouse B cells to 
the IgM+IgD– immature B cell stage (Levin et al., 1999), we also evaluated IgM 
expression on B cell progenitors generated in our selective cytokine cultures. No IgM+ 
immature B cells were produced in control, TSLP, IL-7 nor TSLP+IL-7 conditions 
(Figure 30B). Signaling through IL-7R is known to upregulate CD19 expression   in 
human B cell progenitors (Billips et al., 1995; Parrish et al., 2009; Wolf, Weng, 
Stieglbauer, Shah, & LeBien, 1993). As expected, pro-B cells generated with IL-7 had 
higher levels of CD19 than control (Figure 30B, D and data not shown). However, pro-B 
cells from TSLP conditions did not exhibit increased CD19 expression.  
Collectively, these initial data suggest that B cell progenitors, produced from 
adult bone marrow CD34+ cells, are not responsive to TSLP stimulation, like their 
neonatal CD34+ cells are in our selective cytokine cultures (Chapter 4). It will be of 
interest to evaluate adult B cell differentiation in the +TSLP mice, as they permit the 
differentiation of B cell progenitors through the mature B cell stage. 
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Figure 30. TSLP does not increase B cell production from human adult bone marrow (BM) 
HSCs in selective cytokine co-cultures. (A) Experimental design of selective cytokine co-
cultures. Adult BM CD34+ HSCs were cultured on primary human BM stromal cells with 
combinations of IL-3 (1 ng/ml, for the first week only), Flt-3 ligand (1 ng/ml) and TSLP 
(10 ng/ml) and/or IL-7 (5 ng/ml) for 3 weeks as illustrated. Neutralizing antibodies to TSLP 
and/or IL-7 were added to the cultures to counter the effects of any endogenously produced 
cytokines if TSLP or IL-7 was not added. Cultures were harvested and stained with 
antibodies to identify (B) B cell precursors (CD19+ CD34+ or CD34–) generated in vitro. 
(C) Graphed is the relative number of total B cell precursors (CD19+) produced in each 
condition. Relative cell number was determined by normalizing the number of CD19+ cells 
generated in each condition to the total CD19+ cells generated in all 4 conditions. (D) 
Cultures were also stained with antibodies to distinguish immature B cells (CD19+IgM+) 
from B cell precursors (CD19+ IgM-). Data shown are representative of, or pooled from 6 
independent co-cultures initiated with adult BM HSCs. Statistical significance was 
determined by unpaired t test, 2-tailed (*, p< 0.05). 
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Abstract  
IL-7 receptor (IL-7R) signaling is essential for mouse B cell development, 
however its role in human B lymphopoiesis is controversial. Here we provide the first 
evidence that expression of a single marker, the IL-7R chain, can identify a lymphoid-
restricted CD19–CD34+ human progenitor population (IL-7R+ progenitors) that is 
completely devoid of myeloid potential. Single cell assays show that IL-7R+ progenitors 
include bi-potential B-NK cells, as well as lineage-committed B and NK progenitors. In 
vitro-generated IL-7R+ progenitors produced B and NK cells in xenograft mice. IL-7R+ 
progenitors were able to differentiate into T lineage committed cells with Notch 
signaling. IL-7R+ progenitors are rare (<2% of CD19–CD34+ cells) in circulating 
umbilical cord blood (CB), but comprise 20%-30% of CD19–CD34+ cells produced from 
CB CD34+ cells cultured in vitro or in vivo in the human-mouse xenograft model. These 
data suggest that IL-7R+ progenitors are common lymphoid progenitors in CB 
lymphopoiesis, previously undetected because of their low frequency in circulating CB. 
These committed lymphoid progenitors may provide a therapeutic alternative that have 
impact on clinical outcome such as immune reconstitution after CB stem cell transplant if 
proved to be expandable efficiently. 
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Introduction 
Insufficient lymphopoiesis can lead to compromised, adaptive immune function 
with increased susceptibility to infection and death. Insufficient lymphopoiesis is a 
feature of the early stages of immune reconstitution following hematopoietic stem (HSC) 
transplant (Fry & Mackall, 2005). It can also be a consequence of the myeloid skewing of 
hematopoiesis that has been associated with chronic inflammation (Esplin et al., 2011; 
Nagai et al., 2006) and with aging of the immune system (Ergen, Boles, & Goodell, 2012; 
Ergen & Goodell, 2010). The lymphocytes that are present in these cases often result 
from clonal expansion of mature cells, and thus the diversity of the adaptive immune 
response is also limited (Blackman & Woodland, 2011; Fry & Mackall, 2005). 
Identifying the lymphoid-restricted progenitor populations that are intermediates in the 
differentiation of lymphoid lineage cells from HSCs will provide a foundation for 
developing therapies to augment the production of lymphocytes. These populations could 
potentially be targeted for ex vivo (Zakrzewski et al., 2006) or in vivo (Liuba, Pronk, 
Stott, & Jacobsen, 2009) expansion to increase the de novo production of lymphocytes 
and restore a robust and diverse polyclonal adaptive immune response.  
Umbilical cord blood (CB) is a hematopoietic source used increasingly for HSC 
transplant, even in adults (Jacobson et al., 2012). As compared to adult BM and 
mobilized peripheral blood, CB transplant results in lower incidences of graft versus host 
disease (Broxmeyer, 2008). Thus, CB is an ideal source of stem/progenitors for 
augmenting lymphoid reconstitution. Previous studies aimed at identifying lymphoid-
restricted progenitors in CB lymphopoiesis have focused on cells present in circulating 
CB. The CD19–CD34+ progenitors in those studies were identified based on expression 
CD7 and/or CD10 and required the use of multiple lineage markers and additional 
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surface markers to eliminate cells with myeloid lineage potential (Hao et al., 2001; Rossi 
et al., 2003)  
In the mouse, expression of the IL-7 receptor α chain (IL-7R) is a distinguishing 
feature of the earliest lymphoid-restricted progenitors with B cell potential (Kondo, 
Weissman, & Akashi, 1997). Human B cell development has been thought to differ from 
that in mouse concerning the requirement for IL-7 (Lee, Namen, Gillis, Ellingsworth, & 
Kincade, 1989; Namen et al., 1988). However, in our previous studies we used a novel 
human-only co-culture system to show that IL-7 is critical for expanding human CD19+ 
B cell progenitors produced from HSCs in CB and for the production of human B lineage 
cells from adult BM. Here we show that IL-7R expression can be used alone to identify 
CD19–CD34+ progenitors that give rise to B/NK cells as well as T cells, but completely 
lack myeloid differentiation potential. These IL-7R+ progenitors are rare in circulating 
CB but comprise a substantial fraction of the CD19–CD34+ progenitors generated from 
HSCs during CB lymphopoiesis in vitro and in vivo in the xenograft model. Thus, IL-
7R+ progenitors represent a potential target population for therapies aimed at augmenting 
lymphocyte production to increase adaptive immune responses.  
  
Materials and Methods 
Cell Sources 
Cord blood samples were obtained by informed consent in accordance with 
approved Loma Linda University Institutional Review Board (IRB) protocols. Adult 
human BM was purchased from Poietics Cell Systems (Lonza, Walkersville, Inc., 
Gaithersburg, MD). The murine S17 stromal cell line was kindly provided by Dr. 
Kenneth Dorshkind (Cumano, Dorshkind, Gillis, & Paige, 1990). The murine 
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OP9/OP9Delta1 stromal cell lines were kind gifts from J. C. Zuniga-Pflucker (University 
of Toronto, Ontario, Canada). 
 
Cell Cultures  
 Human CB CD34+ cells were seeded onto primary human BM stromal layers 
plated at 7000 cells/well in 96-well tissue culture plates. Cultures were maintained in B 
cell medium supplemented with IL-3 at 1 ng/ml (first week only) and Flt-3 ligand (FL) at 
1 ng/ml (both from R&D Systems Inc., Minneapolis, MN), as described previously 
(Parrish et al., 2009). After 2 weeks of culture, CD34+CD19– cells were harvested and 
FACS-sorted into IL-7R– and IL-7R+ subpopulations, which were used for lineage 
specific differentiation both in vitro and in vivo. For clonal myelo-erythroid assays 500 to 
1000 FACS sorted cells were plated into 1-mL of 1% methylcellulose media 
(MethoCultGFH4434; Stem Cell Technologies, Vancouver, BC). Colony Forming Units 
(CFUs) including CFU-GM, BFU-E/CFU-E and CFU-GEMM were counted after 14 
days in culture.  
To evaluate B and NK lineage potential, CB-derived cells cultured with the 
murine S17 stromal line for 2 weeks in B cell medium supplemented with IL-7 (5ng/mL), 
Flt-3 ligand (5ng/mL), and IL-15 (20 ng/mL), all from R&D Systems (Minneapolis, MN) 
(Hao et al., 2001). FACS Sorted CB cells (3000-5000 cells per well for bulk cultures or 
single cells per well for clonal assays) were seeded onto S17 stromal cells in 96-well 
plates. In vitro T-cell development cultures were carried out as described previously (La 
Motte-Mohs, Herer, & Zuniga-Pflucker, 2005). OP9-control and OP9-DL1 monolayers 
were prepared 1 day in advance by plating stromal cells at 2x105 cells/well in 6-well 
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culture dishes, and progenitor cell populations were plated at 1x105 cells per well onto 
stromal layer in α-MEM media (Cellgro) containing 20% fetal calf serum (FCS), 
supplemented with L-glutamine and penicillin/streptomycin. Culture medium was 
supplemented with 5 ng/mL of IL-7 and FL (R&D Systems, Minneapolis, MN). Media 
containing cytokines was replaced every 2-3 days and cells were transferred to new 
layers of OP9/OP9Delta1 stromal cells weekly. Cultures were evaluated weekly for T cell 
differentiation status.  
 
Flow Cytometry and Cell Sorting 
Cells were stained for flow cytometry analysis with standard protocols using the 
following mouse-anti-human antibodies: CD34 PerCP, CD19 Pacific Blue or APC, CD7 
PE or PE-Cy5, CD45-PE-Cy7, CD56 FITC and CD1a efluor450 from eBioscience; IL-
7Rα-PE from Miltenyi Biotec Inc; CD10 APC-Cy7, CD11b PE, CD5 APC from BD 
Pharmingen. Flow cytometry acquisition and analysis were performed using a 
MACSQuant® Analyzer (Miltenyi Biotec Inc. Auburn, CA) and FlowJo data analysis 
software v9 (FlowJo LLC, Ashland, OR). Cell sorting was performed using a FACSAria 
(BD Biosciences Immunocytometry Systems). 
 
Transplantation Studies in NOD/SCID/-2mnull mice. 
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NOD/SCID/-2mnull; NSG) mice were 
purchased from Jackson Laboratory (Bar Harbor, ME) and housed and bred under 
pathogen-free conditions in the Loma Linda University animal facility and studied in 
accordance with the Institutional Animal Care and Use Committee (IACUC) approved 
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protocol. CB CD34+ HSCs (2X104) or sorted IL-7R+ and IL-7R- progenitors (1.5X104) 
were intravenously injected into sublethally irradiated (225 cGy) 4 to 6 week-old NSG 
mice. 5–7 weeks after transplantation, mice were sacrificed and cells were harvested from 
BM.  
Results 
IL-7R+ Progenitors are Produced In Vitro from CD34+ CB Cells,  
but are Rare in Circulating CB 
Using a novel human-only co-culture system, our previous studies showed that 
IL-7 is essential for adult human B lymphopoiesis and critical for B cell production from 
HSCs in CB (Parrish et al., 2009). To identify the earliest CD19– lymphoid progenitors 
that are potentially targeted by IL-7 we used flow cytometry to evaluate expression of IL-
7R on CD19–CD34+ progenitors produced from CB CD34+ co-cultured with primary 
human BM stroma (human-only co-cultures). As shown in Figures 1A (left panel) and 
1C, approximately 20% of the CD19–CD34+ progenitors generated in vitro were 
comprised of IL-7R+ cells (designated IL-7R+ progenitors here). Surprisingly, the 
frequency of IL-7R+ progenitors in uncultured CB was significantly lower, making up 
only ~2% of the CD19–CD34+ cells present in circulating CB (Figure 1B, left panel, and 
Figure 1C).  
This led us to ask whether progenitor populations that express CD7 or CD10, two 
markers previously used to identify lymphoid progenitors (Galy, Travis, Cen, & Chen, 
1995; Hao et al., 2001; Rossi et al., 2003) were similarly under-represented among 
circulating CB cells as compared to their counterparts generated in vitro. As shown in 
Figures 1A–C, the CD19–CD34+ cord blood progenitors that express CD10 or CD7 are 
present at similar frequencies in the in vitro-generated progeny of CB CD34+ cells and in 
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uncultured CB. Taken together, these data show that 1) IL-7R+ progenitors are a major 
progenitor population produced from CB HSCs during in vitro culture and 2) unlike 
CD7+ and CD10+ progenitors, IL-7R+ progenitors are largely absent from circulating 
CB.
 
 
 
 
 
 
Figure 1 (Figure 31). IL-7R+ progenitors are produced in vitro from CD34+ CB cells, 
but are rare in circulating CB. Samples were harvested from a “human-only” culture 
based on co-culturing human CB CD34+ HSCs on primary human BM stroma with FL 
for 2 weeks, supplemented with IL-3 for the first week only. (A) The expression of IL-
7Rα, CD10 and CD7 were evaluated on cultured CD34+CD19– cells. (B) The 
representative expressions of IL-7Rα, CD10 and CD7 in CD34+CD19– populations 
were also analyzed in unmanipulated CB samples. Data shown in each dot plot are the 
mean ± SEM of three to 12 independent experiments. Isotype controls are displayed in 
the lower left or right corner of each larger dot plot. Summarized in (C) are the 
frequencies of IL-7Rα, CD10 and CD7 cells in either cultured cells or unmanipulated 
CD19–CD34+ cells, where n = three to 12 independent experiments, **** P < 0.0001. 
 186 
IL-7R Expression Identifies an In Vitro-Generated Progenitor Population with 
Lymphoid but not Myeloid Differentiation Potential 
To determine the differentiation potential of the IL-7R+ progenitors, CFU assays 
were used to assess myeloid lineage potential and stromal cell co-cultures were used to 
determine B and NK lineage potential. CD19–CD34+ cells generated in vitro from 
cultures of CB CD34+ cells (Figure 2A) were FACS sorted into IL-7R– and IL-7R+ 
subsets and assessed for myeloid and lymphoid differentiation potential. For comparison, 
culture-generated CD19–CD34+ cells were also FACS sorted into CD10– and CD10+, as 
well as CD7– and CD7+ subsets.  
CFU assays showed that the IL-7R– subset of CD19-CD34+ cells generated 
myeloid and erythroid colonies, whereas IL-7R+ progenitors were completely devoid of 
myeloid or erythroid differentiation potential (Figure 2B, top panel). In contrast, both 
CD10– and CD10+ subsets of CD19–CD34+ cells retained substantial myelo-erythroid 
potential, although CD10+ cells formed significantly lower numbers of colonies when 
compared to CD10– cells (Figure 2B, middle panel). No difference was observed 
between the ability of CD19– CD34+ cells that were CD7– or CD7+ to generate myeloid 
and erythroid colonies (Figure 2B, bottom panel). These data suggest that IL-7R+ 
progenitors generated in vitro from CD34+ CB cells have lost myelo-erythroid 
differentiation potential.  
To determine the B and NK potential of IL-7R+ progenitors, we seeded these 
cells into murine S17 stromal cell co-cultures under lymphoid conditions (FL, IL-15 
and/or IL-7) as previously described (Hao et al., 2001). As a control, CD19–CD34+ 
progenitors that were IL-7R– were also evaluated. Distinct populations of CD19+ and 
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CD56+ cells were identified in bulk cultures from both the IL-7R– and IL-7R+ 
progenitors (Figures 2C and D). These data provide evidence that IL-7R, but not CD10 or 
CD7, can be used as a single marker to identify an early lymphoid progenitor population 
in CB lymphopoiesis that is completely devoid of myelo-erythroid potential. These 
results also demonstrate that that IL-7R+ progenitors can give rise to both B and NK 
cells.  
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Figure 2 (Figure 32). Expression of IL7R, but not CD10 or CD7 identifies CB-derived 
progenitors with B-NK but not myeloid differentiation potential. (A) Schema of study 
design. “Human-only” co-cultures were used to generate progenitor cells as described 
in Figure 1. CD34+CD19– cells were sorted based on expression of IL-7R, CD10 and 
CD7 and assayed in lineage-specific in vitro assays. (B) CD34+CD19–IL-7R+/IL-7R–
, CD34+CD19–CD10+/CD10– and CD34+CD19–CD7+/CD7– cells were seeded in 
triplicate in methylcellulose-based myeloid-erythroid cultures (CFU-Assay). CFUs 
were counted on day 14. Data are summarized as the number of CFU per progenitor 
plated. Data are presented as mean values ± SEM of triplicate determinations from three 
to seven individual experiments, ** p< 0.01, ****p < 0.0001. CD34+CD19–IL-7R+/IL-
7R– cells were also cultured in B and NK lineage differentiation cultures, supplemented 
with FL, IL-7 and IL-15.  Cells were harvested on day 14 and analyzed by flow 
cytometry. Displayed in (C) are representative dot plots of CD19 versus CD56 staining 
from cultures initiated with sorted CD34+CD19–IL-7R+/IL-7R– cells. (D) Graphed is 
the percent (mean ± SEM) of CD19+ and CD56+ cells generated from cultured IL-7R– 
and IL-7R+ cells in three – five experiments. 
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CB CD34+ Cells Produce Lymphoid-Restricted IL-7R+ Progenitors In Vivo in 
the Human-Mouse Xenograft Model  
To determine if IL-7R+ progenitors are generated during in vivo differentiation 
from CB CD34+ cells we used a human-mouse xenograft model. Xenograft mice were 
produced by transplanting human CB CD34+ cells into sublethally irradiated, immune 
deficient NSG mice. BM was harvested 5–7 weeks post transplant and stained for flow 
cytometry to detect human cells generated in vivo (Figure 3A). Flow cytometry showed 
that human cells (hCD45+) comprised ~90% of harvested BM (Figure 3B, left panel) and 
that CD19–CD34+ cells made up ~13% of the human cells in BM (Figure 3B, middle 
panel). Approximately one third of the CD19–CD34+ cells generated in vivo expressed 
the IL-7R (Figure 3B, right panel). These data show that IL-7R+ progenitors are 
produced from CB CD34+ cells in vivo in the human-mouse xenograft model and suggest 
that IL-7R+ progenitors represent a major intermediate during in vivo hematopoiesis from 
CB HSCs.  
Next we evaluated the lymphoid and myeloid differentiation potential of IL-7R+ 
progenitors produced in vivo. hCD45+CD19–CD34+ cells harvested from BM of human 
mouse xenografts were FACS-sorted into IL-7R– and IL-7R+ subsets and evaluated for 
myeloid potential in CFU assays and for lymphoid potential in stromal cell co-cultures. 
Data obtained from human progenitors generated in vivo in the xenograft model was 
similar to that from culture-generated cells: the IL-7R– progenitor population gave rise to 
myeloid and erythroid colonies in CFU assays, however, no CFU colonies were produced 
from IL-7R+ progenitors (Figure 3C). In stromal cell co-cultures grown under lymphoid 
conditions, both IL-7R– and IL-7R+ subpopulations gave rise to CD19+ and CD56+ cells 
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(Figures 3D and E). These data show that IL-7R+ progenitors generated in vivo from CB 
HSCs have B and NK, but lack myeloid differentiation potential.  
 
 
Clonal Analysis of IL-7R+ Progenitors in a Single Cell Assay of 
Figure 3 (Figure 33). CD34+CD19-IL7R+ progenitors generated in the human-mouse 
xenograft model possess only B-NK potential. (A) Schema of study design. 2x104 
CD34+ CB CD34+ stem cells were transplanted into sublethally irradiated (225 cGy) 
NOD/SCID/-2mnull (NSG) mice, BM cells were harvested five to seven weeks later 
and analyzed by flow cytometry.  A representative diagram of IL-7R expression gated 
on human (h) CD45+CD34+CD19– cells is shown in (B), where isotype controls are 
displayed in either the lower right corner or the lower left corner of the respective plots. 
Data are presented as mean values ± SEM of three separate experiments.  Cells were 
sorted into hCD45+CD34+CD19–IL-7R– and hCD45+CD34+CD19–IL-7R+ 
populations and evaluated in various assays. (C) CFU assays were performed on these 
sorted cells as described in Figure 2. Data are presented as mean ± SEM of CFU per 
progenitor cell from three separate experiments performed in triplicate, ** p < 0.01. 
Cells were also analyzed after being cultured in B cell and NK cell differentiation 
conditions for 2 weeks. The expressions of CD19 and CD56 on the cultured cells were 
analyzed by flow cytometry.  Representative plots of CD19 and CD56 expression are 
shown in (D) and data presented as mean values ± SEM of three separate experiments 
are shown in (E). 
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B and NK Potential 
To determine whether the IL-7R+ progenitor population is comprised of multi-
lineage lymphoid progenitors or a mixture of B- and NK-committed cells, we evaluated 
in vitro- and in vivo-generated IL-7R+ progenitors in single cell assays. IL-7R– and IL-
7R+ cells generated in human only co-cultures or in human-mouse xenografts from 
CD19–CD34+ progenitors, were FACS-sorted as described in Figures 2 and 3. Single 
cells were FACS sorted into co-culture with murine S17 stroma in individual wells of 96-
well plates and grown under lymphoid conditions. After two weeks of culture, each well 
was harvested and evaluated by flow cytometry to detect the presence of B (CD19+) 
and/or NK (CD56+) lineage cells.  
Consistent with enrichment of lymphoid progenitors, the total cloning frequency 
in lymphoid conditions was ~3 fold higher for IL-7R+ progenitors as compared to cells 
that were IL-7R– (Table 1). Bi-potential, B-NK progenitors gave rise to one in 25 of the 
total clones produced from in vitro-generated IL-7R+ progenitors and one in 18 of the 
total clones produced from IL-7R+ progenitors generated in vivo. Single lineage, B- or 
NK-committed cells comprised the majority of in vitro and in vivo-generated IL-7R+ 
progenitors. Taken together with CFU data these results provide evidence that IL-7R+ 
progenitors are a lymphoid committed progenitor population that includes bi-potential B-
NK progenitors, as well as more differentiated B- and NK-committed progenitors. 
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Table 1 (Table 4). In vitro Analysis of the Lymphoid Lineage Potential of Single CD19– 
CD34+ IL-7R– and CD19- CD34+ IL-7R+ Progenitors 
 In Vitro-Generated  
Progenitors 
Xenograft-Generated  
Progenitors 
Progenitor Subset IL-7R– IL-7R+ IL-7R– IL-7R+ 
Total Cloning Frequency 
(#Total clones detected) 
3.7%  
(403) 
12.4%  
(404) 
1.4%  
(479) 
4.71%  
(576) 
B-NK Cloning Frequency 
(# B-NK Cell Clones) 
0% 
(0) 
.5% 
(2) 
0% 
(0) 
.2% 
(1) 
B-Only Cloning Frequency 
(# B Cell-Only Clones) 
1.7% 
(7) 
5.9% 
(24) 
1.3% 
(6) 
3.3% 
(15) 
NK-Only Cloning Frequency 
(# NK Cell-Only Clones) 
2.0% 
(8) 
5.9% 
(24) 
0% 
(0) 
.5% 
(3) 
 
 
In Vitro Exposure of IL-7R+ Progenitors to OP9-Delta1 Co-Culture  
Induces Phenotypic Changes that are Consistent with Early  
T-Cell Development 
The initiation of commitment to the T cell lineage by human HSC/progenitor cells 
is marked by expression of CD7 (Hoebeke et al., 2007) as well as CD1a (Haddad et al., 
2006; La Motte-Mohs et al., 2005) and CD5 (Awong et al., 2009). Specifically, 
CD34+CD7+ cells are the earliest T progenitors detected in cultures induced by the 
Notch signaling (Awong et al., 2009) . To determine the T lineage potential of IL-7R+ 
progenitors generated in vitro and in vivo, IL-7R+ cells were cultured on OP9-DL1 or 
OP9-control cells with FL and IL-7 as previously described (La Motte-Mohs et al., 2005). 
As controls, purified CD34+ stem cells and IL-7R– progenitors were also evaluated. 
Purified CD34+ CB cells and IL-7R– progenitors sorted from in vitro cultures  and in 
vivo xenograft animals  cultured on OP9-DL1, produced a small population of cells 
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expressing CD7 within the first week of culture (data not shown). CD7 expression 
continued to increase between weeks 1 to 2 and corresponded with the emergence of a 
CD34–CD7+ population (Figure 4A, Rows 1–2). The CD34−CD7+ population continued 
to increase through week 6 of culture. A T-cell committed progenitor subset expressing 
CD5 and CD1a emerged from within the CD34−/CD7+ population between weeks 2 and 3 
and peaked between weeks 4 and 5 (Supplemental Figure 1A-B). A higher percentage of 
CD5+CD1a+ cells was generated from IL-7R– sorted cells than purified CD34+ cells 
(Supplemental Figure 1A-B). In contrast, IL-7R+ progenitors, gave rise to a lower 
percentage of CD34+CD7+ early T cell progenitors but higher percentage of  CD34–
CD7+ in the first two weeks of culture (Figures 4A–B, third row), suggesting that at the 
beginning of the culture, this population is more differentiated than IL-7R– cells.  
Consistently, IL-7R+ progenitors generated a higher percentage of  CD7+CD5+CD1a+ T 
lineage committed cells during the first two weeks of culture in contrast to 3–4 week 
from IL-7R– cells (Figure 4B). Robust, early T cell differentiation continued through 
week 6. CD34+CD7+ early T cell progenitors and CD7+CD5+CD1a+ T lineage 
committed cells were not detected in the negative control of CD34+ stem cells on OP9-
control . This data show that IL-7R+ progenitors are able to produce early T cell 
commited progenitors. 
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Figure 4 (Figure 34). IL-7R+ progenitors generated in vitro and in vivo, produce CD7+ 
T cell progenitors. CD34+CD19-IL-7R– and CD34+CD19-IL-7R+ progenitors 
generated (A) in vitro as described in Figure 2 or (B) in vivo as described in Figure 3 
were FACS-sorted and cultured on OP-9DL-1 cells. Total CD34+ cells were cultured 
on OP9–DL1 cells or OP9 cells for positive or negative controls, respectively. Cultures 
were harvested at the intervals shown and cells stained for flow cytometry to identify 
CD34– CD7+ T cell progenitors 
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Supplemental Figure 1 (Figure 35). CD5+CD1a+ T cell committed progenitors are 
generated from IL-7R+ progenitors. Cells were generated and cultured as in Figure 4 
CD5 and CD1a expression were evaluated on CD7+ CD34+/– cells shown in Figure 4. 
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Culture-Generated IL-7R+ Progenitors are Enriched for Cells with  
B and NK Differentiation Potential In Vivo 
To determine the in vivo differentiation capacity of in vitro-generated IL-7R+ 
progenitors, we evaluated hematopoietic differentiation in NSG mice transplanted with IL-
7R+ progenitors and IL-7R– progenitors for comparison, produced in human-only co-
cultures (Figure 5A). Human CD45+ cells were detected in all recipients (Figures 5B and 
C). Recipients of IL-7R+ cells showed BM chimerism that was ~10 fold lower than that 
observed for recipients of IL-7R– cells (0.18 % and 10.85% respectively). As shown in 
Figure 5B, the majority of the human cells produced from transplanted IL-7R+ progenitors, 
fell within lymphoid light scatter gates, while those from recipients of IL-7R– progenitors 
include cells with lymphoid and myeloid light scatter (Figure 5B, left panel). In vivo 
differentiation of IL-7R+ progenitors produced primarily B lineage cells with limited NK 
cell (~5% of hCD45+ cells) and virtually no myeloid cells (Figures 5 D-F, right panels and 
G). In contrast, IL-7R– progenitors showed multi-lineage engraftment that include 
approximately equal proportions of B and myeloid lineage cells and NK cell production 
similar to that observed for IL-7R+ progenitors (Figures 5 D-F, left panels and G). These 
data show that IL-7R+ progenitors generated in vitro from CB CD34+ cells retain in vivo 
B and NK differentiation but lack myeloid differentiation potential.  
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Figure 5 (Figure 36). CD34+CD19-IL7R+ progenitors generated in vitro culture are 
enriched for B-NK but lack myeloid differentiation potential in the human-mouse 
xenograft model. (A) Schema of study design. Cells generated in “Human-only” co-
cultures described in Figure 2 were FACS-sorted into CD34+CD19-IL-7R– and 
CD34+CD19-IL-7R+ populations. Sorted CD34+CD19-IL-7R– or CD34+CD19-IL-7R+ 
cells, were transplanted into sublethally irradiated (225 cGy) NSG mouse at 1.5x104.  Six 
weeks later, animals were sacrificed and BM harvested where lymphoid and myeloid 
lineage markers were evaluated by flow cytometry. Representative dot plots of human 
CD45 (hCD45) versus mouse CD45 (mCD45) engraftment in animals transplanted with 
either IL-7R– or IL-7R+ cells are shown in (B). The forward scatter  (FSC) and side scatter 
(SSC) properties of engrafted hCD45+ cells are shown in the lower left dot plots. 
Displayed in (C) is the engraftment of hCD45 cells from IL-7R– and IL-7R+ mice, * p < 
0.05. Representative diagrams of the myeloid marker, CD11b; B cell marker, CD19 and 
NK cell marker CD56 are shown in (D), (E) and (F), respectively. (G) Data shown are the 
frequencies (mean ± SEM) of CD11b, CD19 and CD56 in total hCD45+ produced in the 
BM of xenograft mice from CD34+CD19-IL-7R+ and CD34+CD19-IL-7R– cells. n = 3, * 
p < 0.05. 
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Discussion 
 Our studies identify a lymphoid progenitor population with B–, NK– and T– 
lineage potential, that suggest a transitional phase between the primitive hematopoietic 
stem cell and early lymphoid commitment in cord blood lymphopoiesis. While these IL-
7R+ progenitors are relatively rare in circulating CB, they can be efficiently cultured in 
vitro and in vivo (Figure 1A). Furthermore, IL-7R+ progenitors when generated in vitro 
(Figure 2), then transplanted into xenograft mice (Figure 5) or in vivo (Figure 3), retain 
their ability to produce B and NK lineages. These progenitors are also capable of 
producing early T cell progenitors (Figure 5 and Supplemental Figure 1). 
 The expression of IL-7R (IL-7R) by Lin–Thy-1–Sca-1loc-Kitlo murine bone 
marrow (BM) progenitors, has been used to identify lymphoid-restricted progenitors in a 
primary pathway of mouse B cell development (Kondo et al., 1997). However the utility 
of IL-7R expression in defining the human CLP counterpart has not previously been 
evaluated.  In attempts to define a CLP in humans, other groups have used expression of 
CD10 and CD7 by primitive CD34+CD38– progenitors from CB and BM, as markers of 
a multi-lymphoid lineage progenitor (Galy et al., 1995; Hao et al., 2001; Six et al., 2007). 
We found that CD34+ progenitors that expressed CD10+ or CD7+ retained the ability to 
generate myeloid and erythroid progenitors as compared to IL-7R+ progenitors that did 
not (Figure 2).    
The IL-7–IL-7R interaction has been seen as unimportant for human lymphoid 
development for the following reasons. Firstly, IL-7R is expressed at low levels on the 
human hematopoietic stem cell (HSC) (Hao et al., 2001; Ryan et al., 1997). Secondly, in 
vitro studies of human progenitors cultured on murine stromal cell lines, showed minimal 
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or reduced IL-7 effects on B cell production, as compared to mice (Rawlings, Quan, 
Kato, & Witte, 1995; Taguchi et al., 2007). Thirdly, early clinical observations of patients 
with severe combined immunodeficiency disease (SCID) due to defects in IL-7R 
signaling, had peripheral B cells, but lacked T cells (Puel, Ziegler, Buckley, & Leonard, 
1998). A previous study from our lab, using a novel “human-only” culture model showed 
that human B cell development is no different from that of mouse, with respect to the 
requirement of IL-7 (Parrish et al., 2009). This study demonstrated that IL-7/IL-7R 
signaling is also important in human B cell development.  Recent clinical reports 
highlight the relationship between IL-7/IL-7R signaling and B cells. A correlation 
between B-cell dysregulation and IL-7/IL-7R expression aberration has been described in 
active HIV-infected children and adult patients or HIV-exposed neonates (Borges-
Almeida et al., 2011; Cagigi et al.; Malaspina, Moir, Chaitt, et al., 2006; Malaspina, 
Moir, Ho, et al., 2006). Therefore, the implications of IL-7R signaling in human 
lymphoid progenitor development, previously ignored, needs to be investigated.  
 CB CD34+ cells are a hematopoietic source used increasingly for stem cell 
transplant in a clinical setting. Slow immune cell reconstitution, especially T cells, is a 
major concern after transplantation. The first few weeks after transplant are characterized 
by a period of lymphopenia followed by rapid recovery of NK cells but a slower recovery 
of T cells (Charrier et al., 2013; Jacobson et al., 2012; Thomson et al., 2000). The slow 
pace of T cell recovery increases opportunistic infections in the patient (Charrier et al., 
2013).   B cell recovery may begin as early as 3 to 6 months post-CB transplantation 
(Nakatani et al., 2014) but can take up to 2 years (Seggewiss & Einsele, 2010). Therefore, 
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co-transplantation of CLPs with HSCs may be an important strategy to accelerate 
immune reconstitution, especially for B and T cells.  
In summary, this is the first report to use IL-7R for characterizing a human 
lymphoid progenitor population. These committed lymphoid progenitors may prove 
useful as targets for expansion and genetic manipulation for clinical purposes, thus 
providing a therapeutic alternative that can impact clinical outcome such as immune 
reconstitution after CB stem cell transplant and also reduction of incidences of acute 
GVHD and transplant related mortality. Moreover, as CD10 and CD7, the previously 
described lymphoid markers do not possess discriminative power for lymphoid 
restriction, at least in CB, further studies on the relationship between IL-7R, CD10 and 
CD7 expressions are warranted. 
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CHAPTER SEVEN 
DISCUSSION 
 
The interactions of hematopoietic progenitors with the bone marrow 
microenvironment; age and immune status of the individual; along with genetic and 
environmental factors, all contribute to creating an adaptive, complex process (Thomas, 
2015). Although an increasing body of data suggests that IL-7R ligands can impact 
human B cell development (S. E. Johnson, Shah, Panoskaltsis-Mortari, & LeBien, 2005; 
Malaspina, Moir, Chaitt, et al., 2006; Malaspina, Moir, Ho, et al., 2006; Scheeren et al., 
2010; Wolf, Weng, Stieglbauer, Shah, & LeBien, 1993), their roles remain controversial.  
Using a unique, in vitro model of B lymphopoiesis, we demonstrate that IL-7 is 
required for the development of B cells in adulthood (Chapter 2), while TSLP may be 
dispensable at this later point in ontogeny (Chapter 5). We also investigated the 
contribution of TSLP and/or IL-7 in an innovative xenograft model with continuous 
human TSLP, and found that in the bone marrow, the increases were specific to the B 
cells and were maintained in the spleen (Chapter 3). Furthermore, in both in vitro and in 
vivo models of B cell differentiation, B cell precursors expanded from post-fetal HSC 
sources in response to TSLP or IL-7 stimulation (Chapter 4). Using CB HSCs, we 
identified a lymphoid progenitor-intermediate, the IL-7R+ progenitor. Although present 
at low frequency in CB, IL-7R+ progenitors were generated both in vitro and in vivo 
(Chapter 6). Collectively, we show that the IL-7R ligands, TSLP and/or IL-7, are 
important for the expansion of early B cell precursors from postnatal sources. 
The cytokines that drive human B cell development remain elusive while those in 
the mouse have been extensively delineated both in vitro and in vivo. Together these data 
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show that the requirement for IL-7 and TSLP during B lymphopoiesis, change during the 
life of the mouse. During fetal life, B cells undergo IL-7 independent development, while 
in adulthood IL-7 is required for maturation of B cell progenitors beyond the pro-B stage 
of differentiation (Carvalho, Mota-Santos, Cumano, Demengeot, & Vieira, 2001; Kikuchi 
& Kondo, 2006; von Freeden-Jeffry et al., 1995). Conversely, in the absence of IL-7, 
TSLP stimulation supported the proliferation of fetal but not adult pro-B cells 
(Vosshenrich, Cumano, Muller, Di Santo, & Vieira, 2003, 2004).  In opposition to the 
previous finding, Jensen et al demonstrated that Flt-3 ligand is a primary cytokine 
responsible for IL-7 independent B lymphopoiesis (Jensen et al., 2008).  The importance 
of IL-7R signaling in developing B cells is further reinforced in adult IL-7R knockout 
mice, which suffer from a more severe B lymphopenia, at an earlier developmental stage 
than IL-7 knockout mice (Kikuchi, Lai, Hsu, & Kondo, 2005; Peschon et al., 1994).  
Collectively, these data establish that IL-7R and Flt-3 ligand induced signals are essential 
to mouse B lymphopoiesis.  
Practical limitations of procuring healthy human bone marrow have made it 
experimentally difficult to evaluate developing B cell precursors in their native 
microenvironment. To address this limitation, in vitro models were developed by 
culturing hematopoietic CD34+ progenitors on murine stromal cells lines (Barker & 
Verfaillie, 2000; Fluckiger et al., 1998; Rawlings, Quan, Kato, & Witte, 1995).  While 
this model produces a substantial pool of B cell precursors, the effects of uncharacterized 
murine proteins cannot be eliminated. To counter the effects of these as yet defined 
factors, others evaluated the process of human B cell differentiation in stromal cell free 
conditions (Kraus et al., 2014); on human bone marrow mesenchymal stem cells  (MSC) 
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(Briquet et al., 2010; Ichii et al., 2008) or in conditioned media from MSC (Ichii et al., 
2010), with or without the addition of exogenous cytokines. Another variable shown to 
influence the in vitro models of lymphopoiesis is the lot of FSC or FBS selected for 
media-supplementation (Ichii et al., 2010). By substituting human serum for FBS or FCS 
in our selective cytokine cultures, we removed the influence of unknown growth factors 
present in FCS while maintaining the stromal cell contact important for B cell 
development (Torlakovic, Tenstad, Funderud, & Rian, 2005).  
While in vitro models provide important information about B lymphopoiesis, they 
are somewhat limiting, as they do not fully recapitulate the native, interactive multi-
cellular bone marrow microenvironment. Humanized mouse models have been developed 
to overcome this limitation, but there are considerations for their use/selection. Firstly, 
the selected mouse strain matters, as each strain differs in its ability to engraft human 
cells. NOD-SCID IL2RGnull (NSG) mice show increased engraftment of human cells 
compared to other strains (Legrand, Weijer, & Spits, 2006; McDermott, Eppert, 
Lechman, Doedens, & Dick, 2010). Secondly, the source of stem cells can affect 
engraftment. HSCs from CB engraft at higher percentages compared to those from 
mobilized PB (Lepus et al., 2009). Thirdly, some cytokines are species specific, e.g. 
TSLP, IL-15 and BAFF. To overcome this limitation some have transgenically expressed 
human cytokines in mice, for example, IL-15 (Huntington et al., 2009), which has been a 
successful strategy. In our humanized model, based on injecting human stromal cells that 
express human TSLP at concentrations similar to that observed in non-diseased children 
(Lee et al., 2010), we saw functional effects of human TSLP on the differentiation of B 
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cell precursors. The utility of this approach is reinforced by studies in mice where 
systemic TSLP levels increased B cell production (Astrakhan et al., 2007). 
Consistent with previous evaluations of fetal-derived and neonatal-derived HSCs 
(S. E. Johnson et al., 2005; Pribyl & LeBien, 1996), we demonstrate that CB HSCs are 
capable of IL-7R ligand independent B cell production in vitro. Unlike an earlier study 
(Pribyl & LeBien, 1996), we found that in vitro supplementation with IL-7 consistently 
augmented the number of B cell progenitors produced from HSC derived from CB. 
TSLP, a known expander of B cells during fetal development in humans and mice 
(Scheeren et al., 2010; Vosshenrich et al., 2003, 2004) also increased the production of B 
cells from CB, but not postnatal sources in our selective cytokine culture model. In 
stromal cell free conditions, Ichii et al, also found that TSLP was unable to expand 
postnatal B cell production (Ichii et al., 2010). 
Understanding the potential role of TSLP in human B cell production is important 
because environmental pollutants, for example, diesel particles, can modulate TSLP 
expression (Bleck, Tse, Gordon, Ahsan, & Reibman, 2010). Significantly higher TSLP 
levels are seen in Th2-mediated inflammatory conditions like asthma (Ying et al., 2008) 
and some (Lee et al., 2010) but not all (Nakamura, Tsuchida, Tsunemi, Saeki, & Tamaki, 
2008) cases of atopic dermatitis. As an assessment of BM is not required for the 
diagnosis of these conditions, it is not known if BM B cell progenitor numbers are 
expanded in these patients in response to increased circulating TSLP. Neither have there 
been reports of increased numbers of immature B cells in the circulation of patients with 
these conditions. Higher TSLP concentrations are also found in the synovial fluid 
(Koyama et al., 2007) and serum (Koyama, Ohba, Haro, & Nakao, 2015) of rheumatoid 
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arthritis patients compared to healthy controls but did not correlate with disease severity. 
Hence, a direct association of TSLP to the initiation or progression of atopic dermatitis 
and rheumatoid arthritis requires further studies.  
The persistence of normal to increased numbers of B cells with decreased T cells 
in the peripheral blood of patients with SCID, due to mutations in either IL-7R or 
common gamma chain, has contributed to the conclusion that IL-7 is dispensable for 
human B lymphopoiesis (Giliani et al., 2005; Puel, Ziegler, Buckley, & Leonard, 1998). 
These studies evaluated patients, who at the time of diagnosis were less than one year 
old.  In mice, HSCs switch from IL-7R independence to dependence one to two weeks 
after birth (Kikuchi & Kondo, 2006), while the characteristics of human HSCs, change 
between one to three years of age (Sidorov, Kimura, Yashin, & Aviv, 2009). It is 
therefore conceivable that the HSCs evaluated in those SCID patients (Giliani et al., 
2005; Puel et al., 1998) were at a point in development where they did not require IL-7R 
signals for B cell development.  
TSLP or TSLPR signaling has been implicated in several cancers including 
precursor B cell lymphoblastic leukemia (pre-B ALL). In an early study, TSLP increased 
the proliferation of and protected primary pre-BALL cells from apoptosis (Brown et al., 
2007). Later studies identified aberrant expression of the TSLP receptor component, 
CRLF2, in pre-B-ALL (Mullighan et al., 2009; Russell et al., 2009; Yoda et al., 2010). 
Mutations in the tyrosine kinase, JAK2, were found to strongly associate with CRLF2 
overexpression (Hertzberg et al., 2010).  Not only do CRLF2 and mutant JAK2 interact 
(Mullighan et al., 2009) but when expressed in BaF3 cells, together these aberrations 
yielded phosphorylation of downstream kinases, in the absence of IL-7R and independent 
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of cytokine stimulation (Yoda et al., 2010), suggesting that the cytokine, TSLP, may not 
be an important contributor to the initiation or progression of the disease. We compared 
the gene expression profiles of cells from primary patients with those from PDX with or 
without TSLP, and found that the gene expression profiles of cells expanded with TSLP 
bore a profile more similar to primary patient cells than those expanded without. These 
findings are important because they demonstrate that along with independent aberrant 
CRLF2/JAK2 signaling, physiological concentrations of TSLP also modulate this 
signaling axis. They further underscore the importance of including TSLP in the 
development of treatments for pre-B ALL. A recent study demonstrated improved 
survival of CRLF2-PDX mice treated with a JAK inhibitor (Wu et al., 2015). As these 
PDX may not have been exposed to physiological concentrations of TSLP, an important 
future consideration will be, does TSLP change the response of CRLF2-PDX to current 
and future JAK inhibitors.  
Transplantation of CB or BM-derived HSCs has been used in the treatment of 
leukemia for many years. While both sources have proven beneficial, they also have 
limitations. As compared to BM, transplantation with CB HSCs, results in a lower 
incidence of graft-versus-host-disease (GvHD) (Broxmeyer, 2008); faster reconstitution 
of B lymphocytes (Nakatani et al., 2014), although the frequency of memory B cells is 
delayed (Charrier et al., 2013); and slower reconstitution of neutrophils and platelets 
(Broxmeyer, 2008). While CB is more accessible, HSCs are present at a lower frequency 
(Broxmeyer, 2008) and cell dose is an important factor in immune reconstitution after 
transplantation (Rocha, Gluckman, Eurocord-Netcord, European, & Marrow Transplant, 
2009). To address this limitation, some physicians have utilized the approach of 
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transplanting more than one CB unit from different donors (Scaradavou et al., 2013). By 
evaluating patient mortality and hematopoietic recovery i.e neutrophils and platelets, this 
strategy proved to be just as successful as transplanting a single CB unit (Scaradavou et 
al., 2013). Ex vivo expansion of IL-7R+ progenitors and co-transplantation with stem 
cells may be an important future step, as a means of boosting lymphoid recovery after 
BM transplantation. 
Human and mouse studies reveal that with increasing age, B cell development is 
impaired (Arakawa-Hoyt et al., 1999). Both cell intrinsic and micro-environmental 
factors contribute to this decline. Micro-environmental changes in older mice include 
decreased IL-7 secretion by BM stromal cells (Stephan, Reilly, & Witte, 1998; Tsuboi et 
al., 2004) and decreased pro-B cell response to IL-7 (Stephan, Lill-Elghanian, & Witte, 
1997); declining pre-B cell numbers in the bone marrow (Kline, Hayden, & Klinman, 
1999) and increased inflammation (Riley, 2013).    Subsequent studies suggest that pre-B 
cell numbers remain constant with age, but in older mice, pools of transitional and mature 
B cells are not efficiently generated (K. M. Johnson, Owen, & Witte, 2002).  Studies of 
normal, BM B cell precursor subsets in elderly patients have been more limited. Our in 
vivo model with selective TSLP or IL-7 may be an important tool to evaluate the 
response of aging, human adult HSCs to the changing cytokine microenvironment in the 
bone marrow.  
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